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Breast cancer – clinical perspective
In women breast cancer is the most common type of cancer, with about 2.1 million 
new cases expected to be diagnosed in 2018 worldwide and this disease accounts 
for most cancer deaths in women (Bray et al., 2018). Within the EU, the number of 
breast cancer deaths is declining from 17.9/100.000 in 2002 to 15.2/100.000 in 2012 
and is expected to reach 13.4/100.000 by 2020 (Carioli et al., 2017). This decline is 
attributed to advances in therapy, management but also to early detection due to 
screening; additionally a decline in incidence in recent generations was observed aiding 
in the predicted decline in breast cancer deaths (Carioli et al., 2017). Furthermore, the 
discontinuation of hormonal use in postmenopausal women has aided as well (Bray 
et al., 2018). In other regions such as South America, Africa and Asia breast cancer 
incidence is, however, still rising (Bray et al., 2018). In the Netherlands incidence rates 
have increased since 1990 and are relatively stable since 2010 when accounting for age 
of the population, but do not show a decrease in incidence in recent years (Nederlandse 
Kankerregistratie (NKR), IKNL).
Breast cancer is a heterogeneous disease and as main distinction tumors can be 
divided into those which express the estrogen receptor (ER) and/or the progesterone 
receptor (PR) and those tumors which do not (Hammond et al., 2010). The difference of 
expression of mainly ER influences the tumors in almost every aspect, such as prognosis 
(Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005; Hammond et al., 
2010) and available therapeutic options for patients (Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG), 2005; Hammond et al., 2010) but also at the molecular 
level affecting the expression of a multitude of genes (Carroll, 2016; Khan et al., 2012). 
ER and PR expression are highly correlated, only few tumors are ER-negative and PR-
positive and this number has further declined due to better assaying techniques ruling 
out some of these tumors as false-negative for ER and warranting re-testing of tissue 
for ER-negative PR-positive samples (Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG), 2011).
Besides this main distinction among tumors, one can further classify those breast 
tumors which express ERBB2, another important targetable receptor with a large impact 
on prognosis and tailored therapy options (Fitzgibbons et al., 2000; Hammond et al., 
2010; Press et al., 2005; Slamon et al., 1987). At the molecular level, breast tumors 
can be grouped into several categories to optimize predictions on the behavior of the 
tumors and the course of disease (Sørlie et al., 2001, 2003). These classifications are 
called molecular subtypes and entail luminal A, luminal B, normal-like, basal-like and 
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ERBB2-overexpressing tumors (Perou et al., 2000; Polyak, 2007; Sørlie et al., 2001, 
2003). The luminal subtypes consist of basically only ER-positive tumors and are called 
luminal because they are characterized by the expression of many genes that are 
also expressed by luminal epithelial cells of the healthy mammary gland (Reis-Filho 
and Pusztai, 2011). Luminal A and luminal B subtypes are differentiated through the 
expression of proliferation-related genes such as Ki67, and overall more ERBB2-positive 
breast cancers fall into the luminal B than the luminal A subtype (Reis-Filho and Pusztai, 
2011). The ERBB2-overexpressing subtype is characterized by its high expression of 
ERBB2 predominantly as a result of ERBB2 gene amplification (Perou et al., 2000) 
and tumors in this subgroup are often ER-negative (Reis-Filho and Pusztai, 2011). The 
basal-like subtype is often triple-negative (lack of expression of ER, PR and ERBB2) 
and expresses high levels of proliferation-related genes (Reis-Filho and Pusztai, 2011). 
This subtype is named based on the finding that it expresses many genes which are 
also expressed by basal and myoepithelial breast cells, such as the cytokeratins 5/6, 
17 and the epidermal growth factor receptor (EGFR) (Reis-Filho and Pusztai, 2011). 
The normal-like breast cancer resembles in its expression profile the normal breast 
and fibroadenomas, however a large part of tumors falling into this classification have 
been found to be miscategorized due to high contents of non-tumor tissue in samples 
(Reis-Filho and Pusztai, 2011). Among these molecular subtypes luminal A tumors have 
the best prognosis, while normal-like tumors show an intermediate prognosis, luminal 
B tumors have an intermediate to poor prognosis and ERBB2-overexpressing as well as 
basal tumors have a poor prognosis (Reis-Filho and Pusztai, 2011).
Current treatments for breast cancer
When it comes to drug treatments the St. Gallen Consensus recommends chemotherapy 
for triple-negative tumors, anti-ERBB2 therapy plus chemotherapy for ERBB2-
overexpressing tumors regardless of ER status and endocrine therapy for ER-positive 
breast cancer (Curigliano et al., 2018). For ER-positive low risk tumors tamoxifen is 
recommended as endocrine therapy in pre-menopausal women, for post-menopausal 
women aromatase inhibitors (AI) are the preferred option for endocrine therapy 
(Curigliano et al., 2018). For higher risk ER-positive tumors in pre-menopausal women 
ovarian function suppression (OFS) plus tamoxifen or OFS plus exemestane or OFS 
plus exemestane plus chemotherapy are recommended (Curigliano et al., 2018). In 
post-menopausal women with ER-positive disease and an intermediate or high risk, AI 
combined with chemotherapy are recommended, while for pre-menopausal women 
with high risk tumors with low ER expression chemotherapy and AI are recommended, 
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supplemented with OFS (Curigliano et al., 2018). In the metastatic or advanced setting 
of ER-positive, ERBB2-negative breast cancer CDK4/6 inhibitors such as palbociclib have 
recently shown great benefit in combination with AI as well (Sobhani et al., 2019). For 
(neo-)adjuvant chemotherapy anthracycline- or taxane-based therapies are preferred 
for triple-negative patients (Curigliano et al., 2018). In tumors with deficiencies in BRCA1 
or BRCA2 alkylating therapy is recommended next to anthracycline- or taxane-based 
chemotherapy, while some experts consider platinum-based chemotherapy useful as 
well (Curigliano et al., 2018). Recently, PARP inhibitors have also been approved for 
treatment of BRCA-deficient breast cancers (Ashworth and Lord, 2018). For ERBB2-
overexpressing tumors different treatments are recommended based on tumor grade; 
low grade should be treated with trastuzumab and chemotherapy e.g. paclitaxel but 
not anthracyclines, while higher grade should be treated with anthracyclines followed 
by taxanes with concurrent trastuzumab (Curigliano et al., 2018). Depending on the risk 
for relapse pertuzumab can be added next to trastuzumab in all settings independent of 
grade (Curigliano et al., 2018). For those ERBB2-overexpressing tumors that also express 
ER, chemotherapy plus endocrine therapy plus trastuzumab are recommended up to 
adding neratinib in some cases (Curigliano et al., 2018). While the aforementioned drugs 
are the most commonly prescribed treatments (Curigliano et al., 2018), other drugs are 
also used in certain circumstances and the National Cancer Institute in the US currently 
lists 64 drugs as approved for the treatment of breast cancer (www.cancer.gov, 2019).
Current biomarkers for breast cancer
Cancer biomarkers are measurable patient or tumor characteristics such as expression 
of a certain protein, a certain gene or levels of signaling molecules (Sawyers, 2008). 
Biomarkers can ideally be easily screened in a patient and enable predictions for 
prognosis to avoid over-treating patients which have a very good prognosis and might 
not need treatments with severe side effects (Duffy et al., 2016; Sawyers, 2008). Besides 
prognosis, biomarkers have also an important role in prediction, i.e. to predict which 
patients will respond best to a certain therapy or will likely be intrinsically resistant (i.e. 
meaning being resistant from the start of treatment in contrast to patients who develop 
resistance over time) (Duffy et al., 2016; Sawyers, 2008).
Gene signatures such as Oncotype DX® and MammaPrint® can aid in identifying 
patients who likely benefit from systemic therapy such as extended endocrine therapy 
or chemotherapy, however, the gain using these signatures does not replace clinical 
parameters such as tumor size and lymph node status but provides complementary 
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information and should be used in combination with the respective clinical parameters 
(Hayes, 2015; Weigelt et al., 2012). Furthermore, similar performance with regard to 
prognosis between Oncotype DX® and semiquantitative measurements of ER, PR, ERBB2 
and Ki-67 by immunohistochemistry has been shown (Weigelt et al., 2012). However, 
the test of these four proteins, also called IHC4 carries the risk for low analytical validity 
as it has not been extensively validated and therefore, different outcomes depending 
on the lab determining the test might be observed (Hayes, 2015).
So far predictive power has overall been limited using these different molecular 
signatures, however, they do aid in fine-charting prognosis (Weigelt et al., 2012). For 
the gene signatures Oncotype DX®, EndoPredict®, PAM50-ROR (Prosigna®), Breast 
Cancer Index®, as well as the biomarker urokinase plasminogen activator combined 
with plasminogen activator inhibitor type 1 (uPA and PAI-1), sufficient evidence could 
be obtained that these biomarkers may be used in the clinic to aid in determining 
which patients should receive systemic adjuvant chemotherapy in early ER/PR-positive 
ERBB2-negative node-negative breast cancer (Harris et al., 2016). However, these 
biomarkers are not suitable for node-positive, ERBB2-positive or triple-negative breast 
cancers (Harris et al., 2016). In the scenario of advanced breast cancer the biomarker 
situation is not optimal either. In metastatic breast cancer it is recommended to analyze 
metastases also for ER, PR and ERBB2 expression if accessible (Van Poznak et al., 2015). 
However, when results are discordant with the primary tumor, considerations have 
to be made whether a switch in therapy based on the result of the metastasis seems 
useful as clinical evidence is currently lacking to support whether treatment based on 
primary measurements or treatment based on metastasis measurements generates a 
better outcome (Van Poznak et al., 2015). The current suggestion is to guide treatment 
based on the metastasis outcome though (Van Poznak et al., 2015). ER, PR and ERBB2 
are currently the only biomarkers available (besides clinical parameters) for clear-cut 
recommendations for metastatic breast cancer in regard to e.g. systemic therapy (Van 
Poznak et al., 2015). The number of circulating tumor cells (CTCs) in metastatic breast 
cancer is prognostic, but CTC abundance does not predict benefit in switching to an 
alternate therapy (Van Poznak et al., 2015). Carcinoembryonic antigen (CEA), cancer 
antigen (CA) 15-3, and CA 27-29 may be used to provide complimentary information 
in metastatic breast cancer, as these markers provide indications, when properly 
interpreted, for disease progression under treatment, however, this is a suggestion 
based on clinical experience and not clinical studies (Van Poznak et al., 2015). For 
predictive biomarkers one challenge is that different mechanisms can achieve resistance 
against one drug, thereby complicating predictive studies in patients (Weigelt et al., 
2012). Other issues are limited availability of archived tumor specimen for predictive 
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studies as well as drug resistance due to patient-specific factors such as blood supply 
of the tumor, tumor necrosis or drug metabolism (Weigelt et al., 2012). While different 
predictive biomarkers are available for tamoxifen, AIs, taxanes, anthracyclines and 
trastuzumab (in the latter case PTEN and soluble ERBB2 levels), these biomarkers do not 
provide the level of evidence required with regard to analytical validity, clinical validity 
or clinical utility (Harris et al., 2016). In breast cancer ER, PR and ERBB2 are the only 
biomarkers for systemic therapy which meet the requirements in regard to analytical 
validity, clinical validity and clinical utility and should be used to guide treatment 
decisions (Van Poznak et al., 2015).
For breast cancer there are several classical prognosis/prediction markers such as 
tumor grade, tumor size, lymph node status, ER, PR and ERBB2 expression, as well 
as age, menopausal status and comorbidities which are taken into consideration in 
the decision-making process for systemic adjuvant therapy in early invasive disease 
(Henry et al., 2016). Chemotherapy is recommended for the following disease situations: 
positive lymph nodes (≥ 1 lymph node containing a tumor metastasis > 2mm), absence 
of ER expression & tumor size > 5 mm, ERBB2 expression, high risk lymph node negative 
tumors with a tumor size > 5 mm & an additional high risk feature, poor risk profile in the 
Adjuvant Online! risk stratification tool of > 10% risk of breast-cancer associated death 
within 10 years (Henry et al., 2016). High risk features in lymph-node negative tumors 
above 5 mm are: grade 3, triple negative tumors, lymphovascular invasion, ERBB2 
expression and an Oncotype DX® risk score of ≥ 20% for distant recurrence within 10 
years (Henry et al., 2016). The biomarker assay MammaPrint® may also be used for high 
clinical risk patients (as defined in the MINDACT trial) with hormone-receptor positive, 
ERBB2-negative tumors, who are node-negative or have up to three positive lymph 
nodes for aiding in the decision-making process if systemic adjuvant chemotherapy 
may be withheld, as MammaPrint® can identify good prognosis subgroups within these 
patient populations (Krop et al., 2017). However, in the case of one or more positive 
lymph nodes, systemic adjuvant chemotherapy should be discussed with a patient even 
if the MammaPrint® assay shows a good prognosis, as benefits through chemotherapy 
treatment cannot be excluded (Krop et al., 2017).
Patients with node negative small tumors below 5 mm and no further risk factors as 
well as strongly ER-positive, PR-positive, ERBB2-negative tumors less than 5 mm in 
size with micrometastatic nodal involvement (< 2mm) and Oncotype DX® assessed 
risk < 10% within 10 years, however, gain little benefit from chemotherapy and might 
be spared from this treatment (Henry et al., 2016). Furthermore, well-differentiated 
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tumors should be considered to be spared from chemotherapy especially if they show 
a luminal A gene expression signature (Henry et al., 2016).
Breast cancer – biological perspective
Breast cancer is a disease of the genome (Stephens et al., 2012; Stratton et al., 2009), 
caused by alterations in the DNA (Nik-Zainal et al., 2016; Stephens et al., 2009, 2012). 
These alterations include genomic instability as well as mutations and are together 
important hallmarks of cancer itself, which enable the cells to subsequently obtain 
further hallmarks/characteristics of cancer such as sustained proliferative signaling, 
evaded growth suppression, enhanced invasion and metastasis, escape from replicative 
senescence, enhanced angiogenesis, repressed cell death, evaded immune destruction, 
deregulated cellular energetics and tumor-promoting inflammation (Dai et al., 2016; 
Hanahan and Weinberg, 2011). These hallmarks or characteristics are general properties 
that cancer cells must gain or, if it concerns the environment, interplay with, to grow into 
a solid tumor (Hanahan and Weinberg, 2011). Depending on the type of cancer/tissue of 
origin each cancer type has specific traits such as reliance on certain growth signaling 
pathways or expression of certain cell surface markers which aid in determining the 
tissue of origin of a tumor as well as guide treatment options (Ke and Shen, 2017; 
Mohammed et al., 2017; Uhlén et al., 2005; Xu et al., 2016).
Mutations in breast cancer
The mutations that are found in cancer can be grouped in driver mutations and 
passenger mutations (Stratton et al., 2009). Driver mutations are mutations that provide 
a selective advantage to a cancer cell such as an enhanced growth rate over normal 
cells of the surrounding tissue; while passenger mutations do not carry an advantage 
for the cancer cell but have arisen e.g. in the normal progenitor of the cancer cell or 
the cancer cell itself by endogenous or exogenous DNA damage and/or by defective 
DNA repair (Stratton et al., 2009). Driver mutations are therefore enriched in tumors 
and more than 576 genes with driver mutations, which are linked to oncogenesis, have 
been identified in cancer to date (http://cancer.sanger.ac.uk/census, 2019). For breast 
cancer specifically 93 driver genes have been described with the five most commonly 
mutated genes being TP53, PIK3CA, MYC, CCND1 and PTEN (Nik-Zainal et al., 2016). 
The number of mutated driver genes within a tumor varies between two to eight for 
most cancers (Vogelstein et al., 2013). Driver genes can be roughly grouped in three 
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functional categories: genes involved in cell fate, those involved in cell survival and 
finally genes playing a role in genome maintenance (Vogelstein et al., 2013). For breast 
cancer, Vogelstein et al. found a median of 3 driver genes within a dataset of 111 
tumors taking mutations in oncogenes and tumor suppressors as well as driver gene 
amplifications and deletions into account (supplemental data) (Vogelstein et al., 2013).
Looking not only at the driver genes but all mutations present in a tumor, specific 
signatures can be detected, based on the prevalence of specific mutation types (Nik-
Zainal and Morganella, 2017). These mutational signatures are characteristic for the 
type of mutagenic burden the DNA was exposed to, such as normal aging, deficient 
DNA damage repair (e.g. deficiency in homologous recombination or mismatch repair), 
carcinogens and APOBEC enzymatic activity (Nik-Zainal and Morganella, 2017). One 
tumor can have several mutational signatures in respective subclones representing the 
history of exposure to these mutagenic threats (Nik-Zainal and Morganella, 2017). So 
far 12 base substitution signatures have been discovered of which five are common, 
i.e. present in more than 20% of breast tumors (Nik-Zainal and Morganella, 2017). All 
of these signatures have also been detected in other tumor types representing wide-
spread mechanisms of DNA damage (Nik-Zainal and Morganella, 2017). The mutational 
signatures in breast cancer have shown that within ERBB2-positive tumors the APOBEC-
typical mutation pattern is more frequently observed (Ng et al., 2015). Furthermore, 
TP53 mutations are associated with the mutational profile caused by APOBEC activity, 
potentially representing a consequence of the loss of function of TP53 (Ng et al., 2015).
Furthermore, genomic rearrangements present in a cancer can also be classified into 
signatures and for breast cancer six have been described (Nik-Zainal and Morganella, 
2017). Three of these signatures are present in tumors with deficiencies in the 
homologous recombination repair (Nik-Zainal and Morganella, 2017).
Prognostic and predictive genetic alterations in breast cancer
Mutations and genomic events (such as the gain or loss of a gene) can influence 
prediction and prognosis. E.g. in breast cancer the gene ERBB2 is frequently amplified 
and serves as a biomarker for poor prognosis and response to different therapies but 
is itself a therapeutic target as well (Fitzgibbons et al., 2000; Incorvati et al., 2013; 
Mariani et al., 2009; Press et al., 2005; Slamon et al., 2011, 1987). High ERBB2 levels have 
been found to be associated with lower response to methotrexate-based therapies and 
tamoxifen-based therapies, while doxorubicin-based therapies were more successful in 
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this patient population (Carlomagno et al., 1996; Clark, 1998; Fitzgibbons et al., 2000; 
Gusterson et al., 1992; Leitzel et al., 1995; Muss et al., 1994; Paik et al., 1998; Pritchard 
et al., 2006; Thor et al., 1998; Wright et al., 1992). Besides, the protein product of ERBB2 
also presents a target for drug therapy reducing cancer-associated deaths (Incorvati et 
al., 2013; Slamon et al., 2011, 2001). Another example in breast but also ovarian cancer 
are germline mutations in the genes BRCA1 and BRCA2, which do not only increase the 
risk of developing breast or ovarian cancer (Ashworth and Lord, 2018; Dziadkowiec et 
al., 2016; Fong et al., 2009) but have also predictive power to PARP inhibitor therapy, in 
the sense that only tumor cells deficient of functional BRCA genes are sensitive to PARP 
inhibitor therapy due to synthetic lethality (Ashworth and Lord, 2018; Dziadkowiec et 
al., 2016; Fong et al., 2009).
Breast tumors often consist of several subclones with different sets of mutations 
(Ng et al., 2015). Upon therapy these clones can gain a selective advantage e.g. due 
to intrinsic drug resistance (Ng et al., 2015). The acquisition of additional mutations 
conferring drug resistance can, however, also happen by chance during drug treatment 
or even be a by-product of mutagenic drug treatments (Ng et al., 2015). A rare event in 
breast cancer is, that 0.6% of luminal breast cancers show mutations within the ligand-
binding domain of the ESR1 gene (Ng et al., 2015). However, in metastases of patients 
receiving prior treatment with an aromatase inhibitor, the number of these mutations 
in ESR1 is increased, arguing for enrichment of the ESR1-mutated subclones due to 
selective pressure induced by the drug therapy (Ng et al., 2015). Interestingly, activating 
mutations in the tyrosine kinase domain of the ERBB2 gene have been identified in 
about 1.5% of breast cancers, likely affecting response to ERBB2-targeted therapies (Ng 
et al., 2015). Another mutation described in ERBB2, L755S, does not cause activation of 
the protein, however, it does cause resistance to lapatinib, a drug targeting the proteins 
ERBB2 and EGFR (Ng et al., 2015). The observed resistance is likely due to changed 
binding kinetics between the drug and the protein ERBB2 caused by this amino acid 
change (Ng et al., 2015).
Interestingly, not only single mutations but also the rate of mutations in a cancer can 
be associated with therapy outcome, e.g., AI-resistant tumors show a higher rate of 
mutations than AI-sensitive tumors, which might be due to tumor heterogeneity as 
tumors with high mutation rates are more heterogeneous (Ng et al., 2015).
To conclude, it is worthwhile to study single mutations as well as genomic aberrations 
on a more global scale as these might indicate sensitivity or resistance to specific drugs.
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Non-coding RNAs
For a long time protein-coding genes have been the main focus of research into 
cancer (Futreal et al., 2004; Greenman et al., 2007; Stratton et al., 2009). In 2004 a 
detailed report of build 35 of the human genome project showed that only a small 
part of the human genome actually encodes proteins, and that the number of protein-
coding genes was substantially lower than estimated (International Human Genome 
Sequencing Consortium, 2004). This sparked the question whether the remaining part 
had functional value (International Human Genome Sequencing Consortium, 2004; 
The ENCODE Project Consortium, 2004), a topic which had gained popularity due to 
the identification of new classes of functional “elements”, such as new types of RNA 
molecules with a surprising range of functions, in the genomes of different organisms 
(Storz, 2002). Subsequently the ENCODE project began to study the human genome 
for its functional sequences (The ENCODE Project Consortium, 2004). To this day the 
ENCODE project has determined a large part of the human genome as functional and 
identified transcription factor binding sites and regulatory elements (e.g. enhancers), 
besides the protein-coding genes (The ENCODE Project Consortium, 2012). Additionally, 
another class of genes was established to be well-represented in the human genome, 
which is the class of non-coding RNAs (ncRNAs) (The ENCODE Project Consortium, 
2012). ncRNA genes are defined as DNA regions which are transcribed into RNAs but 
not further translated into proteins and are neither a tRNA nor a rRNA (Storz, 2002). 
Among ncRNAs are, for example, microRNAs (miRNAs) (Hombach and Kretz, 2016) and 
circular RNAs (circRNAs) (Ashwal-Fluss et al., 2014), both of which will be discussed in 
the subsequent sections.
MiRNAs
MiRNAs are small oligonucleotides which consist of roughly 22 nucleotides (Fang et al., 
2013) and were first discovered in the nematode Caenorhabditis elegans in 1993 (Lee et 
al., 1993). Subsequently this type of gene was discovered in many other animal species 
including humans but also in plants (Li et al., 2010; Tarver et al., 2012). MiRNAs bind 
mRNAs in a sequence-dependent fashion and in this way affect protein production post-
transcriptionally (Calin and Croce, 2006) (see Fig.1). Via this mechanism of action they 
can affect up to several hundred transcripts (Hausser and Zavolan, 2014; Huntzinger 
and Izaurralde, 2011; Iorio and Croce, 2012; Krol et al., 2010; Lin and Gregory, 2015; 
Selbach et al., 2008; Varela et al., 2013). MiRNAs have been found to be dysregulated 
in many human diseases such as in viral infections, disorders of the nervous system, 
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cardiovascular diseases, muscular diseases, diabetes but also cancer (Wang et al., 
2016). Using miRNA expression, it has been shown that the developmental lineage 
and differentiation stage of human cancers can be characterized (Lu et al., 2005) and 
miRNAs were shown to be able to predict prognosis in disease (Wang et al., 2016). 
A dysregulation of the miRNA expression profile has been found in multiple cancer 
types such as leukemia, liver cancer, ovarian cancer, pancreatic cancer, prostate cancer 
and also breast cancer (Wang et al., 2016). Specifically the oncogenic hsa-miR-21 has 
been found to be upregulated in many cancer types (Wang et al., 2016). On the tumor 
suppressor side a few miRNAs have been found but while some apply to several cancer 
types, the roles of others depend on the cancer type and are less generally applicable 
(Wang et al., 2016).
With regard to ease of study, it has been found that miRNAs are less prone to get 
damaged than mRNAs in formalin-fixed paraffin embedded tissue (Lu et al., 2005) – 
which makes them a great candidate to be assessed in solid tumor samples. Others 
have found that miRNAs overall show a higher stability to stress e.g. heating of RNA 
samples than mRNA (Jung et al., 2010) and also show high stability in serum samples 
(Grasedieck et al., 2012). MiRNAs can be easily measured using different methods such 
as microarrays, qRT-PCR and next-generation sequencing (NGS) to name a few (Wang 
et al., 2016). MiRNAs hold therefore great promise for evaluation in different disease 
scenarios.
1
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Figure 1. Mechanisms of action for miRNAs and circRNAs. A. miRNAs bind to their mRNA target genes 
based on sequence complementarity within the RNA-induced silencing complex (RISC). If sequence 
complementarity is perfect, the target mRNA is degraded, if sequence complementarity is imperfect the 
target mRNA is repressed from being translated. B. CircRNAs can have different roles. I. Through interaction 
with the transcription complex they can enhance the transcription of their host genes. II. CircRNAs can 
function as a miRNA sponge by providing multiple binding sites for a specific miRNA and in this way scavenge 
miRNAs. III. Furthermore, circRNAs can present competition in regard to splicing of their host gene and 
thus influence splicing. IV. Another function is providing protein binding sites and in this way sponging 
proteins. V. Finally, circRNAs have been observed to provide a scaffold for different proteins, bringing them 
into physical proximity.
19
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CircRNAs
CircRNAs are a class of ncRNAs, which are characterized through their circular form 
(Wang et al., 2018). They were first described in 1979 (Wang et al., 2018) and have 
a wide variety of functions such as increasing transcription of their host genes by 
association with RNA polymerase II, influencing splicing of their linear host gene based 
on competition, providing a sponge for miRNAs, by reducing protein availability through 
sponging them and serving as scaffolds providing binding sites for interacting proteins 
(Kristensen et al., 2018) (see Fig. 1). Through these ways of action circRNAs have been 
shown to affect multiple cancer-relevant processes such as apoptosis, angiogenesis, 
migration or cell cycle progression and proliferation (Kristensen et al., 2018). So far 
dysregulation of circRNAs has been observed in a large number of human cancers 
such as malignancies of the hematological system, liver cancer, lung cancer, breast 
cancer, prostate cancer, bladder cancer, ovarian cancer, kidney cancer, gastric cancer 
and malignancies of the central nervous system (Kristensen et al., 2018). Besides this 
frequent dysregulation it has been noted that due to their circular structure circRNAs 
show a high transcript half-life probably due to exonuclease resistance (Jeck et al., 
2013) and these two characteristics underline the potential of circRNAs as biomarkers.
1
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Chapter 2
The need for new therapies – the value of drug screenings
Tumors are fine-charted into subcategories to improve current predictions regarding 
prognosis and to help guide treatment decisions. Much success has been gained with 
drug treatments since the advance of the targeted agents tamoxifen, as well as AIs alone 
(or recently in combination with CDK4/6 inhibitors) against ER-positive breast cancers 
and anti-HER2 (ERBB2) therapy for ERBB2-overexpressing tumors, however, a significant 
proportion of patients with metastatic or advanced disease will eventually become 
resistant to therapy (Carroll, 2016; Curigliano et al., 2018; Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG), 2011; Incorvati et al., 2013; Slamon et al., 2011; Sobhani 
et al., 2019). Chemotherapy has been the longest available type of anti-cancer drug 
treatment, however, while it can potentially benefit all patients, this type of treatment 
is also associated with various types of side effects and patients will as well develop 
resistance (Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005; Greene 
et al., 1994; Ke and Shen, 2017).
As targeted therapies hold great promise for mainly affecting the tumor but less so 
healthy tissues in the body, many investigations have been undertaken to study tumors 
for those proteins crucial for fueling the cancerous growth or enabling the cells to 
survive (Gerber, 2008; Sawyers, 2004; Widakowich et al., 2007). Many potential targets 
have been identified and targeted drugs have been developed (Gerber, 2008; Sawyers, 
2004; Widakowich et al., 2007). Furthermore, some medications already prescribed 
for other conditions have shown indications for anti-cancer effects as well (Würth et 
al., 2016). It is therefore necessary to study these newly developed but also already 
available drugs for a potential use in the treatment of cancer. A first step to assess 
whether drugs might show benefit in a certain condition are drug screenings, i.e. 
monitoring cell line growth/behavior under drug treatment (Allen et al., 2005; Monks 
et al., 1991).
The need for new biomarkers to predict course of the disease and 
therapy response
Besides new available treatments, there is also a need for better biomarkers (Begley 
and Ellis, 2012; Hayes et al., 2013). For breast cancer the intrinsic molecular subtypes 
provided prognostic information but had only limited predictive value (Weigelt et 
al., 2012). Luminal A tumors, with a good prognosis have a neglectable benefit from 
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adjuvant chemotherapy, while the other intrinsic subtypes do show substantial benefit 
from adjuvant chemotherapy treatments (Weigelt et al., 2012).
Among the new biomarkers available in breast cancer, however, few are robust enough 
in their capabilities to be used in the clinics (see above for an overview of current clinical 
grade biomarkers) (Duffy et al., 2016; Győrffy et al., 2015; Harris et al., 2016).
To chart more potential biomarkers which might increase the capability for an optimal 
prediction forecast is therefore of great benefit (Duffy et al., 2016; Harris et al., 2016; 
Hayes et al., 2013). Furthermore, as new types of treatments evolve, it would be of 
great help to have also accompanying biomarkers in the near future available when 
such new therapies are migrating into the clinics.
A first step to improve patient management is to test drugs on a model system for their 
response profile (Begley and Ellis, 2012), preferably taking into account the biological 
diversity such as subtypes of the cancer. In this thesis, we have made use of our large 
collection of breast cancer cell lines to perform an extensive drug sensitivity screening 
using a wide array of newly developed targeted drugs, as well as chemotherapeutics 
for comparison of their response profiles. Chapter 3 discusses the outcomes and 
conclusions from this study in further detail.
In the search for biomarkers, miRNAs hold great promise and are worth assessing in 
the search for suitable prognostic or predictive biomarkers. In chapter 4 we studied 
the potential of miRNAs as predictive biomarkers for drug response in breast cancer 
cell lines.
As mutations can also influence drug response e.g. in the case of BRCA1/2 (Ashworth 
and Lord, 2018), in chapter 5 mutations and copy number aberrations (CNAs) were 
studied for their value as biomarkers in breast cancer cell lines for sensitivity to a wide 
array of drugs.
In the past hsa-miR-7 was found to be a prognostic biomarker in breast cancer (Foekens 
et al., 2008); as subsequently the circRNA CDR1-AS, was identified to act as a miRNA 
sponge for hsa-miR-7 (Hansen et al., 2013), we investigated whether CDR1-AS itself was 
also a biomarker in breast cancer, and this study is detailed in chapter 6.
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In chapter 7 we investigated the abundance of circRNAs in an unbiased manner in 
human primary breast tumors and could identify one of them (circCNOT2) as a predictive 
biomarker of progression-free survival for AI therapy in patients with advanced disease.
Overall, this thesis has provided further information on non-coding RNAs, as well as 
drug response in breast cancer.
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Abstract
With substantial numbers of breast tumors showing or acquiring treatment resistance, 
it is of utmost importance to develop new agents for the treatment of the disease, to 
know their effectiveness against breast cancer and to understand their relationships 
with other drugs to best assign the right drug to the right patient. To achieve this goal 
drug screenings on breast cancer cell lines are a promising approach. In this study a 
large-scale drug screening of 37 compounds was performed on a panel of 42 breast 
cancer cell lines representing the main breast cancer subtypes. Clustering, correlation 
and pathway analyses were used for data analysis. We found that compounds with a 
related mechanism of action had correlated IC
50
 values and thus grouped together when 
the cell lines were hierarchically clustered based on IC
50
 values. In total we found six 
clusters of drugs of which five consisted of drugs with related mode of action and one 
cluster with two drugs not previously connected. In total, 25 correlated and four anti-
correlated drug sensitivities were revealed of which only one drug, Sirolimus, showed 
significantly lower IC
50
 values in the luminal/ERBB2 breast cancer subtype. We found 
expected interactions but also discovered new relationships between drugs which might 
have implications for cancer treatment regimens.
Keywords: Drugs, screening, cell line, subtype, pathway, breast cancer
Background
Life expectancy and survival of breast cancer patients have increased significantly over 
the last decades, due to – amongst other factors – an increasing number of effective 
drug therapies (Berry et al., 2005; Lichtenberg, 2009, 2011). Drug resistance remains a 
major issue (Gonzalez-Angulo et al., 2007) and since the discovery that expression of the 
protein markers ER, PR and her-2/neu determines response to a given targeted therapy 
(Bast et al., 2001), the assessment of their expression in breast cancer has become an 
important first step in selecting a patient’s treatment (Bast et al., 2001). Subsequently, 
microarray studies have shown insight into molecular processes active in the tumor and 
linked those to diverse clinical outcomes (Sorlie et al., 2001; van ’t Veer et al., 2002; 
Wang et al., 2005) including therapy failure (Jansen et al., 2005). In the last couple of 
years large scale next generation sequencing efforts have made a big contribution 
to our understanding of breast cancer by delivering precise information on cancer 
driver mutations (Desmedt et al., 2012; Kangaspeska et al., 2012; Previati et al., 2013; 
Radovich et al., 2013; The Cancer Genome Atlas Network, 2012). All these sources of 
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information combined have helped to elucidate how breast cancer evolves, progresses 
and metastasizes and some of them have led to the development of diagnostic tests 
to characterize breast cancer better (Kittaneh et al., 2013). Nevertheless, there is 
still significant room for improvement in regard to available drug therapies, as many 
patients do not respond to current treatments or become resistant during the course 
of treatment (Gonzalez-Angulo et al., 2007). New agents are therefore needed to 
target breast cancer, and screenings of multiple compounds for their activity against 
the various breast cancer subtypes are a good starting point. As a first step to test 
new compounds breast cancer cell lines are a good model, because they are easy to 
maintain, represent different subtypes of breast cancer, and the response to drug 
treatment can be easily assessed. For these reasons, we studied the activity of a wide 
variety of cytotoxic and targeted drugs in a large panel of breast cancer cell lines. The 
drugs were chosen based on current clinical utility e.g. for discrete cancer subtypes, 
potential clinical utility such as promising compounds in pre-clinical testing, aiming at 
molecular targets, and – for comparison – current state of the art drugs for the therapy 
of breast cancer. We investigated which drugs showed similar activity in the panel of 
breast cancer cell lines and could therefore potentially substitute or complement each 
other in the clinic, and, in addition, we aimed to identify shared biology in cell lines that 
are affected by highly correlated drugs.
Results
Relationships between drugs: clustering and correlation analysis
To investigate the relationships between different drugs the IC
50
 values of all 7 
cytotoxic drugs and 30 targeted agents, measured in the 42 breast cancer cell lines, 
were correlated (Fig. 1). Capecitabine, cMet 605 and Cyclophosphamide exhibited no 
differential IC
50
 values and were consequently omitted from the clustering and further 
analyses. To express the relationships among drugs and cell lines hierarchical clustering 
was performed (Fig. 2). Clustering and correlation performed fairly similarly and are 
therefore discussed together.
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Fig. 1. Pearson correlation plot of absolute drug IC50 values. The red color indicates a positive correlation 
between the IC
50
 values of two drugs, and blue a negative correlation. The color intensity illustrates the 
correlation coefficient as shown in the legend at top right. Drugs are clustered on the basis of similarity; 
distances in the tree indicate the degree of difference between drugs.
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Fig. 2. Similar drugs cluster together. Depicted is a hierarchical unsupervised clustering of the analyzable 
drugs and cell lines. Blue color indicates low IC
50
 values (i.e. cells are drug-sensitive), and red color high IC
50
 
values (i.e. cells are drug-resistant). Color intensity illustrates the degree of drug sensitivity or resistance; 
outliers exceeding the legend boundaries are set to the maxima colors of the legend to ensure visibility of 
small differences instead of few outliers. Breast-cancer subtypes are color-coded on the basis of the intrinsic 
subtypes of breast cancer cell lines as previously described (Riaz et al., 2013). The respective legend can be 
found on the top right. Tree distance is representative for similarity of drugs or cell lines. Drugs with similar 
response profiles among the cell lines are highlighted by red boxes.
Strong correlation and expected co-clustering was observed between Gefitinib and 
Erlotinib (cluster 1; r = 0.88), between Quisinostat, Panobinostat, Vorinostat and 
Belinostat (cluster 2; r = 0.85-0.96), between Docetaxel and Paclitaxel (cluster 3; 
r = 0.73), between JNJ-707 and JNJ-493 (cluster 4; r = 0.62) and between MI-219 and 
Nutlin-3 (cluster 6; r = 0.98); all correlations are listed additionally in Table 1. To illustrate 
the close relationship between related drugs, the IC
50
 values of MI-219 and Nutlin-3, the 
two drugs with the highest correlation, were ranked and plotted for all cell lines (Fig. 3). 
Interestingly, Serdemetan, a drug which acts on cholesterol transport but also targets 
MDM2 (Jones et al., 2013) – a mechanism shared with Nutlin-3 and MI-219 (Shangary 
and Wang, 2009) – showed no correlation with these two compounds.
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Table 1. Correlated drugs
Drug 1 Drug 2 p-value
Pearson 
correlation 
coefficient
MI-219 Nutlin-3 1.77E-28 0.98
Panobinostat (Faridak®) Vorinostat (Zolinza®) 2.14E-24 0.96
Panobinostat (Faridak®) Quisinostat 1.66E-19 0.93
Belinostat Vorinostat (Zolinza®) 2.05E-18 0.92
Belinostat Panobinostat (Faridak®) 1.70E-16 0.91
Erlotinib (Tarceva®) Gefitinib (Iressa®) 3.49E-14 0.88
Quisinostat Vorinostat (Zolinza®) 1.05E-13 0.87
Belinostat Quisinostat 8.08E-13 0.85
Paclitaxel (Taxol®, OnxalTM) Docetaxel (Taxotere®) 4.61E-08 0.73
Azacitidine (Vidaza®) Doxorubicin (Adriamycin®) 3.77E-07 0.7
JNJ-493 JNJ-707 1.39E-05 0.62
Decitabine (Dacogen®) 5-Fluorouracil 7.77E-05 0.58
Decitabine (Dacogen®) Serdemetan 1.17E-04 0.56
Vandetanib (Zactima®) Gefitinib (Iressa®) 1.52E-04 0.56
Serdemetan Tipifarnib (Zarnestra®) 5.15E-04 0.52
Decitabine (Dacogen®) Lapatinib 5.29E-04 0.52
Veliparib Serdemetan 5.47E-04 0.51
JNJ-493 Sunitinib (Sutent®) 1.37E-03 0.48
Veliparib Decitabine (Dacogen®) 1.63E-03 0.48
Vandetanib (Zactima®) Erlotinib (Tarceva®) 1.78E-03 0.47
Bortezomib (Velcade®) Vandetanib (Zactima®) 1.94E-03 0.47
ARQ197 Docetaxel (Taxotere®) 1.95E-03 0.47
Cisplatin Sunitinib (Sutent®) 2.00E-03 0.47
JNJ-707 Brivanib 2.16E-03 0.46
Mitoxantrone (Novantrone®) JNJ-707 2.98E-03 0.45
JNJ-707 Nutlin-3 2.87E-03 -0.45
Cisplatin Azacitidine (Vidaza®) 2.16E-04 -0.55
JNJ-208 Bortezomib (Velcade®) 1.96E-06 -0.66
Cisplatin Doxorubicin (Adriamycin®) 5.22E-08 -0.73
Correlation pairs were determined using IC
50
 values. Statistical thresholds for significance were 
defined as a p-value <0.01 and a Pearson correlation coefficient above 0.45 or below -0.45.
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Fig. 3. Nutlin-3 and MI-219 have similar drug sensitivity profiles among the cell lines (relative IC50 values). 
The relative IC
50
 is inverted, with high numbers indicating sensitivity in this case and not resistance. Few 
cell lines are sensitive to these drugs, while the majority is resistant.
Unanticipated but highly significant correlations were observed between particularly 
Doxorubicin and Azacitidine (cluster 5; r = 0.70), between Decitabine and 5-Fluorouracil 
(r = 0.58) and Serdemetan (r = 0.56); and between Serdemetan and Tipifarnib (r = 0.52). 
Additional weaker, but expected correlations were found for Vandetanib with Erlotinib 
and Gefitinib (r = 0.47, r = 0.56). Decitabine was correlated with Lapatinib (r = 0.52) and 
Veliparib with Serdemetan and Decitabine (r = 0.51, r = 0.48). Furthermore, we also 
detected a remote relation between various tyrosine kinase inhibitors like JNJ-493 with 
the multi-receptor tyrosine kinase inhibitor Sunitinib (Keyvanjah et al., 2012) (r = 0.48), 
JNJ-707 with FGFR- and VEGFR-inhibitor Brivanib (Huynh et al., 2008) (r = 0.46) and 
between Docetaxel and ARQ197 (r = 0.47). The DNA targeting drug Cisplatin (Becker 
et al., 2014) showed surprisingly a correlation with Sunitinib (r = 0.47); Bortezomib 
was correlated with Vandetanib (r = 0.47) and the type II topoisomerase inhibitor 
Mitoxantrone (Hajihassan and Rabbani-Chadegani, 2009) was correlated with JNJ-707 
(r = 0.45). In total, 25 pairs of positively correlated drugs were found.
Apart from positive correlations – and even more interesting – we also discovered 
significant negative correlations between certain drugs (Table 1). Particularly, 
Doxorubicin and the correlated drug Azacitidine had negative correlations with Cisplatin 
(r = -0.73, r = -0.55), the ERR1 targeting JNJ-208 with Bortezomib (r = -0.66), and the 
MDM2-targeting Nutlin-3 (Shangary and Wang, 2009) with the FGFR inhibitor JNJ-707 
(r = -0.45).
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Shared pathways between correlated drugs
To further understand the biology behind correlated drugs we used mRNA expression 
data of the untreated cell lines and the pathway information of the databases Biocarta 
and KEGG (Ogata et al., 1999) to characterize drug resistance in R (R_Core_Team, 2013). 
We identified significant pathways for each of the evaluable drugs, but focused on 
the pathways which were shared among correlated drugs, i.e. for the 23 positively 
and 3 negatively correlated remaining drug-drug pairs. Furthermore, we performed a 
pathway analysis where cell lines were grouped per subtype to identify subtype-related 
pathways. Subtype-specific pathways were excluded from further study in the 
pathway-drug resistance analysis. At a significance level of p < 0.01, only one of all 26 
correlation pairs had pathways in common. This pair, Nutlin-3 and MI-219, had, after 
correction for subtype-specific pathways, only the DNA replication pathway in common. 
The Nutlin-3- and MI-219-associated genes of this pathway are displayed in Fig. 4.
Fig. 4. Differentially expressed genes of the DNA replication pathway for Nutlin-3 and MI-219. Bar graphs 
display the differentially expressed genes of this pathway between resistant and sensitive cell lines for 
Nutlin-3 and MI-219. Red shades indicate an association with resistance, blue shades indicate an association 
with sensitivity.
Breast cancer subtype specific drugs
Earlier, several subtype-specific differences in drug sensitivity were observed (Heiser 
et al., 2012) and since breast cancer subtypes are biologically very different (Parker et 
al., 2009), we also explored whether drug response in our study was ER- or subtype-
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related. Only one drug, Sirolimus, exhibited a significantly different subtype-specific 
effectiveness. Normal-like and basal cell lines were more resistant to this drug compared 
to luminal and ERBB2-overexpressing cell lines with a change in sensitivity of two orders 
of magnitude (p = 0.005). The expression of ER by the latter two subtypes was not the 
sole explanation though, as none of the screened drugs was associated with ER status 
(p-value > 0.01).
Discussion
Drug response to one drug indicates the response to another
To understand drug resistance in breast cancer, we compared drug sensitivity of a 
large set of drugs within a large panel of breast cancer cell lines. It became evident that 
some drugs target breast cancer cell lines similarly and thus may have unanticipated 
overlapping mechanisms while others display opposing effects indicating that 
vulnerability to a given drug is protective for another unrelated treatment.
The results of the overall clustering (Fig. 2) show that every breast cancer cell line had 
a unique drug response profile, which might be true for patients as well. This – first 
– observation underlines the personal factor in drug sensitivity, which we need to 
understand upfront to provide optimal patient care.
The second, expected, conclusion is that drugs with identical targets such as MDM2-
antagonists (MI-219 and Nutlin-3) (Shangary and Wang, 2009), EGFR-inhibitors (Gefitinib 
and Erlotinib) (Cohen, 2003), FGFR-inhibitors (JNJ-707 and JNJ-493), HDAC inhibitors 
(Quisinostat, Panobinostat, Vorinostat, Belinostat) (Lemoine and Younes, 2010) and 
taxanes (Docetaxel and Paclitaxel) (Hagiwara and Sunada, 2004), showed correlated 
sensitivities and clustered together explaining five of the six observed clusters.
More interesting was the third observation that unrelated drugs showed co-
clustering, which is best exemplified by the sixth cluster (Figs. 1, 2), made up of the 
positively correlated intercalating agent Doxorubicin (Frederick et al., 1990) and the 
DNA-methyltransferase-targeting Azacitidine (Creusot et al., 1982). Interestingly and 
remarkably, Decitabine, a derivative of Azacitidine (Lyko and Brown, 2005), which also 
targets a DNA-methyltransferase (Creusot et al., 1982), did not cluster with these two 
drugs. The reason for this might be that both Azacitidine and Doxorubicin have, next 
to their well-known properties, also the less known capability to interfere with RNA 
synthesis (Christman, 2002; Momparler et al., 1976), while Decitabine can only act on 
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DNA (Christman, 2002). Next to this most notable finding we also observed a less strong 
correlation of Decitabine sensitivity with sensitivity to various unrelated drugs, i.e. the 
thymidylate synthetase inhibitor 5-Fluorouracil (Longley et al., 2003), the cholesterol 
transport inhibitor and MDM2-antagonist Serdemetan (Jones et al., 2013; Lehman et al., 
2013), the EGF-receptor- and HER2-inhibitor Lapatinib (Huang and Rizzo, 2012) and the 
PARP-inhibitor Veliparib (Glendenning and Tutt, 2011). Some of these drugs additionally 
correlated with each other. Although several of these compounds target DNA synthesis 
and/or repair, there is no real common denominator between them. While these drugs 
could be targeted by the same drug efflux pumps, we could not find any among the 
drug-associated genes (pre-treatment gene expression) and suspect another, unknown 
mechanism. The same holds true for the associations of Serdemetan with Veliparib and 
the farnesyltransferase inhibitor Tipifarnib (Armand et al., 2007).
Additionally, we also observed a rather surprising correlation between Docetaxel, which 
disorganizes microtubules (Hagiwara and Sunada, 2004), and the c-met kinase inhibiting 
agent ARQ197 (Scagliotti et al., 2013). However, supporting our findings, ARQ197 has 
also been linked to inhibition of microtubuli polymerization recently (Katayama et al., 
2013).
Finally, sensitivity to Bortezomib, a proteasome inhibitor (Teicher et al., 1999), was 
also predictive of sensitivity to the multi-kinase inhibitor Vandetanib (Sathornsumetee 
and Rich, 2006) - the combination of these two drugs is currently in clinical trial testing 
(Gramza et al., 2011). Thus a protein or complex whose stability is proteasome-
dependent, may affect sensitivity to this multi-kinase inhibitor. Furthermore, Cisplatin 
and JNJ-493 were somewhat correlated to Sunitinib sensitivity and JNJ-707 weakly 
correlated with response to Mitoxantrone, findings which remain to be understood.
The fourth finding was the absent or poor correlation of drugs acting on the same 
target, such as Serdemetan which was not correlated with the other two well-known 
and highly correlated MDM2-inhibitors Nutlin-3 and MI-219 (Shangary and Wang, 2009). 
Furthermore, Serdemetan lacked a correlation with TP53 mutation status (data not 
shown) highlighting that this putative MDM2-inhibitor acts differently from the other 
MDM2-inhibitors. This unexpected observation can be explained by the additional 
characteristics of Serdemetan, inhibition of the cholesterol transport and the increased 
degradation of ABCA1 (Jones et al., 2013). Clearly these additional properties dominate 
over the MDM2-inhibiting role. Moreover, another study confirms that sensitivity to 
Serdemetan is independent of TP53-mutation status (Jones et al., 2013).
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Furthermore, we noted that Lapatinib and Vandetanib, two EGFR-antagonists (Nelson 
and Dolder, 2006; Sathornsumetee and Rich, 2006) neither clustered immediately next 
to Gefitinib or Erlotinib nor next to each other and the correlation coefficient was also 
lower than expected for Vandetanib, while Lapatinib did not correlate with the other 
EGFR-antagonists at all. In both cases this is less surprising as both Vandetanib and 
Lapatinib act on additional targets, like HER2 for Lapatinib (Nelson and Dolder, 2006), 
and the two proteins VEGFR2 and RET Kinase for Vandetanib (Sathornsumetee and 
Rich, 2006). We tried to support this hypothesis by correlating the drug response with 
mRNA expression data of EGFR, HER2, FGFR, VEGFR2, and RET Kinase for all those drugs. 
However, none of the correlations was significant, which might be different if pre-
treatment protein expression data is used, as the proteins are the direct drug targets.
Similarly, Brivanib showed only a weak correlation with one of the FGFR-inhibitors, JNJ-
707, in our panel, which might be due to its additional target VEGFR (Huynh et al., 2008).
Drug response to one drug indicates resistance to another
The fifth interesting observation was that for some drugs sensitivity predicted 
insensitivity to another drug. For instance – and most prominent – Cisplatin resistance 
correlated with Doxorubicin sensitivity. Cisplatin’s mode of action involves DNA and RNA 
interstrand linkage (Stordal and Davey, 2007), while Doxorubicin blocks DNA unwinding 
(Fornari et al., 1994), this difference does however not explain the clearly opposing 
character in drug response. The clinical implication might, nevertheless, be, that a 
patient showing insensitivity to Doxorubicin upon treatment start, might be more likely 
to respond to a course of Cisplatin therapy (Perilongo et al., 2009). Another implication 
of this finding is that a mechanism responsible for resistance to Doxorubicin reveals a 
target that provides synthetic lethality to Cisplatin or vice versa.
Previously, Cisplatin resistance was found to correlate with Taxane sensitivity (Stordal 
et al., 2007), a finding, we could not confirm in the present study.
The FGFR inhibitor JNJ-707 had an inverse correlation with Nutlin-3 response. Therefore, 
we also investigated whether TP53 wild-type cell lines (Riaz et al., 2013), which are 
sensitive to Nutlin-3, have a different expression of FGFR genes in contrast to mutant cell 
lines, but found no significant difference (data not shown). While a true biological effect 
cannot be excluded, it has to be mentioned that only few cell lines were sensitive to 
Nutlin-3 and our observation might be due to the low numbers. Finally, the proteasome 
inhibitor Bortezomib is negatively correlated to JNJ-208. Thus, if this observation implies 
causality, a proteasome-dependent mechanism affects vulnerability to this drug.
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Biology of correlated drugs
Next, we wanted to uncover shared biology of drug sensitivity in correlated drugs by 
performing a pathway analysis. The first thing we discovered was that there were hardly 
any shared pathways after excluding pathways with a strong subtype-association. This 
was rather surprising as we did not find many subtype-associated drugs, but can be 
explained by the analysis type since for the pathway analysis we used only the cell lines 
around the minimum and maximum drug response, while for the subtype analysis all 
cell lines were included. Hence the smaller number of cell lines might have introduced a 
bias, but generally, it seems that the biology driving the subtypes in breast cancer largely 
obscures the possible drug-related pathways. The two correlated drugs which had the 
DNA replication pathway in common were Nutlin-3 and MI-219. Nutlin-3 has been 
previously shown to downregulate proteins involved in DNA replication (Kumamoto 
et al., 2008), a process likely influenced by MI-219, as well. The cell lines which were 
sensitive to these drugs had intrinsically low expression of most pathway-associated 
genes pre-treatment and the drug-related shutdown of the remaining expression might 
be contributing to lethality.
From the results of the subtype-specific pathways it became obvious that normal-
like cell lines are very different from luminal ones. However, when we did a global 
test to evaluate whether a certain breast cancer subtype showed an overall increased 
sensitivity to the tested compounds we found no differences. Therefore, we could not 
confirm a general drug resistance of normal-like cells which would be expected due to 
their mesenchymal and stem cell like properties (Al-Hajj et al., 2003; Ponti et al., 2006; 
Sieuwerts et al., 2009).
Subtype-specific drugs
Of all tested drugs in this screening only one drug, Sirolimus, was more active in the 
luminal and ERBB2-high subtypes, as was noted previously in a comparable study 
(Heiser et al., 2012). However, in contrast to this earlier study (Heiser et al., 2012), who 
discovered 23 subtype-related drugs, we did not find subtype-dependent sensitivity for 
the other eight drugs screened in both studies. This discrepancy is likely due to several 
differences in study design, e.g. drug incubation times, type of readout assay, the use 
of collagen-coated plates in our study to mimic cellular context better and differences 
in the assayed cell lines to name a few.
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Conclusion
Through our cell line screening with new and well-known drugs, we found a number 
of interesting interactions between drugs of which several were not noticed earlier. 
Those findings have great potential for an application in the clinic as they might present 
opportunities when tumors show already resistance upon start of the treatment.
Next to expected similar sensitivity profiles for related drugs such as Gefitinib and 
Erlotinib, we also found opposing sensitivity profiles such as Cisplatin with Doxorubicin 
and confirmed one subtype-related drug, Sirolimus, which has been identified earlier. 
Further validation on the discovered positive and negative correlations and the subtype-
specific drug are needed e.g. in the form of an animal study. In that aspect it would be 
very interesting to investigate whether animals with e.g. a Cisplatin-resistant tumor 
benefit from Doxorubicin treatment.
To conclude, our study provides new leads in the search for effective treatments 
especially in the context of inherent drug resistance.
Methods
Cell lines and drug screening
Forty-five breast cancer cell lines with confirmed identity (Riaz et al., 2013) and known 
origin (Hollestelle et al., 2010a) were cultured and screened in RPMI 1640 medium 
(Life Technologies, Paisley, UK) containing 10% FBS (Lonza, Walkersville, USA). Ninety-
six well collagen I-coated plates (BD Biosciences, San Jose, USA) were used for drug 
screening. Each drug - cell line combination was assayed in triplicate. Cells were seeded 
at the density required to reach the end of the exponential growth phase at 120h of 
culture. Drug incubation was started 24h post-seeding and lasted 96h. For each drug 
12 different dilutions were tested starting from 1.00-5 to 3.00-11 M (final concentration), 
except for Bortezomib (2.00-5 to 6.00-11 M), Sirolimus and 17-AAG (both: 2.00-6 to 6.00-12 
M). Drug diluent was used as negative control treatment. DMSO was used as drug 
solvent and diluent for all drugs except for Methotrexate (drug solvent: 1M NaOH, drug 
diluent: 0.9% NaCl solution) and Cyclophosphamide (drug solvent: PCR-grade water, 
drug diluent: 0.9% NaCl solution).
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Three cell lines, SUM225CWN, MDA-MB-134VI, and SKBR5, failed in our drug screening 
due to slow growth or half-suspension growth, which is incompatible with the SRB assay, 
resulting in 42 cell lines for analysis.
Assessment of drug sensitivity and IC50 calculation
Cell line growth was determined by measuring the total protein amount per well using 
the Sulforhodamine B Assay (SRB) (Voigt, 2005): After the medium was discarded 
the cells were incubated with 10% TCA for 60 min at 4°C for fixation. Then the cells 
were thoroughly washed 5x with distilled water, air-dried and incubated with 0.4% 
SRB solution for 2h for protein-staining. Additional washing steps followed using 1% 
acetic acid (4x) and cells were again air-dried. TRIS (10 mM) was added to the cells 
to dissolve the SRB overnight. Absorbances were measured at 570 nm in an Ascent 
MultiSkan (Thermo Electron Corporation, Waltham, USA). If required, samples were 
further diluted with TRIS to ensure optimal measurements. IC
50
 values were calculated 
using the respective absorbance values and are listed, besides all IC
50
 profiles, in the 
supplemental Excel file (Additional File 1).
Clustering of cell lines and drug-drug correlation analyses
Cell lines were clustered in a hierarchical fashion based on their IC
50
 values. For drug 
correlation analysis, IC
50
 values per compound of each cell line were correlated with 
each other in Excel 2007 (Microsoft, Redmond, USA) using Pearson correlation. Cell 
lines with missing data for several drugs were discarded from correlation and cluster 
analysis, as were drugs that did not show differential IC
50
 values. The programs Cluster 
3.0 (Eisen Lab, Stanford University, Stanford, USA) and Java Treeview version 1.1.6r2 
(Saldanha, 2004) were used to generate heatmaps of the correlation coefficients and 
the cluster analysis (Figs. 1, 2). Cluster 3.0 settings were as follows: normalize, median 
- center and average linkage using uncentered correlation as similarity metric. Figure 3 
was generated in Excel. To generate the figures Inkscape 0.91 (Free Software Foundation 
Inc., Boston, USA) was used, next to the aforementioned programs.
Association of signaling pathways with drug response
For pathway analysis we analyzed gene expression levels of cell lines with a high IC
50
- 
versus cell lines with a low IC
50
-value per drug. Cell lines were grouped in the high or low 
group by individual evaluation per drug instead of pre-selecting a fixed IC
50
 value for all 
drugs. This method was chosen to test the drug response extremes rather than testing 
values with little difference, which are present in gradual IC
50
 distributions. For this 
distribution type we used the cell lines at the distribution extremes and removed the 
intermediate values to reduce noise. A few drugs showed an IC
50
 profile that precluded 
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a sensible grouping; e.g. Paclitaxel had only two cell lines with a high IC
50
 value while 
the others had a very low IC
50
; too few cell lines in a group renders the pathway analysis 
useless. For this reason, we excluded JNJ-208, Sirolimus, Docetaxel and Paclitaxel from 
the pathway analysis. For all other drugs, we were able to use meaningful group sizes 
of at least five samples each (Additional File 1).
For all cell lines, previously published mRNA expression data of our laboratory (Riaz et 
al., 2013) was used for pathway analysis (NCBI’s Gene Expression Omnibus database, 
entry GSE41313). Pathway analysis was performed using the Global Test package 
(Goeman et al., 2004) in R (R_Core_Team, 2013) with information of the databases 
BioCarta LLC (San Diego, USA) and KEGG (Ogata et al., 1999). This R package was also 
used to generate Figure 4, next to Excel 2007 and Inkscape 0.91. Furthermore, we also 
tested the identified pathways for a stronger association with breast cancer subtypes 
and disregarded those subtype-associated pathways (Additional File 2). The pathways 
significantly associated with a drug, including the subtype-associated ones, are listed 
in Additional File 2.
Association of drug response with breast cancer subtype and ER status
All drugs were tested for association with breast cancer cell line subtypes. First, cell lines 
were grouped into luminal, basal, ERBB2-overexpressing and normal-like on the basis 
of intrinsic subtypes as previously reported (Hollestelle et al., 2010b). Statistical testing 
was performed either in BRB Array Tools version 4.2.1 Class Comparison using a T-test 
or in Analyse-it version 2.26 (Leeds, UK) for Chi-Square tests. To test whether ER protein 
expression was significantly associated with drug response, a Mann-Whitney test was 
used for linear IC
50
 profiles and a Chi-Square or Fisher’s Exact test for two-group IC
50
 
profiles. Previously published ER protein expression data (Riaz et al., 2013) was used 
as a categorical variable for ER status.
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HER2 human epidermal growth factor receptor 2, Erb-b2 receptor tyrosine kinase 2
Her2-/neu Erb-b2 receptor tyrosine kinase 2
IC
50
inhibitory concentration 50, half maximal inhibitory concentration
KEGG Kyoto Encyclopedia of Genes and Genomes
MDM2 MDM2 proto-oncogene, E3 ubiquitin protein ligase
NaCl sodium chloride
NaOH sodium hydroxide
NCBI National Center for Biotechnology Information
PARP poly ADP ribose polymerase
PR progesterone receptor
RET ret proto-oncogene
RNA ribonucleic acid
RPMI Roswell Park Memorial Institute
SRB sulforhodamine B
TCA trichloroacetic acid
TP53 tumor protein p53
TRIS tris(hydroxymethyl)aminomethane
VEGFR vascular endothelial growth factor receptor, kinase insert domain receptor
VEGFR2 vascular endothelial growth factor receptor 2, kinase insert domain receptor
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Additional files can be accessed via https://doi.org/10.1186/s40064-015-1406-8.
Additional file 1. Detailed results of the drug screening and additional information 
regarding the data analysis. This table contains all calculated IC
50
 values for each 
drug and cell line. Furthermore the plotted IC
50
 values per drug are displayed and the 
categorization of the cell lines into resistant and sensitive per drug for the pathway 
analysis are listed.
Additional file 2. Pathways associated with drugs. This file lists all Biocarta and KEGG 
pathways that are significantly associated with at least one drug. Pathways that are 
more significantly associated with a breast cancer subtype are in italic. The p-values 
given are for the drug-pathway association.
3
50
Chapter 3
References
Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. (2003). Prospective 
identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. 100, 3983–3988.
Armand, J.-P., Burnett, A.K., Drach, J., Harousseau, J.-L., Löwenberg, B., and San Miguel, J. (2007). 
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib 
and tipifarnib. The Oncologist 12, 281–290.
Bast, R.C., Jr., Ravdin, P., Hayes, D.F., Bates, S., Fritsche, H., Jr., Jessup, J.M., Kemeny, N., Locker, 
G.Y., Mennel, R.G., and Somerfield, M.R. (2001). 2000 update of recommendations for the 
use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the 
American Society of Clinical Oncology. J Clin Oncol 19, 1865–1878.
Becker, J.P., Weiss, J., and Theile, D. (2014). Cisplatin, oxaliplatin, and carboplatin unequally inhibit 
in vitro mRNA translation. Toxicol. Lett. 225, 43–47.
Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, M., Mandelblatt, J.S., 
Yakovlev, A.Y., Habbema, J.D.F., and Feuer, E.J. (2005). Effect of Screening and Adjuvant 
Therapy on Mortality from Breast Cancer. N. Engl. J. Med. 353, 1784–1792.
Christman, J.K. (2002). 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: 
mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483–5495.
Cohen, R.B. (2003). Epidermal Growth Factor Receptor as a Therapeutic Target in Colorectal 
Cancer. Clin. Colorectal Cancer 2, 246–251.
Creusot, F., Acs, G., and Christman, J.K. (1982). Inhibition of DNA methyltransferase and induction 
of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2’-deoxycytidine. 
J Biol Chem 257, 2041–2048.
Desmedt, C., Voet, T., Sotiriou, C., and Campbell, P.J. (2012). Next-generation sequencing in 
breast cancer: first take home messages. Curr. Opin. Oncol. 24, 597–604.
Fornari, F.A., Randolph, J.K., Yalowich, J.C., Ritke, M.K., and Gewirtz, D.A. (1994). Interference by 
doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 45, 649–656.
Frederick, C.A., Williams, L.D., Ughetto, G., van der Marel, G.A., van Boom, J.H., Rich, A., and 
Wang, A.H. (1990). Structural comparison of anticancer drug-DNA complexes: adriamycin 
and daunomycin. Biochemistry 29, 2538–2549.
Glendenning, J., and Tutt, A. (2011). PARP inhibitors--current status and the walk towards early 
breast cancer. Breast Edinb. Scotl. 20 Suppl 3, S12-19.
Goeman, J.J., van de Geer, S.A., de Kort, F., and van Houwelingen, H.C. (2004). A global test for 
groups of genes: testing association with a clinical outcome. Bioinformatics 20, 93–99.
Gonzalez-Angulo, A.M., Morales-Vasquez, F., and Hortobagyi, G.N. (2007). Overview of resistance 
to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608, 1–22.
51
Understanding drugs in breast cancer through drug sensitivity screening
Gramza, A.W., Wells, S.A., Balasubramaniam, S., and Fojo, A.T. (2011). Phase I/II trial of vandetanib 
and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: 
Phase I results. J. Clin. Oncol. 29, 5565–5565.
Hagiwara, H., and Sunada, Y. (2004). Mechanism of taxane neurotoxicity. Breast Cancer 11, 
82–85.
Hajihassan, Z., and Rabbani-Chadegani, A. (2009). Studies on the binding affinity of anticancer 
drug mitoxantrone to chromatin, DNA and histone proteins. J. Biomed. Sci. 16:31.
Heiser, L.M., Sadanandam, A., Kuo, W.L., Benz, S.C., Goldstein, T.C., Ng, S., Gibb, W.J., Wang, 
N.J., Ziyad, S., Tong, F., et al. (2012). Subtype and pathway specific responses to anticancer 
compounds in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 109, 2724–2729.
Hollestelle, A., Elstrodt, F., Timmermans, M., Sieuwerts, A.M., Klijn, J.G.M., Foekens, J.A., den 
Bakker, M.A., and Schutte, M. (2010a). Four human breast cancer cell lines with biallelic 
inactivating α-catenin gene mutations. Breast Cancer Res. Treat. 122, 125–133.
Hollestelle, A., Nagel, J.H.A., Smid, M., Lam, S., Elstrodt, F., Wasielewski, M., Ng, S.S., French, 
P.J., Peeters, J.K., Rozendaal, M.J., et al. (2010b). Distinct gene mutation profiles among 
luminal-type and basal-type breast cancer cell lines. Breast Cancer Res. Treat. 121, 53–64.
Huang, Y., and Rizzo, R.C. (2012). A water-based mechanism of specificity and resistance for 
lapatinib with ErbB family kinases. Biochemistry 51, 2390–2406.
Huynh, H., Ngo, V.C., Fargnoli, J., Ayers, M., Soo, K.C., Koong, H.N., Thng, C.H., Ong, H.S., Chung, 
A., Chow, P., et al. (2008). Brivanib alaninate, a dual inhibitor of vascular endothelial growth 
factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth 
inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14, 6146–
6153.
Jansen, M.P.H.M., Foekens, J.A., van Staveren, I.L., Dirkzwager-Kiel, M.M., Ritstier, K., Look, 
M.P., Meijer-van Gelder, M.E., Sieuwerts, A.M., Portengen, H., Dorssers, L.C.J., et al. (2005). 
Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression 
Profiling. J. Clin. Oncol. 23, 732–740.
Jones, R.J., Gu, D., Bjorklund, C.C., Kuiatse, I., Remaley, A.T., Bashir, T., Vreys, V., and Orlowski, 
R.Z. (2013). The novel anticancer agent JNJ-26854165 induces cell death through inhibition 
of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther 346, 381–392.
Kangaspeska, S., Hultsch, S., Edgren, H., Nicorici, D., Murumagi, A., and Kallioniemi, O. (2012). 
Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple 
isoforms. PLoS One 7, e48745.
Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-hara, T., Song, Y., Engelman, J.A., and Fujita, 
N. (2013). Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition. 
Cancer Res. 73, 3087–3096.
3
52
Chapter 3
Keyvanjah, K., DePrimo, S.E., Harmon, C.S., Huang, X., Kern, K.A., and Carley, W. (2012). Soluble 
KIT correlates with clinical outcome in patients with metastatic breast cancer treated with 
sunitinib. J. Transl. Med. 10, 165.
Kittaneh, M., Montero, A.J., and Glück, S. (2013). Molecular Profiling for Breast Cancer: A 
Comprehensive Review. Biomark Cancer 5, 61–70.
Kumamoto, K., Spillare, E.A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., Nagashima, M., 
Takenoshita, S., Yokota, J., and Harris, C.C. (2008). Nutlin-3a activates p53 to both down-
regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, 
and induce senescence. Cancer Res 68, 3193–3203.
Lehman, J.A., Hauck, P.M., Gendron, J.M., Batuello, C.N., Eitel, J.A., Albig, A., Kadakia, M.P., and 
Mayo, L.D. (2013). Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels 
of glycolytic enzymes. PloS One 8, e74741.
Lemoine, M., and Younes, A. (2010). Histone deacetylase inhibitors in the treatment of lymphoma. 
Discov Med 10, 462–470.
Lichtenberg, F.R. (2009). The effect of new cancer drug approvals on the life expectancy of 
American cancer patients, 1978–2004. Econ. Innov. New Technol. 18, 407–428.
Lichtenberg, F.R. (2011). Despite steep costs, payments for new cancer drugs make economic 
sense. Nat Med 17, 244.
Longley, D.B., Harkin, D.P., and Johnston, P.G. (2003). 5-fluorouracil: mechanisms of action and 
clinical strategies. Nat. Rev. Cancer 3, 330–338.
Lyko, F., and Brown, R. (2005). DNA methyltransferase inhibitors and the development of 
epigenetic cancer therapies. J. Natl. Cancer Inst. 97, 1498–1506.
Momparler, R.L., Karon, M., Siegel, S.E., and Avila, F. (1976). Effect of adriamycin on DNA, RNA, 
and protein synthesis in cell-free systems and intact cells. Cancer Res 36, 2891–2895.
Nelson, M.H., and Dolder, C.R. (2006). Lapatinib: a novel dual tyrosine kinase inhibitor with 
activity in solid tumors. Ann Pharmacother 40, 261–269.
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., and Kanehisa, M. (1999). KEGG: Kyoto 
Encyclopedia of Genes and Genomes. Nucleic Acids Res. 27, 29–34.
Parker, J.S., Mullins, M., Cheang, M.C., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, 
X., Hu, Z., et al. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. 
J Clin Oncol 27, 1160–1167.
Perilongo, G., Maibach, R., Shafford, E., Brugieres, L., Brock, P., Morland, B., de Camargo, B., Zsiros, 
J., Roebuck, D., Zimmermann, A., et al. (2009). Cisplatin versus cisplatin plus doxorubicin for 
standard-risk hepatoblastoma. N. Engl. J. Med. 361, 1662–1670.
Ponti, D., Zaffaroni, N., Capelli, C., and Daidone, M.G. (2006). Breast cancer stem cells: an 
overview. Eur. J. Cancer Oxf. Engl. 1990 42, 1219–1224.
53
Understanding drugs in breast cancer through drug sensitivity screening
Previati, M., Manfrini, M., Galasso, M., Zerbinati, C., Palatini, J., Gasparini, P., and Volinia, S. 
(2013). Next generation analysis of breast cancer genomes for precision medicine. Cancer 
Lett. 339, 1–7.
Radovich, M., Clare, S.E., Atale, R., Pardo, I., Hancock, B.A., Solzak, J.P., Kassem, N., Mathieson, 
T., Storniolo, A.M., Rufenbarger, C., et al. (2013). Characterizing the heterogeneity of triple-
negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. 
Breast Cancer Res Treat 143(1), 57-68.
R_Core_Team (2013). R: A Language and Environment for Statistical Computing (Vienna, Austria).
Riaz, M., van Jaarsveld, M.T., Hollestelle, A., Prager-van der Smissen, W.J., Heine, A.A., Boersma, 
A.W., Liu, J., Helmijr, J., Ozturk, B., Smid, M., et al. (2013). MicroRNA expression profiling of 
51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. 
Breast Cancer Res 15, R33.
Saldanha, A.J. (2004). Java Treeview-extensible visualization of microarray data. Bioinformatics 
20, 3246–3248.
Sathornsumetee, S., and Rich, J.N. (2006). Vandetanib, a novel multitargeted kinase inhibitor, in 
cancer therapy. Drugs Today Barc 42, 657–670.
Scagliotti, G.V., Novello, S., and von Pawel, J. (2013). The emerging role of MET/HGF inhibitors 
in oncology. Cancer Treat. Rev. 39, 793–801.
Shangary, S., and Wang, S. (2009). Small-molecule inhibitors of the MDM2-p53 protein-protein 
interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev 
Pharmacol Toxicol 49, 223–241.
Sieuwerts, A.M., Kraan, J., Bolt, J., Spoel, P. van der, Elstrodt, F., Schutte, M., Martens, J.W.M., 
Gratama, J.-W., Sleijfer, S., and Foekens, J.A. (2009). Anti-Epithelial Cell Adhesion Molecule 
Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. J. Natl. Cancer 
Inst. 101, 61–66.
Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de 
Rijn, M., Jeffrey, S.S., et al. (2001). Gene expression patterns of breast carcinomas distinguish 
tumor subclasses with clinical implications. Proc Natl Acad Sci U A 98, 10869–10874.
Stordal, B., and Davey, M. (2007). Understanding cisplatin resistance using cellular models. 
IUBMB Life 59, 696–699.
Stordal, B., Pavlakis, N., and Davey, R. (2007). A systematic review of platinum and taxane 
resistance from bench to clinic: an inverse relationship. Cancer Treat. Rev. 33, 688–703.
Teicher, B.A., Ara, G., Herbst, R., Palombella, V.J., and Adams, J. (1999). The proteasome inhibitor 
PS-341 in cancer therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 5, 2638–2645.
The Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast 
tumours. Nature 490, 61–70.
3
54
Chapter 3
van ’t Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A.M., Mao, M., Peterse, H.L., van 
der Kooy, K., Marton, M.J., Witteveen, A.T., et al. (2002). Gene expression profiling predicts 
clinical outcome of breast cancer. Nature 415, 530–536.
Voigt, W. (2005). Sulforhodamine B assay and chemosensitivity. Methods Mol Med 110, 39–48.
Wang, Y., Klijn, J.G.M., Zhang, Y., Sieuwerts, A.M., Look, M.P., Yang, F., Talantov, D., Timmermans, 
M., Meijer-van Gelder, M.E., Yu, J., et al. (2005). Gene-expression profiles to predict distant 
metastasis of lymph-node-negative primary breast cancer. Lancet Lond. Engl. 365, 671–679.
55
Understanding drugs in breast cancer through drug sensitivity screening
3

Chapter 4MicroRNAs as possible 
indicators of drug sensitivity 
in breast cancer cell lines
Katharina Uhr, Wendy J. C. Prager-van der Smissen, 
Anouk A. J. Heine, Bahar Ozturk, Marijn T. M. van Jaarsveld, 
Antonius W. M. Boersma, Agnes Jager, Erik A. C. Wiemer, 
Marcel Smid, John A. Foekens, John W. M. Martens
PLoS One 2019;14(5):e0216400
58
Chapter 4
Abstract
MicroRNAs (miRNAs) regulate gene expression post-transcriptionally. In this way they 
might influence whether a cell is sensitive or resistant to a certain drug. So far, only a 
limited number of relatively small scale studies comprising few cell lines and/or drugs 
have been performed. To obtain a broader view on miRNAs and their association with 
drug response, we investigated the expression levels of 411 miRNAs in relation to drug 
sensitivity in 36 breast cancer cell lines. For this purpose IC
50
 values of a drug screen 
involving 34 drugs were associated with miRNA expression data of the same breast 
cancer cell lines. Since molecular subtype of the breast cancer cell lines is considered 
a confounding factor in drug association studies, multivariate analysis taking subtype 
into account was performed on significant miRNA-drug associations which retained 13 
associations. These associations consisted of 11 different miRNAs and eight different 
drugs (among which Paclitaxel, Docetaxel and Veliparib). The taxanes, Paclitaxel and 
Docetaxel, were the only drugs having miRNAs in common: hsa-miR-187-5p and hsa-
miR-106a-3p indicative of drug resistance while Paclitaxel sensitivity alone associated 
with hsa-miR-556-5p. Tivantinib was associated with hsa-let-7d-5p and hsa-miR-18a-
5p for sensitivity and hsa-miR-637 for resistance. Drug sensitivity was associated with 
hsa-let-7a-5p for Bortezomib, hsa-miR-135a-3p for JNJ-707 and hsa-miR-185-3p for 
Panobinostat. Drug resistance was associated with hsa-miR-182-5p for Veliparib and 
hsa-miR-629-5p for Tipifarnib. Pathway analysis for significant miRNAs was performed 
to reveal biological roles, aiding to find a potential mechanistic link for the observed 
associations with drug response. By doing so hsa-miR-187-5p was linked to the cell cycle 
G2-M checkpoint in line with this checkpoint being the target of taxanes. In conclusion, 
our study shows that miRNAs could potentially serve as biomarkers for intrinsic drug 
resistance and that pathway analyses can provide additional information in this context.
Introduction
Biomarkers of drug sensitivity/resistance are of great interest for the clinic as they 
allow for patient stratification – thereby identifying the most effective therapy for 
patients faster, reducing overtreatment and toxicity burden as well as saving costs. In 
the search for highly suited biomarkers irrespective of research field or application, 
microRNAs (miRNAs) have become increasingly popular due to their stability and broad 
applicability, underlining their potential as biomarkers (Cortez et al., 2011; Kim, 2015).
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MiRNAs are small oligonucleotides involved in multiple processes such as aging, tissue 
development and also cancer (Hammond, 2015; Lovat et al., 2011; Wiemer, 2007). 
They bind in a sequence-dependent fashion to mRNA 3’ UTRs leading to inhibition of 
messenger RNA (mRNA) translation, endonucleolytic cleavage of the mRNA or mRNA 
destabilization. Through affecting mRNA translation and stability, miRNAs ultimately 
regulate protein expression (Guo et al., 2010; Lin and Gregory, 2015). As miRNA-
recognition sequences are present in many genes, one miRNA can impact up to several 
hundred transcripts (Hausser and Zavolan, 2014; Huntzinger and Izaurralde, 2011; Iorio 
and Croce, 2012; Krol et al., 2010; Lin and Gregory, 2015; Varela et al., 2013).
Until now, several studies have been conducted to link miRNAs to treatment outcome 
(Fanini and Fabbri, 2016; Li and Yang, 2013). In these earlier studies, mainly drug-
resistant cell lines were generated, which were then compared to their parental cell 
lines to reveal differentially expressed miRNAs, which were subsequently studied in 
functional experiments. While these experiments are instrumental for a mechanistic 
understanding of miRNAs in drug sensitivity/resistance, such experiments do not 
necessarily identify predictors of drug resistance or sensitivity. Furthermore, most of 
these studies involved only one drug and were performed with a limited number of cell 
lines. As breast tumors can be classified into distinct subtypes with different clinical 
outcome (Blows et al., 2010; Sørlie et al., 2003) this should also be reflected in study 
design by including larger series of cell lines, together better resembling the clinical 
variability. Furthermore, screening for drug resistance against many drugs may not only 
identify miRNAs associated with one compound but may also identify miRNAs linked 
to sensitivity/resistance of more than one drug.
Therefore, we analyzed 36 well-characterized breast cancer cell lines that we screened 
for sensitivity to 34 compounds to obtain more clinically meaningful results on miRNAs 
and their potential as biomarkers for drug response in breast cancer. Our study showed 
that this approach was feasible and led to the identification of several miRNA-drug 
associations not found earlier.
Materials and methods
Breast cancer cell lines
Cell lines were cultured and profiled for correct identity as described previously (Riaz 
et al., 2013). In summary: Cell lines were cultured for RNA isolation until 70-80% 
confluence on collagen-coated petri dishes in triplicate. RPMI 1640 medium with 
4
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10% heat-inactivated fetal bovine serum and antibiotic agents (80 µg/ml (0.08 kg/m3) 
Streptomycin and 100 µg/ml (0.1 kg/m3) Penicillin G) was used as medium.
To ensure cell line identity, DNA of the 36 breast cancer cell lines was isolated using the 
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and subsequently subjected to short-
tandem repeat (STR) profiling using the PowerPlex16 system (Promega, Madison, WI, 
USA) following manufacturer’s protocol. A 3130xl Genetic Analyzer (Applied Biosystems, 
Foster City, CA, USA) was used for detection and Genemarker 1.91 software from 
Softgenetics (State College, PA, USA) was employed for analysis. STR profiles were 
compared with those deposited at the American Type Culture Collection (Manassas, 
VA, USA) and the Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(Braunschweig, Germany). For SUM cell lines, STR profiles were not available, so in-
house profiles from the earliest passages were compared with those generated later. 
Cell lines had been obtained between 1997 and 2006 from the following sources:
American Type Culture Collection (BT-20 (Lasfargues and Ozzello, 1958), BT-474 
(Lasfargues et al., 1978), BT-549 (Littlewood-Evans et al., 1997), CAMA-1 (Fogh et 
al., 1977), HCC1143 (Gazdar et al., 1998), HCC1395 (Gazdar et al., 1998), HCC1569 
(Ahmadian et al., 1997), HCC1806 (Ahmadian et al., 1997), HCC-1937 (Tomlinson et al., 
1998), HCC1954 (Gazdar et al., 1998), HCC202 (Gazdar et al., 1998), HCC38 (Sundaresan 
et al., 1998), HCC70 (Gazdar et al., 1998), Hs578T (Hackett et al., 1977), MCF-7 (Soule et 
al., 1973), MDA-MB-175VII (Cailleau et al., 1974), MDA-MB-231 (Cailleau et al., 1974), 
MDA-MB-361 (Cailleau et al., 1974), MDA-MB-415 (Cailleau et al., 1978), MDA-MB-436 
(Cailleau et al., 1978), MDA-MB-468 (Cailleau et al., 1978), SK-BR-3 (Trempe, 1976), T47D 
(Keydar et al., 1979), UACC812 (Meltzer et al., 1991)),
Dr. N. de Vleesschouwer (Institut Jules Bordet, Brussels, Belgium) (EVSA-T (Lippman 
et al., 1976)),
Dr. H.S. Smith (California Pacific Medical Center, San Francisco, CA, USA) (MPE-600 
(Smith et al., 1987)),
Dr. E. Stockert (Sloan-Kettering Institute for Cancer Research, New York, NY, USA) (SK-
BR-7 (Davidson et al., 2000)),
Ethier laboratory (BioIVT, West Sussex, UK) (SUM1315M02 (Forozan et al., 1999), 
SUM149PT (Forozan et al., 1999), SUM159PT (Forozan et al., 1999), SUM185PE (Forozan 
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et al., 1999), SUM190PT (Forozan et al., 1999), SUM229PE (Forozan et al., 1999), 
SUM44PE (Ethier et al., 1993), SUM52PE (Ethier et al., 1996)),
Riken Gene Bank (Tsukuba, Japan) (OCUB-M (Sawada et al., 1994))
Drug screening
Drug screening data was previously published for an extended cell line panel and the 
detailed description of drug-drug relations as well as the entire drug response dataset 
is available there (Uhr et al., 2015). In brief: The breast cancer cell lines were cultured 
and plated in triplicate in 96-well collagen-coated plates, and then incubated for 96 
hours with 12 serial dilutions of 37 drugs or vehicle per cell line. The drugs were supplied 
by Janssen Pharmaceutica (Beerse, Belgium) except for Veliparib, which was supplied 
by Abbott Laboratories (North Chicago, IL, USA). After 96 hours the Sulforhodamine B 
Assay was used to quantify total protein as a measure of cell number (Voigt, 2005) and 
IC
50
 values were computed subsequently (Uhr et al., 2015). Three drugs did not exhibit 
differential responses among the cell lines and were excluded from the final dataset 
(Uhr et al., 2015). Therefore, the present study included 34 drugs which were used for 
further analyses.
RNA isolation
RNA isolation was performed as described earlier (Riaz et al., 2013). To summarize: 
RNAzol-B reagent (Campro Scientific BV, Veenendaal, the Netherlands) was used 
for isolation of total RNA from all cell lines according to manufacturer’s protocol. 
Quality of isolated RNA was verified using spectrophotometric assessments of the 
A
260nm
/A
280 nm
 and the A
260nm
/A
230nm 
ratios, with the first required to have a value of 
approximately 2 and the second to have a value of 2 or higher. For these measurements 
a NanoDrop ND-1000 (Isogen Life Science, De Meern, the Netherlands) was used. 
Additional quality checks were performed as described earlier (Sieuwerts et al., 2005).
Gene expression profiling
Gene expression profiling was performed as previously described (Riaz et al., 2013). 
Reverse transcription was performed on 200 ng (2E-10 kg) of total RNA, followed by 
cDNA synthesis and the generation of biotin-labeled cRNA using the 3’ IVT express kit 
(Affymetrix, Santa Clara, CA, USA). Fragmentation of the labeled cRNA ensued and 
finally the fragmented and labeled cRNA was loaded on the Affymetrix GeneTitan. 
The hybridization mixture was loaded on Affymetrix Human_Genome_HT_HG-U133_
Plus_PM GeneChip 96-well arrays. The subsequent steps (hybridization, washing and 
scanning) were performed within the GeneTitan. In the Affymetrix Expression Console 
4
62
Chapter 4
the generated “.CEL” files were subjected to normalization employing the default 
settings of the RMA method. The generated data have been uploaded to the Gene 
Expression Omnibus data repository under the following access code: [GEO:GSE41313].
Breast cancer subtypes were determined using hierarchical clustering. Clusters were 
obtained with average distance linkage hierarchical clustering with non-centered 
correlation as distance metric. The three resulting clusters were matched to previously 
established intrinsic subtypes (Hollestelle et al., 2010) of these cell lines (which were 
based on a different chip-type) and the clusters were labeled as ‘basal’, ‘luminal’ and 
‘normal-like’.
miRNA expression profiling
The procedure employed for miRNA expression profiling has been described previously 
in detail (Pothof et al., 2009; Riaz et al., 2013). MiRNA expression data of cell lines with 
confirmed identity were used. To generate the data set, one microgram (1E-09 kg) 
of total RNA was labeled with the dye Cy3 using the ULS aRNA labeling kit (Kreatech, 
Amsterdam, the Netherlands). Only RNA samples with a labeling efficiency higher than 
15 pmol Cy3/µg RNA (1.5E-20 mol/kg) were used for hybridization. One sample was 
used per cell line. Hybridization was performed overnight. Normalization of the data was 
performed as previously described (Pothof et al., 2009). Labeled total RNA isolated from 
all cell lines was hybridized to home-made microarrays containing LNA modified capture 
probes from Exiqon (Vedbaek, Denmark) for the miRNA capture. This miRNA microarray 
design was based on miRBase version 10.0 (annotation version 13), contained 1344 
probes and had the capacity to measure the expression levels of 725 human miRNAs.
Within this dataset two miRNAs (hsa-miR-185 and hsa-miR-620) were represented twice 
on the microarray with differential probes. We removed the measurements with the 
older probes (hsa-miR-185 probe ID 5560 and hsa-miR-620 probe ID 32825) and kept 
the measurements of the newer probes (miRNA hsa-miR-185 probe ID 42902 and miRNA 
hsa-miR-620 probe ID 42994). We assessed whether the probe version influenced 
results, however, this was not the case.
The removal of the older probes resulted in a final number of 411 miRNAs expressed 
above background. MiRNA expression data has been published earlier (Riaz et al., 2013), 
except for the cell line OCUB-M, the miRNA expression data for this cell line can be 
found in S1 Table. The significant miRNAs are listed with the Exiqon oligonucleotide 
ID and the different miRBase (Griffiths-Jones et al., 2006) annotations, as well the 
corresponding MIMAT identifier in S2 Table.
63
MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines
Association of miRNA expression with IC50 values and co-expression analysis
By inspecting the results of the drug screening it became evident that the IC
50
 response 
curves for different drugs were very different across cell lines (see also Uhr et al. (Uhr 
et al., 2015)). While for some drugs most cell lines had different IC
50
 values, other drugs 
had a large number of cell lines with the same IC
50
 value up to almost all cell lines 
having identical IC
50
 values. Due to this it became clear that different analyses would 
be required to account for the different IC
50
 drug profiles. For most drugs, several cell 
lines had an IC
50
 value which was at the maximum of the tested drug concentration. 
Depending on the number of cell lines with values at maximum drug level, we chose 
to either use Spearman correlation (≤ 5 maximum IC
50
 values), a 2-step analysis (>5 IC
50
 
values at maximum & ≥10 IC
50
 values not at the maximum) or a Mann-Whitney test (<10 
IC
50
 values which are not at the maximum). MiRNA data were log10 – transformed for 
analyses, drug data were transformed to negative log 10 values.
The first step of the 2-step analysis consisted of Spearman correlation of those IC
50
 
values that were not at the maximum drug concentration (“variable IC
50
 values”) with 
miRNA expression values. Identified miRNA-drug associations were then tested in 
the second step, a Mann-Whitney test, classifying all IC
50
 values at maximum drug 
concentration as resistant and the remaining variable IC
50
 values as sensitive.
Over the results of each analysis group (Spearman correlation, 2-step analysis, Mann-
Whitney test), q-values (Storey and Tibshirani, 2003) were calculated to account for 
multiple testing. A q-value of 0.3 or lower was determined significant. The analysis type 
used per drug is listed in S3 Table. Analyses were performed in R (versions 3.4.4 up to 
3.5.1) (R Core Team, 2018) using the psych package (Revelle, 2018) and corr.test function 
for Spearman correlations, setting alpha at 0.05. The R function wilcox.test was used 
for Mann-Whitney testing. Q-values were calculated using the q value Bioconductor 
package (Dabney and Storey) in R.
Fig. 1 was created in Inkscape 0.92 (Free Software Foundation Inc., Boston, USA).
Multivariate analysis
MiRNAs significantly associated with drug response were evaluated in a multivariate 
analysis, including gene-expression-based breast cancer subtype as a co-variate. Linear 
regression was used, as only drugs with a linear IC
50
 profile had shown significant 
associations with miRNA expression. Subtypes were used as a binary variable: basal vs 
rest, luminal vs rest and normal-like vs rest. The IC
50
 values were used as the dependent 
variable, while the miRNA levels as well as one of the binary subtype groups were used 
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as independent variables. This regression model was run for each of the three binary 
subtype-groups separately and was calculated using Stata - version 13 (StataCorp, 
College Station, TX, USA).
Pathway analyses
Pathway analyses were performed on the mRNA data described above. The 11 significant 
miRNAs that were not related to subtype were analyzed by grouping the cell lines into 
top and bottom 25% based on the expression of the respective miRNA. This led to 9 
cell lines per group. The mRNA expression of top and bottom cell lines was analyzed for 
differences in R (R Core Team, 2018) using the Global Test package (Goeman et al., 2004) 
and Biocarta (San Diego, CA, USA) and KEGG (Ogata et al., 1999) pathway information. 
P-values were subjected to multiple testing correction (method “BH”, also known as 
“FDR”) and a permutation test (1000 permutations) of the non-adjusted p-value was 
used as an additional selection criterion. Associations with BH-adjusted p-values below 
0.1 and permutation p-values below 0.05 were deemed significant.
Results
Association of miRNAs with drug sensitivity
In the analysis we combined the data of 36 cell lines for which 34 drugs gave differential 
responses among the included cell lines (Uhr et al., 2015) and the expression data of 
411 miRNAs (Riaz et al., 2013).
To associate miRNA expression with drug response, we first inspected the IC
50
 profiles 
of all 34 compounds among the breast cancer cell lines. Based on the number of cell 
lines with a maximum IC
50
 value we chose one of three different analysis approaches 
as defined in Materials and Methods.
Only the drugs with “linear” IC
50
 values showed significant associations with miRNA 
expression upon q-value correction, totaling to 27 miRNA-drug associations (see Table 
1 and Fig 1).
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Table 1. MiRNAs associated with drug response
Drug MiRNA Association type R p-value q-value
Tivantinib hsa-let-7d-5p Sensitivity 0.57 3.96E-04 0.18
Tivantinib hsa-miR-18a-5p Sensitivity 0.57 3.88E-04 0.18
Tivantinib hsa-miR-637 Resistance -0.55 6.51E-04 0.24
Bortezomib hsa-let-7a-5p Sensitivity 0.57 2.94E-04 0.18
Docetaxel hsa-miR-187-5p Resistance -0.65 1.89E-05 0.07
Docetaxel hsa-miR-586 Resistance -0.65 1.99E-05 0.07
Docetaxel hsa-miR-106a-3p Resistance -0.58 2.26E-04 0.18
Docetaxel hsa-miR-338-3p Resistance -0.58 1.85E-04 0.18
JNJ-707 hsa-miR-135a-3p Sensitivity 0.55 5.15E-04 0.21
Mitoxantrone hsa-miR-497-3p Sensitivity 0.56 3.83E-04 0.18
Mitoxantrone hsa-miR-640 Resistance -0.58 1.95E-04 0.18
Mitoxantrone hsa-miR-101-3p Resistance -0.53 8.85E-04 0.27
Mitoxantrone hsa-miR-522-3p Resistance -0.53 9.67E-04 0.27
Mitoxantrone hsa-miR-125b-1-3p Sensitivity 0.52 1.07E-03 0.29
Paclitaxel hsa-miR-106a-3p Resistance -0.56 4.17E-04 0.18
Paclitaxel hsa-miR-187-5p Resistance -0.57 2.64E-04 0.18
Paclitaxel hsa-miR-522-3p Resistance -0.56 3.44E-04 0.18
Paclitaxel hsa-miR-586 Resistance -0.56 3.40E-04 0.18
Paclitaxel hsa-miR-556-5p Sensitivity 0.54 7.65E-04 0.26
Panobinostat hsa-miR-185-3p Sensitivity 0.54 6.47E-04 0.24
Quisinostat hsa-miR-27a-3p Resistance -0.53 9.06E-04 0.27
Serdemetan hsa-miR-182-5p Resistance -0.58 2.08E-04 0.18
Sirolimus hsa-miR-23a-3p Resistance -0.57 2.46E-04 0.18
Sunitinib hsa-miR-589-5p Sensitivity 0.54 7.35E-04 0.26
Tipifarnib hsa-miR-586 Resistance -0.57 3.54E-04 0.18
Tipifarnib hsa-miR-629-5p Resistance -0.54 9.01E-04 0.27
Veliparib hsa-miR-182-5p Resistance -0.63 4.25E-05 0.1
MiRNAs significantly associated with drug response. Associations were computed using Spearman’s 
correlation and the correlation coefficient (R) is given, next to the unadjusted p-value and the q-value.
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Fig 1. Overview of miRNAs associated with different drugs. The correlation coefficient is given on the 
y-axis. Associations with drug resistance are given in orange; associations with drug sensitivity are given 
in blue. Bor = Bortezomib, JNJ = JNJ-707, Mit = Mitoxantrone, Pan = Panobinostat, Qui = Quisinostat, 
Ser = Serdemetan, Sir = Sirolimus, Sun = Sunitinib, Tip = Tipifarnib, Vel = Veliparib.
Breast cancer subtype as potential confounder of miRNA drug associations
In a previous study (Uhr et al., 2015) we had found that certain breast cancer subtypes 
can respond differently to some drugs. As expression of certain miRNAs might be 
related to a specific subtype, we assessed our significant findings in a multivariate 
analysis. In this analysis we modeled the association between drug response and 
miRNA expression and subtype. All 27 associations were tested with subtype and the 
respective results are listed in S4 Table. Fourteen miRNA-drug associations were linked 
to one or more breast cancer subtypes. Basal subtype was associated stronger with 
the respective miRNA than the associated drug for the following associations: hsa-
miR-586 and Paclitaxel, hsa-miR-589-5p and Sunitinib and hsa-miR-586 and Tipifarnib. 
Luminal subtype affected the association between hsa-miR-27a-3p and Quisinostat as 
well as hsa-miR-23a-3p and Sirolimus. Normal-like subtype confounded the associations 
between hsa-miR-101-3p and Mitoxantrone, hsa-miR-125b-1-3p and Mitoxantrone, hsa-
miR-497-3p and Mitoxantrone, hsa-miR-640 and Mitoxantrone and hsa-miR-522-3p and 
Paclitaxel. Several associations were related to more than one subtype: These were the 
subtypes basal and luminal for the two Docetaxel-associated miRNAs hsa-miR-338-
3p and hsa-miR-586. Furthermore, the subtypes luminal and normal-like showed an 
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effect on the association between hsa-miR-522-3p and Mitoxantrone and the subtypes 
basal and normal-like were implicated in the association between hsa-miR-182-5p and 
Serdemetan.
Molecular subtype did not affect the 13 remaining miRNA-drug associations (8 drugs, 
11 miRNAs), which are highlighted in more detail below.
Sensitivity to the c-Met inhibitor Tivantinib (Munshi et al., 2010) was associated with 
the expression of two miRNAs, i.e. hsa-let-7d-5p and hsa-miR-18a-5p, while drug 
resistance was associated with hsa-miR-637. Drug sensitivity to the proteasome inhibitor 
Bortezomib (Lightcap et al., 2000) was associated with hsa-let-7a-5p expression. Among 
the microtubule-targeting taxanes Docetaxel and Paclitaxel (de Weger et al., 2014), we 
found that hsa-miR-106a-3p and hsa-miR-187-5p expression were positively correlated 
with drug resistance for both drugs. Hsa-miR-556-5p expression, however, was solely 
associated with Paclitaxel sensitivity. Hsa-miR-135a-3p expression was related to 
sensitivity to JNJ-707, a drug targeting FGF receptors (Uhr et al., 2015). Panobinostat, 
one of the HDAC inhibitors (Lemoine and Younes, 2010) in our screening, showed a 
positive correlation with hsa-miR-185-3p expression for drug sensitivity. For Tipifarnib, 
a farnesyltransferase inhibitor targeting RAS signal transduction (Norman, 2002), 
expression of hsa-miR-629-5p was associated with resistance to the drug, while drug 
resistance to the PARP inhibitor Veliparib (Glendenning and Tutt, 2011) was associated 
with hsa-miR-182-5p expression.
Besides the confounding effect of the breast cancer subtypes on some miRNA-drug 
associations, we also noted that several drugs had more than one associated miRNA, 
which led to our next analysis whether miRNAs are co-expressed.
Co-expression among miRNAs associated with the same drug
To study whether miRNAs that significantly associated with the same drug in univariate 
analysis showed a correlated expression pattern, we performed a correlation analysis. 
Below we discuss Tivantinib, Docetaxel and Paclitaxel, as each of these three drugs 
had several associated miRNAs unrelated to one of the breast cancer subtypes (see S4 
Table). Correlation coefficients and p-values are given in the S5-S7 Tables. In the case 
of Tivantinib the miRNAs hsa-miR-18a-5p and hsa-let-7d-5p showed a mild positive 
correlation with each other (R = 0.28), which was however not significant, while hsa-
miR-637 showed a significant negative association with the aforementioned miRNAs 
(R = -0.49 and -0.46, respectively). The two Docetaxel- and Paclitaxel-associated miRNAs 
hsa-miR-187-5p and hsa-miR-106a-3p showed an intermediate significant positive 
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correlation with each other (R = 0.40), while the other Paclitaxel-associated miRNA 
hsa-miR-556-5p was significantly negatively associated with hsa-miR-187-5p and hsa-
miR-106a-3p (R = -0.50 and -0.44, respectively).
Pathway analyses on significant miRNAs
In the next step, we performed pathway analyses to learn more about the biology of the 
miRNAs associated with drug response in the breast cancer cell lines. For this purpose 
we used those 11 miRNAs which were significantly associated with drug response 
independent of subtypes (see Table 1 and S4 Table). Messenger RNA expression data 
from the cell lines with the most differential expression of each miRNA (high versus 
low expression were compared; 9 per subgroup) were used as input for the pathway 
analysis. Pathways which were significantly different between samples with high or low 
expression of a tested miRNA are shown in Table 2.
Table 2. Pathways associated with miRNAs
MiRNA Pathway
Permutation 
p-value
BH-
adjusted 
p-value
Associated 
drugs
hsa-miR-106a-3p TPO Signaling Pathway (Biocarta) 1.00E-03 7.48E-02
Docetaxel, 
Paclitaxel
Nerve growth factor pathway NGF 
(Biocarta)
1.00E-03 7.48E-02
T Cell Receptor Signaling Pathway 
(Biocarta)
0.00E+00 9.74E-02
Insulin Signaling Pathway (Biocarta) 2.00E-03 9.74E-02
Signaling Pathway from GProtein 
Families (Biocarta)
3.00E-03 9.74E-02
Cadmium induces DNA synthesis 
and proliferation in macrophages 
(Biocarta)
3.00E-03 9.74E-02
EPO Signaling Pathway (Biocarta) 6.00E-03 9.74E-02
hsa-miR-135a-3p Pantothenate and CoA biosynthesis 
(KEGG)
0.00E+00 5.39E-02
JNJ-707
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Table 2. Continued
MiRNA Pathway
Permutation 
p-value
BH-
adjusted 
p-value
Associated 
drugs
hsa-miR-182-5p Intrinsic Prothrombin Activation 
Pathway (Biocarta)
4.00E-03 5.02E-02
Veliparib
Role of Tob in Tcell activation 
(Biocarta)
8.00E-03 5.02E-02
Acute Myocardial Infarction (Biocarta) 1.20E-02 5.02E-02
Actions of Nitric Oxide in the Heart 
(Biocarta)
1.20E-02 5.02E-02
Erythrocyte Differentiation Pathway 
(Biocarta)
1.30E-02 5.02E-02
Signal transduction through IL1R 
(Biocarta)
1.70E-02 5.02E-02
ALK in cardiac myocytes (Biocarta) 1.70E-02 5.02E-02
Cytokines and Inflammatory Response 
(Biocarta)
1.90E-02 5.02E-02
Integrin Signaling Pathway (Biocarta) 2.30E-02 5.02E-02
Estrogenresponsive protein Efp 
controls cell cycle and breast tumors 
growth (Biocarta)
3.00E-02 5.02E-02
Selective expression of chemokine 
receptors during Tcell polarization 
(Biocarta)
3.30E-02 5.02E-02
Cell Cycle G1 S Check Point (Biocarta) 3.30E-02 5.02E-02
Cytokine Network (Biocarta) 3.30E-02 5.58E-02
Phosphoinosit ides and their 
downstream targets (Biocarta)
4.10E-02 5.02E-02
Role of ERBB2 in Signal Transduction 
and Oncology (Biocarta)
4.30E-02 5.02E-02
Hypoxia and p53 in the Cardiovascular 
system (Biocarta)
4.40E-02 5.36E-02
Trefoil Factors Initiate Mucosal 
Healing (Biocarta)
4.70E-02 6.71E-02
TGFbeta signaling pathway (KEGG) 8.00E-03 8.41E-02
Focal adhesion (KEGG) 1.30E-02 8.41E-02
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Table 2. Continued
MiRNA Pathway
Permutation 
p-value
BH-
adjusted 
p-value
Associated 
drugs
hsa-miR-187-5p Selective expression of chemokine 
receptors during Tcell polarization 
(Biocarta)
3.00E-03 7.70E-02
Docetaxel, 
Paclitaxel
Trefoil Factors Initiate Mucosal 
Healing (Biocarta)
3.00E-03 7.70E-02
CXCR4 Signaling Pathway (Biocarta) 1.60E-02 7.70E-02
Regulation of eIF4e and p70 S6 Kinase 
(Biocarta)
1.80E-02 7.70E-02
Skeletal muscle hypertrophy is 
regulated via AKT mTOR pathway 
(Biocarta)
2.00E-02 7.70E-02
CARM1 and Regulation of the 
Estrogen Receptor (Biocarta)
2.10E-02 7.70E-02
Neuropeptides VIP and PACAP inhibit 
the apoptosis of activated T cells 
(Biocarta)
2.30E-02 7.70E-02
Estrogenresponsive protein Efp 
controls cell cycle and breast tumors 
growth (Biocarta)
2.80E-02 7.70E-02
Role of BRCA1 BRCA2 and ATR in 
Cancer Susceptibility (Biocarta)
2.80E-02 7.70E-02
Role of ERBB2 in Signal Transduction 
and Oncology (Biocarta)
3.30E-02 7.70E-02
Role of Tob in Tcell activation 
(Biocarta)
3.30E-02 8.44E-02
Cell Cycle G2 M Checkpoint (Biocarta) 3.50E-02 7.70E-02
mTOR Signaling Pathway (Biocarta) 3.90E-02 7.70E-02
Effects of calcineurin in Keratinocyte 
Differentiation (Biocarta)
4.20E-02 7.70E-02
Nitrogen metabolism (KEGG) 3.00E-03 2.56E-02
AminoacyltRNA biosynthesis (KEGG) 3.00E-03 2.77E-02
Valine leucine and isoleucine 
degradation (KEGG)
1.90E-02 3.35E-02
Pentose phosphate pathway (KEGG) 6.00E-03 4.87E-02
Wnt signaling pathway (KEGG) 4.80E-02 8.28E-02
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Table 2. Continued
MiRNA Pathway
Permutation 
p-value
BH-
adjusted 
p-value
Associated 
drugs
hsa-miR-556-5p Signaling Pathway from GProtein 
Families (Biocarta)
1.00E-03 4.86E-02
Paclitaxel
hsa-miR-637 Links between Pyk2 and Map Kinases 
(Biocarta)
1.00E-03 5.46E-02
Tivantinib
Pathways significantly associated with drug-associated miRNAs. Selection criteria for significant pathways 
were a permutation p-value below 0.05 and a Benjamini-Hochberg adjusted p-value below 0.1. The 
respective associated drugs are listed and highlighted in orange for an association of the miRNA with 
resistance to the respective drug and blue for an association with sensitivity.
For 6 of the 11 miRNAs we found significantly associated pathways. The miRNAs hsa-
miR-135a-3p, hsa-miR-556-5p and hsa-miR-637 each had only 1 pathway associated, 
while hsa-miR-106a-3p had 7 pathways associated and hsa-miR-182-5p and hsa-miR-
187-5p each had 19 pathways significantly associated. For the 3 miRNAs associated 
with multiple pathways, these pathways typically included the same genes such as in 
the case of hsa-miR-106a-3p with the genes JUN and FOS upregulated in all significant 
pathways and PIK3R1 being upregulated in 3 of the 7 pathways. In the case of hsa-miR-
182-5p many of the associated pathways had genes of the COL4A family and the TGF-β 
family downregulated, while for hsa-miR-187-5p several of the pathways contained the 
genes CXCR4, ESR1, PDK2, PTEN; as well as the ER-regulated genes TFF1 (Carroll et al., 
2005) and TFF3 (Tozlu et al., 2006).
Discussion
Our exploratory investigation showed that the expression of specific miRNAs can 
indicate drug sensitivity or resistance in breast cancer cell lines. In total, we were able 
to identify 21 different miRNAs associated with response to 13 different drugs, totaling 
up to 27 miRNA-drug associations. After excluding miRNAs that also associate with 
breast cancer subtype in multivariate analyses, 11 miRNAs involved in 13 miRNA-drug 
associations remained. Additional pathway analyses using available gene expression 
data gave insights into the associated biology for 6 of the significant miRNAs. To 
assess the applicability of these miRNAs as clinical biomarkers, further validation in 
independent sample series is needed to correct for possible additional parameters 
influencing drug response which were not considered here. Separately, the causal 
relation between the identified miRNA-drug associations in this hypothesis-generating 
study could be explored.
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To try to understand the subtype independent miRNA-drug associations we discuss 
the possible mechanistic links for the most significant results based on current state-
of-the-art knowledge.
The strongest miRNA-drug interaction was the association of hsa-miR-187-5p with 
Docetaxel resistance. This miRNA was additionally associated with Paclitaxel resistance. 
As taxanes have been known for a long time for their anti-tumorigenic activity and 
have been studied extensively (Band Horwitz, 1992), several resistance mechanisms 
are known: One of the main contributors to taxane resistance is the overexpression of 
multidrug transporters (e.g. P-gp; HGNC symbol: ABCB1) (Galletti et al., 2007). Besides, 
tubulin modifications (e.g. mutations) and alterations in the tubulin-microtubule 
system have been found such as altered expression of tubulin isoforms or associated 
proteins (e.g. MAP4 and Stathmin) (Galletti et al., 2007). While we did not find a clear 
link between hsa-miR-187-5p and one of these well-known resistance mechanisms, we 
found that this miRNA is associated with the pathway “Cell cycle G2-M checkpoint” 
and the “MTOR signaling” pathway (see Table 2). This is an interesting observation, 
as Paclitaxel is known to block cells between the G2 and the mitotic phase of the cell 
cycle (Band Horwitz, 1992). Furthermore, genes involved in the G2-M checkpoint and 
MTOR signaling were differentially expressed in residual breast tumors after Docetaxel 
treatment when compared to pre-treatment biopsies (Chang et al., 2005). In our study 
the genes in the G2-M checkpoint pathway are mainly downregulated in cell lines with 
high hsa-miR-187-5p expression, arguing that this miRNA might target several of the 
involved genes or an upstream regulator and in this way potentially increases cell cycle 
progression. Alternatively, hsa-miR-187-5p could be co-regulated with the genes in this 
pathway and as a result might affect events downstream.
The miRNA hsa-miR-106a-3p was also associated with Docetaxel and Paclitaxel 
resistance. In the pathway analysis, 7 pathways were significantly associated with 
this miRNA. Looking further into similarities between the pathways, it became clear 
that the genes JUN and FOS were part of all pathways and were clearly upregulated. 
Unfortunately only little is known about this miRNA and no link could be found between 
either the genes JUN and FOS or this miRNA with resistance to the two taxanes Docetaxel 
and Paclitaxel. As the expression of this miRNA is correlated to the expression of hsa-
miR-187-5p in our study, this miRNA could act in concert with hsa-miR-187-5p or its 
associated pathways but based on current knowledge the role of this miRNA in taxane 
resistance remains to be clarified at this stage.
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Within our drug screening, we had one PARP inhibitor, Veliparib (Bitler et al., 2017) 
and we observed that hsa-miR-182-5p was associated with resistance to this drug. This 
finding contrasts an earlier study in which hsa-miR-182-5p was found to target BRCA1 
and sensitized the breast cancer cell line MDA-MB-231 to PARP inhibitors (Moskwa 
et al., 2011). Neijenhuis et al. have studied miRNAs which sensitize cells to the PARP 
inhibitor Olaparib using a large miRNA mimic screening, but did not identify hsa-miR-
182-5p as involved in drug sensitivity (Neijenhuis et al., 2013). It is tempting to speculate 
that different miRNAs might play a role in the action of different PARP inhibitors, but 
the genetic makeup of studied cell lines/models might contribute (Neijenhuis et al., 
2013). Since our study contained a large number of cell lines we reduced the influence 
of the genetic makeup on the identified miRNA-drug association favoring a more general 
link with Veliparib response. In our study hsa-miR-182-5p was associated with a large 
number of pathways, including the pathway “Cell cycle G1-S check-point” (see Table 
2), which showed overall a downregulation. It remains, however, unclear how the 
downregulation of this cell cycle checkpoint might exactly contribute to drug resistance, 
although cell cycle changes have been earlier found as a drug resistance mechanism 
for PARP inhibitors (Bitler et al., 2017).
The drug Tivantinib targets the c-MET kinase and prevents it from downstream signaling 
(Pievsky and Pyrsopoulos, 2016). In our screening we found 3 miRNAs significantly 
associated with Tivantinib drug response. Hsa-let-7d-5p and hsa-miR-18a-5p were 
associated with drug sensitivity and hsa-miR-637 with drug resistance. Interestingly, 
others have found that hsa-miR-637 expression leads to downregulation of STAT3 
activity in hepatocellular carcinoma cells (Zhang et al., 2011) and STAT3 is one of the 
downstream activated proteins of c-MET activity (Organ and Tsao, 2011). Furthermore, 
HGF-c-MET signaling also leads to activation of the PI3K/AKT pathway (Gherardi et al., 
2012) and AKT1 has been identified as a direct target of hsa-miR-637 in pancreatic 
ductal adenocarcinoma cells (Xu et al., 2018). One can speculate that the inactivation of 
c-MET effector pathways (through AKT1 and STAT3) through this miRNA characterizes 
cells which rely on different pathways for growth and survival and therefore identifies 
cell lines inherently resistant to c-MET inhibitors.
Regarding Tivantinib sensitivity, one of the identified miRNAs was hsa-let-7d-5p. This 
miRNA has been shown to be downregulated by STAT3 in breast cancer cells (Guo 
et al., 2013). This contradicts the above hypothesis that Tivantinib-sensitive cells are 
characterized by active STAT3 and high hsa-let-7d-5p expression and Tivantinib-resistant 
cells have inactive/low STAT3 and high hsa-miR-637 expression. Nevertheless, we also 
observed a negative correlation between hsa-miR-637 and hsa-let-7d-5p in line with 
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their opposing association with drug sensitivity. Other factors might play an additional 
role here. The last Tivantinib-associated miRNA, hsa-miR-18a-5p, associated with 
drug sensitivity, did not show significantly correlated expression with hsa-let-7d-5p. 
Others have found that hsa-miR-18a-5p targets PIAS3 directly and in this way causes 
an increase in STAT3 transcriptional activity in gastric cancer cell lines (Wu et al., 2013) 
fitting with the hypothesis for hsa-miR-637.
For the proteasome inhibitor Bortezomib (Lightcap et al., 2000) several resistance 
mechanisms have been found. Thioredoxin reductase 1 (HGNC symbol: TXNRD1) 
upregulation has been linked to Bortezomib resistance via upregulation of NF-κB-
regulated genes in myeloma cells (Raninga et al., 2016), as well as the upregulation 
of heat shock proteins and related genes in several cancer types (Farrell and Reagan, 
2018). Further resistance mechanisms are upregulation of proteasome subunits or 
increased proteasome activity which were observed in mesothelioma and myeloma 
(Farrell and Reagan, 2018). Upregulation of the aggresome/autophagy pathway (both 
in myeloma), and constitutive NF-κB or AKT signaling in multiple myeloma have also 
been observed (Wallington-Beddoe et al., 2018). Hsa-let-7a-5p was associated with 
Bortezomib sensitivity in our study. This miRNA has been shown to target KBRAS2 
(NKIRAS2), an inhibitor of NF-κB signaling and seems to be itself upregulated upon 
NF-κB signaling in human macrophages (Murphy et al., 2010). Hsa-let-7a-5p targets 
furthermore a negative regulator of NF-κB signaling, TNFAIP3, in HEK293T cells (Liu et 
al., 2015). NF-κB pathway inhibition is one of the effects of Bortezomib treatment (Farrell 
and Reagan, 2018), but generally activation of NF-κB signaling has been implicated in 
Bortezomib resistance (Wallington-Beddoe et al., 2018). Interestingly, there has been 
one report stating that upregulation of NF-κB signaling due to treatment with Lapatinib 
sensitized cells to Bortezomib in triple-negative breast cancer (Chen et al., 2013). It 
remains therefore unclear whether upregulation of NF-κB signaling aids to sensitize 
cells to Bortezomib or increases drug resistance in breast cancer and whether hsa-let-
7a-5p increases Bortezomib sensitivity via downregulation of NKIRAS2 and TNFAIP3.
Sensitivity to the FGFR inhibitor JNJ-707 (Uhr et al., 2015) was associated with hsa-miR-
135a-3p, however, so far very little is known about this miRNA and unfortunately no 
information supporting the association with this drug could be found.
For the histone deacetylase (HDAC) inhibitor Panobinostat (Lemoine and Younes, 2010) 
several resistance mechanisms have been observed such as overexpression of the anti-
apoptotic protein Bcl-2 in cutaneous T-cell lymphoma patients (Lee et al., 2012). Of 
interest is also the observation that Panobinostat treatment led to activation of NF-κB 
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signaling in leukemic cells and the blockage of this signaling increased sensitivity to the 
drug (Rosato et al., 2010). In our study, we found that the expression of hsa-miR-185-3p 
was associated with sensitivity to Panobinostat. However, little is known so far about 
the functions of this miRNA and there are no known targets which could explain how 
this miRNA might sensitize cells to Panobinostat.
For the farnesyltransferase inhibitor Tipifarnib (Norman, 2002), there are a few reports 
on resistance mechanisms. In previously untreated AML patients a 2-gene-classifier 
has been found which can predict response to Tipifarnib (Raponi et al., 2008). Patients 
responding to treatment are characterized by high expression of RASGRP1, a guanine 
nucleotide exchange factor which can activate RAS and low expression of APTX, a 
protein involved in DNA excision repair (Raponi et al., 2008). One of the properties 
Tipifarnib has is the inhibition of RAS farnesylation (Raponi et al., 2007) and the 
upregulation of RASGRP1 might characterize cancer cells which rely on RAS signaling. 
In our study hsa-miR-629-5p was associated with Tipifarnib resistance, however, based 
on the current knowledge about this miRNA, it is unclear if there is a direct mechanistic 
link between the observed drug resistance and the miRNA and how this miRNA might 
influence drug response.
Among the miRNA-drug associations where subtype played a role, hsa-miR-23a-3p was 
expressed lower in luminal cell lines. Others have found that this miRNA targets the 
progesterone receptor (Gilam et al., 2017) and seems to be downregulated by estradiol 
(Saumet et al., 2012), which could support preferential expression of this miRNA in 
triple-negative cell lines. Hsa-miR-338-3p was expressed lower in the basal subtype 
and higher in the luminal subtype. The basal subtype in cell lines is characterized by 
EGFR expression in contrast to the luminal subtype which typically lacks expression 
of this protein (Hollestelle et al., 2010). Interestingly it has been shown that EGFR 
expression downregulates hsa-miR-338-3p expression (Liang et al., 2017), matching 
our observations on the breast cancer cell lines.
Conclusions
We were able to identify several miRNAs associated with drug resistance or drug 
sensitivity in our large panel of breast cancer cell lines. Several of the miRNAs found 
in our screen have been linked to pathways targeted by the drugs or genes involved in 
drug-resistance mechanisms. Next to those associations, we also identified a number 
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of miRNAs, which have not been researched much in the context of drug sensitivity/
resistance so far but may hold great potential once more is known about their biology.
Besides identifying miRNAs associated with drugs already used in the clinic we also 
identified miRNAs associated with several new anticancer agents, which are expected 
to enter the clinic in the coming years. Since biomarkers can help in discriminating 
those patients which will respond better to therapy and miRNAs are well measurable, 
further research into this topic will be of great value and might potentially validate 
these miRNAs as biomarkers.
In conclusion, our hypothesis-generating study suggests that miRNAs could be used as 
predictors of drug response and once independently validated and/or experimentally 
confirmed holds great potential for an application in the clinic.
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Abstract
The large number of non-coding RNAs (ncRNAs) and their breadth of functionalities 
has fuelled many studies on their roles in cancer. We previously linked four microRNAs 
to breast cancer prognosis. One of these microRNAs, hsa-miR-7, was found to be 
regulated by another type of ncRNA, the circular non-coding RNA (circRNA) CDR1-AS, 
which contains multiple hsa-miR-7 binding sites. Based on this finding, we studied the 
potential clinical value of this circRNA on breast cancer prognosis in a cohort based on 
a cohort that was previously analysed for hsa-miR-7 and in an adjuvant hormone-naïve 
cohort for 1st-line tamoxifen treatment outcomes, in which we also analysed hsa-miR-7.
A negative correlation was observed between hsa-miR-7 and CDR1-AS in both cohorts. 
Despite associations with various clinical metrics (e.g., tumour grade, tumour size, and 
relapse location), CDR1-AS was neither prognostic nor predictive of relevant outcomes 
in our cohorts. However, we did observe stromal CDR1-AS expression, suggesting a 
possible cell-type specific interaction. Next to the known association of hsa-miR-7 
expression with poor prognosis in primary breast cancer, we found that high hsa-
miR-7 expression was predictive of an adverse response to tamoxifen therapy and poor 
progression-free and post-relapse overall survival in patients with recurrent disease.
Introduction
Non-coding RNAs (ncRNAs) (The ENCODE Project Consortium, 2012) are defined as 
genes that are transcribed into RNAs, but not translated into proteins, and are not 
structural RNAs like tRNA or rRNA (Storz, 2002). MicroRNAs, which regulate mRNA 
translation (Esteller, 2011), are likely the best studied subgroup of ncRNAs; however, 
apart from this family is the recently recognised large group of long non-coding RNAs 
(lncRNAs) (Iyer et al., 2015). These lncRNAs are over 200 nt long (Ma et al., 2013) and 
have a multitude of mechanisms that affect cellular activity, e.g., (1) by influencing the 
accessibility of genes to the transcriptional machinery by interacting with chromatin 
modifiers (Delás and Hannon, 2017); (2) by supporting DNA looping, promoter binding 
and activator/transcription factor recruitment, which can increase gene expression 
(Delás and Hannon, 2017; Iyer et al., 2015); (3) by influencing mRNA splicing and mRNA 
stability and increasing translation (Delás and Hannon, 2017); and (4) by influencing 
protein phosphorylation, methylation and stability (Delás and Hannon, 2017).
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Importantly, it has been recognised that specific lncRNAs can also interfere with 
microRNA functionality via several binding sites on their sequence, soaking up target 
microRNAs like a sponge (Hansen et al., 2013). Interestingly, microRNA binding does 
not necessarily lead to the degradation of a particular lncRNA (Hansen et al., 2013). One 
recently described lncRNA of this type is CDR1-AS, a circular RNA (circRNA) (Hansen 
et al., 2013), which is also known as ciRS-7, CDR1as or CDR1NAT, that specifically 
binds human microRNA-7 (hsa-miR-7) via 73 binding sites (Hansen et al., 2013). This 
interaction is conserved between human and mouse and probably other species as 
well (Hansen et al., 2013). CDR1-AS is generated from a linear transcript, following the 
general observation that circRNAs are spliced from longer transcripts and it shares 
a promoter with the lncRNA LINC00632, which is about 50x less abundant than the 
circRNA (Barrett et al., 2017).
CircRNAs are generally characterised as having high stability (transcript half-life), which 
is likely due to their resistance to exonucleases because of their circular conformation 
(Jeck et al., 2013). Furthermore, it has been shown that circRNAs show tissue-specific 
expression (Maass et al., 2017) and are involved in cellular differentiation (Kristensen 
et al., 2018a) and pluripotency (Yu et al., 2017). CircRNAs have a diverse range of 
functions, including influencing transcription, splicing and the translation of their host 
genes; serving as scaffolds for enzymes and substrates to enhance reaction kinetics 
and co-localization; functioning as protein sponges for RNA-binding proteins that can 
influence protein decoy; acting as microRNA sponges; and expressing peptides under 
rare circumstances (Kristensen et al., 2018b). At this point, there are several known 
mechanisms of circRNA biogenesis from linear transcripts, besides factors influencing 
their splicing (Kristensen et al., 2018b). It has been shown that reverse-complement 
ALU repeats are located to the right and left of the circularised sequence in some 
cases (Kristensen et al., 2018b). Furthermore, splicing factors have been shown to bind 
in the vicinity of encoded circRNAs, while in other cases, a lariat structure has been 
observed as a precursor molecule that includes the exon that was later identified to be 
a circRNA (Kristensen et al., 2018b). Finally, a less common mechanism involves RNA-
binding proteins that are located further away from the circRNA, which can be classified 
as trans-acting factors (Kristensen et al., 2018b).
In regard to expression in malignancies, circRNAs have been found to show abnormal 
expression in haematological cancers as well as in several solid tumour types, such 
as colorectal cancer, lung cancer, kidney cancer, liver cancer, bladder cancer, gastric 
cancer, prostate cancer, CNS tumours, ovarian cancer and breast cancer (Kristensen 
et al., 2018b).
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The multi-facetted microRNA hsa-miR-7 is known to play roles in the differentiation 
of the intestinal epithelium (Nguyen et al., 2010) and regulation of β-cell proliferation 
(Wang et al., 2013b), as well as to influence toll-like receptor 9 growth signalling in 
lung cancer cells (Xu et al., 2013) and photoreceptor development in Drosophila (Li and 
Carthew, 2005). Hsa-miR-7 has also been implied in several cancer types, including lung 
cancer (Chou et al., 2010), renal cancer (Yu et al., 2013) and colorectal cancer (Zhang 
et al., 2013).
In 2008, we discovered that hsa-miR-7 was a prognostic marker in hormone receptor-
positive breast cancer (Foekens et al., 2008). Considering the fact that CDR1-AS is now 
recognised to be an hsa-miR-7 sponge (Hansen et al., 2013), we addressed whether 
CDR1-AS expression was related to hsa-miR-7 expression and, if so, whether its 
expression was also associated with breast cancer prognosis. To determine this, we 
used a cohort of patients with lymph node-negative (LNN) disease who did not receive 
any type of systemic adjuvant treatment to study the link with pure prognosis, i.e., the 
natural course of the disease (hereafter also named prognostic cohort). Additionally, to 
determine whether CDR1-AS and/or hsa-miR-7 expression may have predictive value, 
we studied their relationship with the response to tamoxifen therapy and the lengths of 
progression-free survival (PFS) and post-relapse overall survival (PR-OS) in an adjuvant 
hormone-naïve cohort of patients who received tamoxifen as a 1st-line treatment for 
recurrent disease (hereafter named predictive cohort).
Results
Cell lines
To determine whether CDR1-AS is variably expressed, we initially measured CDR1-AS 
expression in several breast cancer cell lines, a breast tumour pool, an endothelial cell 
line, a stromal fibroblast strain, and several sorted immune cells of healthy donors (for 
included specimens, see Supplementary Fig. 1). This analysis showed that CDR1-AS was 
differentially expressed among the breast cancer cell line subtypes (see Supplementary 
Table S1), with higher CDR1-AS levels in the luminal and normal-like subtypes (Fig. 1). 
CDR1-AS expression was not only confined to breast cancer cells but was also detectable 
in other cell types present in tumours, as shown by the CDR1-AS expression in the 
endothelial cell line, the T cells, the granulocytic NK cells and the fibroblast strain, with 
especially high expression levels in the fibroblast strain derived from a patient’s stroma 
(Fig. 1). Furthermore, CDR1-AS was not only expressed by the cultured cell lines but was 
also present in a pooled sample containing cDNA from 100 different breast tumours. 
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Altogether, the variable CDR1-AS expression provided a rationale to proceed with our 
study on the clinical relevance of this circRNA in our two breast cancer cohorts.
Figure 1. CDR1-AS expression in breast cancer cells and cell lines. Normalised CDR1-AS expression is shown 
in different breast cancer cell line subtypes (basal-like, ERBB2+, luminal and normal-like) on a logarithmic 
scale. Variations in expression levels within one subtype group are displayed as the standard deviation using 
error bars. N indicates the number of cell lines assessed per subtype group. Aside from the breast cancer 
cell lines, the expression is also shown for several immune cell types (CD4+ T helper cells, CD8+ cytotoxic 
T cells, CD56+ granulocytic NK cells and HLA-DR+ APCs), an endothelial cell line, a stromal fibroblast strain 
and a sample consisting of pooled material from different breast tumours. The HLA-DR+ APCs were from 
donor A, all other immune cells are from donor B. Of note is that the CD8+ T cells unfortunately showed a 
lower purity (61%) in contrast to the other immune cells (75%-96% purity). The measured expression value 
is listed below each sample type.
Hsa-miR-7 and CDR1-AS expression and prognosis
The first cohort evaluated for CDR1-AS expression consisted of RNA isolated from primary 
tumours from LNN breast cancer patients, including oestrogen receptor (ER, ESR1)-positive 
and ER-negative patients, who did not receive systemic adjuvant therapy (n = 345) (see the 
REMARK diagram in Supplementary Fig. 1) (prognostic cohort). This cohort included some 
of the ER-positive breast cancers in which we originally discovered that high hsa-miR-7 
expression was a marker for worse prognosis (Foekens et al., 2008) (see Supplementary 
Table S2 and Supplementary Fig. 1 for details). The patient overlap with our previous study 
was substantial (244 out of the n = 345 samples included in this study). The number of 
patients included in this study differed from our previous study because of the inclusion of 
additional available eligible patients (n = 101) as well as the exclusion of patients due to the 
lack of RNA or available qPCR data (n = 55). Furthermore, due to the differences in the ER 
expression measurement methods (mRNA- versus protein-based), the classification of some 
patients differed between the two studies (see Supplementary Table S2). As CDR1-AS has 
been shown to counteract hsa-miR-7 (Hansen et al., 2013), we determined the association 
between hsa-miR-7 and CDR1-AS in the 345 primary breast tumours from this prognostic 
cohort (Table 1). We observed an inverse correlation with CDR1-AS expressed at higher levels 
in the tumours with lower hsa-miR-7 expression levels (Spearman rs -0.245, P < 0.0001).
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Table 1. Associations of hsa-miR-7 with CDR1-AS and clinical parameters in the prognostic patient cohort
CDR1-AS hsa-mir-7
Parameters n
median 
expression
[IQR]
P
median 
expression 
[IQR]
P
All patients 345 4.97 [8.74] 0.034 [0.053]
hsa-miR-7 expression
1st quantile (low) 173 7.16 [10.02]
2nd quantile (high) 172 3.52 [6.78] < 0.001
Age at time of surgery (years)
≤40 38 3.37 [8.88] 0.039 [0.044]
>40-≤ 55 134 5.09 [7.84] 0.032 [0.057]
>55-≤ 70 117 5.65 [9.04] 0.033 [0.050]
>70 56 4.46 [8.26] 0.37 0.047 [0.063] 0.58
Menopausal status
Premenopausal 153 4.69 [8.31] 0.033 [0.057]
Postmenopausal 192 5.19 [8.90] 0.84 0.035 [0.057] 0.74
Pathological tumour size
pT1 161 6.95 [9.31] 0.029 [0.042]
pT2 + unknown 171 3.97 [7.14] 0.037 [0.066]
pT3+pT4 13 3.66 [13.7] 0.013 0.055 [0.032] 0.024
Tumour grade
Poor 197 4.72 [8.07] 0.043 [0.062]
Unknown 95 3.58 [7.87] 0.033 [0.051]
Moderate/Good 53 8.63 [7.87] 0.001 0.023 [0.027] <0.001
Tumour cell content
30-70% 230 6.10 [9.38] 0.033 [0.053]
>70% 115 3.48 [7.78] < 0.001 0.042 [0.061] 0.08
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Table 1. Continued
CDR1-AS hsa-mir-7
Parameters n
median 
expression 
[IQR]
P
median 
expression 
[IQR]
P
Hormone receptor/growth factor status (RT-qPCR)*
ESR1-negative 120 4.21 [7.84] 0.046 [0.062]
ESR1-positive 225 5.41 [8.92] 0.10 0.030 [0.047] 0.007
PGR-negative 158 4.21 [7.84] 0.046 [0.066]
PGR-positive 187 5.41 [9.47] 0.08 0.028 [0.045] <0.001
ERBB2-non-amplified 294 5.49 [9.07] 0.033 [0.054]
ERBB2-amplified 51 3.97 [6.17] 0.22 0.039 [0.059] 0.43
EGFR quantile 1 (low) 115 2.84 [4.85] 0.042 [0.062]
EGFR quantile 2 (in between) 116 7.61 [9.61] 0.031 [0.059]
EGFR quantile 3 (high) 114 6.24 [10.12] <0.001 0.032 [0.046] 0.042
For the analysis on the association between hsa-miR-7 expression and CDR1-AS expression, patients were 
divided into two equally sized groups based on median hsa-miR-7 expression level. Next to this analysis 
result, the associations of the clinical parameters with hsa-miR-7 and CDR1-AS gene expression are 
listed. The median CDR1-AS and hsa-miR-7 expression levels per subcategory, including the interquartile 
range (IQR) are given additionally. Pathological tumour size is defined as follows: pT1 <= 2 cm, pT2 > 2 
cm and <= 5 cm, pT3 > 5 cm, and pT4 = tumour with direct extension to chest wall and/or skin. *Cut-offs 
for positive and negative hormone receptor/growth factor status established as previously described 
(van Agthoven et al., 2009; Sieuwerts et al., 2007). P = p-value and n = number of patients. Significant 
p-values are printed in bold.
Association of hsa-miR-7 and CDR1-AS with clinical variables
We next assessed whether CDR1-AS expression associated with the same traditional 
prognostic clinical parameters as hsa-miR-7 did. No association was found for both 
markers with age, menopausal status or ERBB2 status, while only hsa-miR-7 was negatively 
associated with ESR1 and progesterone receptor (PGR). By contrast, both markers were 
associated, although in opposite directions, with tumour size and tumour grade, indicating 
that high CDR1-AS levels were associated with good prognosis characteristics and high 
hsa-miR-7 levels with poor prognosis characteristics. Additionally, CDR1-AS expression 
was found to be higher in tumours with a tumour cell content below 70%, i.e., tumours 
with a higher number of immune or stromal cells (Table 1).
A well-known target of hsa-miR-7 is the epidermal growth factor receptor (EGFR) (Webster 
et al., 2009). We therefore also assessed whether CDR1-AS might show a positive 
association with EGFR mRNA expression, and this was the case. The results showed higher 
CDR1-AS (and lower hsa-miR-7) expression in EGFR-high expressing tumours (Table 1).
6
122
Chapter 6
Hsa-miR-7 and CDR1-AS in metastasis-free survival (MFS) and overall survival (OS) in 
the prognostic patient cohort
We next studied whether the length of metastasis-free survival time (MFS) was 
correlated with hsa-miR-7 and/or CDR1-AS expression. In the Cox univariate regression 
analysis, high hsa-miR-7 levels were associated with poor prognosis in this cohort, 
including 225 ER-positive and 120 ER-negative patients, while CDR1-AS expression was 
not associated (Table 2).
Table 2. Univariate association of CDR1-AS and hsa-miR-7 with MFS in the prognostic cohort
Clinical parameters
CDR1-AS hsa-miR-7
n HR (95% CI) P n HR (95% CI) P
All patients 345 1.02 (0.90-1.16) 0.76 345 1.14 (1.00-1.30) 0.043
Hormone receptor/growth factor expression (RT-qPCR)*
ESR1-negative 120 1.10 (0.83-1.45) 0.50 120 1.03 (0.77-1.37) 0.86
ESR1-positive 225 0.98 (0.84-1.12) 0.31 225 1.21 (1.06-1.38) 0.006
The association of CDR1-AS/hsa-miR-7 expression and MFS in all patients and the patient subgroups 
based on ESR1 expression is displayed. *Cut-offs for positive and negative hormone receptor/growth 
factor status were established as previously described (van Agthoven et al., 2009; Sieuwerts et al., 2007). 
n = number of patients, HR = hazard ratio, CI = confidence interval, and P = p-value. Significant p-values 
are printed in bold.
As ER-positive and ER-negative breast cancers can be considered two different diseases (due 
to different treatment requirements (Hammond et al., 2010) and profound differences in gene 
expression (Perou et al., 2000)), we also evaluated whether our genes of interest showed an 
association with MFS in the respective ER subgroups. High hsa-miR-7 levels were strongly 
associated with a shorter MFS in ER-positive patients, but not in ER-negative patients, while 
CDR1-AS expression was not associated with the length of MFS in either ER subgroup (Table 2). 
Similar to our previous study (Foekens et al., 2008), hsa-miR-7 (split at the median expression 
level) remained an independent biomarker for poor prognosis among ER-positive patients after 
correcting for the traditional prognostic factors: age, menopausal status, tumour size, grade, 
ESR1, PGR and ERBB2 status (HR = 1.53, 95% CI 1.02-2.31, P = 0.04). Finally, we also related 
hsa-miR-7 and CDR1-AS expression to the length of overall survival time (OS) in the complete 
prognostic cohort. Using Cox univariate regression analysis, among the two genes, only hsa-
miR-7 expression was associated with the OS length, with high hsa-miR-7 levels being predictive 
of an earlier death (Table 3). However, this finding was not significant in the multivariate 
analysis (P > 0.05) (Table 3). In the ER-positive subset hsa-miR-7 was associated with OS, a 
finding which remained significant in the multivariate analysis, including the traditional clinical 
factors (HR = 1.19, 95% CI 1.01-1.42, P = 0.041) (cohort size was n = 225 in the univariate analysis 
and n = 213 in the multivariate analysis due to the lack of some clinical data).
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Table 3. Uni- and multivariate association of overall survival (OS) with CDR1-AS, hsa-miR-7 and other 
clinical variables in the prognostic cohort
Parameters
univariate model n = [345] multivariate model [n = 331]
n HR (95% CI) P n** HR (95% CI) P
345
Age at time of surgery (years)
≤40 years 45 1 43 1
41-50 years 96 0.94 (0.57-1.54) 0.80 94 1.10 (0.64-1.87) 0.74
51-70 years 159 1.14 (0.72-1.80) 0.58 152 1.29 (0.60-2.75) 0.51
>70 years 45 0.93 (0.49-1.77) 0.83 42 0.97 (0.37-2.52) 0.95
Menopausal status
Premenopausal 153 1 149 1
Postmenopausal 192 1.11 (0.82-1.51) 0.50 182 0.93 (0.49-1.78) 0.84
Pathological tumor size**
≤2 cm 155 1 155 1
>2 cm 176 1.30 (0.95-1.78) 0.10 176 1.31 (0.94-1.83) 0.11
Tumour grade
Poor 197 1 194 1
Unknown 95 1.01 (0.71-1.44) 0.94 85 0.75 (0.64-1.38) 0.75
Moderate/ Good 53 0.74 (0.47-1.18) 0.21 52 0.58 (0.53-1.42) 0.58
Hormone/growth factor receptors*
ER (log continuous ESR1) 345 0.99 (0.94-1.05) 0.88 331 1.08 (0.99-1.18) 0.08
PR (log continous PGR) 345 0.95 (0.89-1.00) 0.07 331 0.90 (0.82-0.98) 0.020
HER2 (ERBB2) status
Not amplified 294 1 280 1
Amplified 51 1.44 (0.97-2.14) 0.07 51 1.51 (1.00-2.27) 0.048
hsa-miR-7 separately added to the 
base model
CDR1-AS (log 
continuous)
345 1.03 (0.90-1.17) 0.69
hsa-miR-7 (log 
continuous)
345 1.16 (1.02-1.32) 0.028 331 1.12 (0.97-1.29) 0.11
≤median 173 1 165 1
>median 172 1.42 (1.04-1.92) 0.025 166 1.37 (0.98-1.92) 0.07
The association of CDR1-AS and hsa-miR-7 gene expression with overall survival is displayed for the 
prognostic cohort. The univariate model is on the left side of the table and the multivariate model is 
displayed on the right side. *Cut-offs for positive and negative hormone receptor/growth factor status 
were established as previously described (van Agthoven et al., 2009; Sieuwerts et al., 2007). **In these 
analyses, clinical data are missing, and therefore, the included patients do not add up to 345. n = number 
of patients, HR = hazard ratio, CI = confidence interval, P = p-value. Significant p-values are highlighted 
in bold.
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Hsa-miR-7 and CDR1-AS in the recurrent breast cancer cohort
Based on the prognostic value of hsa-miR-7 in the ER-positive patients, we were 
interested to assess whether the two ncRNAs could be predictive factors for the type 
of response to 1st-line tamoxifen therapy, PFS or PR-OS in recurrent disease. For these 
analyses, we had data available from 188 hormone-naïve breast cancer patients with 
ER-positive primary tumours who received tamoxifen as 1st-line therapy for recurrent 
disease (predictive cohort). Among this cohort, 39 patients had been included in our 
previous study (Foekens et al., 2008) (see also Supplementary Fig. 1).
Association of hsa-miR-7 and CDR1-AS with clinical parameters in the predictive cohort
As 91 patients in this cohort were also included in our prognostic cohort (discussed 
above; see also Supplementary Fig. 1) and the overlap is therefore substantial, we will 
only discuss associations with clinical parameters that have not been discussed for 
the prognostic cohort or show a different result (all associations assessed are listed 
in Table 4). The hsa-miR-7 and CDR1-AS expression levels were once again inversely 
correlated with one another (Spearman rs -0.277, P < 0.0001). In the analysis with the 
clinical parameters, hsa-miR-7 was significantly positively associated with tumour cell 
content. In the predictive cohort, the pathological tumour size was not significantly 
associated with the two markers; similar results were noted for the nodal status with 
CDR1-AS and PGR expression with hsa-miR-7. However, the variable “dominant site of 
relapse” showed an association with CDR1-AS expression with the lowest expression 
in the primary tumours metastasising to distant sites other than local regional or bone.
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Table 4. Associations of CDR1-AS and hsa-miR-7 with clinical parameters in the predictive patient cohort 
CDR1-AS hsa-mir-7
Parameters n median 
expression 
[IQR]
P median 
expression 
[IQR]
P
All patients with ESR1-positive primary 
tumours
188 4.45 [6.42] 0.042 [0.077]
Age in years at start of 1st-line treatment
≤55 75 4.52 [5.82] 0.042 [0.083]
56-70 67 3.84 [5.40] 0.040 [0.067]
>70 46 4.35 [7.79] 0.65 0.045 [0.076] 1.00
Menopausal status at start of 1st-line 
treatment
Premenopausal 53 4.69 [5.68] 0.046 [0.099]
Postmenopausal 135 4.36 [6.91] 0.4 0.042 [0.069] 0.66
Adjuvant chemotherapy
No 153 4.35 [6.87] 0.045 [0.086]
CMF 21 4.82 [4.44] 0.033 [0.032]
Anthracycline containing 14 4.36 [4.41] 0.24 0.047 [0.080] 0.18
Tumour cell content
30-70% 111 4.98 [6.77] 0.033 [0.077]
>70% 77 2.55 [5.22] <0.001 0.049 [0.079] 0.025
Pathological tumour size
pT1 53 4.85 [7.77] 0.038 [0.059]
pT2 + unknown 116 4.39 [6.23] 0.040 [0.082]
pT3+pT4 19 4.55 [4.79] 0.63 0.078 [0.225] 0.16
Tumour grade
Poor 104 3.90 [5.35] 0.048 [0.084]
Unknown 57 4.12 [6.71] 0.040 [0.067]
Moderate/Good 27 6.07 [10.42] 0.093 0.034 [0.073] 0.35
Nodal status
Negative 91 5.00 [7.49] 0.045 [0.068]
Positive 67 3.73 [6.08] 0.034 [0.068]
Positive (tumour outside lymph nodes) 30 3.52 [4.93] 0.085 0.077 [0.275] 0.024
Hormone/growth factor receptors*
PGR-negative 35 3.31 [8.08] 0.060 [0.235]
PGR-positive 153 4.47 [6.05] 0.26 0.038 [0.073] 0.21
ERBB2-non-amplified 165 4.42 [6.65] 0.044 [0.086]
ERBB2-amplified 23 4.66 [5.48] 0.54 0.029 [0.047] 0.14
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Table 4. Continued
CDR1-AS hsa-mir-7
Parameters n median 
expression 
[IQR]
P median 
expression 
[IQR]
P
Disease-free interval before start 1st-line 
tamoxifen
≤1 year 76 4.67 [6.35] 0.046 [0.165]
1 - 3 years 48 3.58 [7.16] 0.048 [0.074]
>3 years 64 4.62 [6.33] 0.96 0.034 [0.060] 0.61
Dominant site of relapse
Local regional 21 4.96 [10.53] 0.029 [0.021]
Bone 101 4.90 [6.48] 0.044 [0.084]
Other distant metastasis 66 3.43 [5.34] 0.028 0.050 [0.086] 0.33
Clinical parameters were analysed for their association with the gene expression of the two genes of 
interest; the median expression per gene including the interquartile range (IQR) and the number of 
patients per analysis (n) is shown. Pathological tumour size is defined as follows: pT1 <= 2 cm, pT2 > 2 cm 
and <= 5 cm, pT3 > 5 cm, and pT4 = tumour with direct extension to chest wall and/or skin. *Cut-offs for 
positive and negative hormone receptor/growth factor status were established as previously described 
(van Agthoven et al., 2009; Sieuwerts et al., 2007). P = p-value. Significant p-values are printed in bold.
Hsa-miR-7, CDR1-AS and the response to 1st-line tamoxifen therapy in the predictive cohort
We also investigated whether hsa-miR-7 or CDR1-AS expression levels in the primary 
tumours had an influence on the type of response to tamoxifen in the predictive cohort 
(Table 5). To this end, we evaluated the contribution of our two markers using logistic 
regression analysis in a univariate model as well as a multivariate model. The latter 
model contained age at start of the 1st-line tamoxifen therapy, disease-free interval, 
dominant site of relapse, ESR1 and PGR expression levels and ERBB2 status.
Table 5. Uni- and multivariate association of response with CDR1-AS, hsa-miR-7 and other clinical 
variables in the predictive cohort
Parameters base model
univariate model multivariate model
n OR (95% CI) P OR (95% CI) P
188
Age at start 1st-line tamoxifen
≤55 years 75 1 1
56-70 years 67 1.63 (0.82-3.25) 0.16 1.23 (0.55-2.72) 0.61
>70 years 46 3.06 (1.29-7.23) 0.011 2.05 (0.81-5.18) 0.13
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Table 5. Continued
Parameters base model
univariate model multivariate model
n OR (95% CI) P OR (95% CI) P
Disease-free interval
≤1 year 76 1 1
1- 3 years 48 1.52 (0.71-3.25) 0.28 1.44 (0.63-3.30) 0.38
>3 years 64 2.07 (0.99-4.28) 0.05 1.88 (0.86-4.14) 0.12
Dominant site of relapse
Local regional 21 1 1
Bone 101 0.25 (0.07-0.92) 0.037 0.20 (0.05-0.77) 0.020
Other distant metastasis 66 0.41 (0.11-1.56) 0.19 0.28 (0.07-1.19) 0.08
Hormone/growth factor receptors*
ER (log continuous ESR1) 188 1.65 (1.22-2.23) 0.001 1.65 (1.15-2.36) 0.006
PR (log continuous PGR) 188 1.07 (0.92-1.25) 0.39 1.00 (0.84-1.20) 0.99
HER2 (ERBB2) status
Not amplified 165 1 1
Amplified 23 0.60 (0.25-1.45) 0.26 0.97 (0.33-2.85) 0.96
hsa-miR-7 separately added to 
the base model
CDR1-AS (log continuous) 188 1.01 (0.78-1.31) 0.96
hsa-miR-7 (log continuous) 188 0.76 (0.60-0.96) 0.023 0.73 (0.57-0.95) 0.017
≤median 94 1 1
>median 94 0.56 (0.30-1.03) 0.064 0.59 (0.30-1.16) 0.13
The association of the different parameters, including CDR1-AS and hsa-miR-7 expression, with the 
therapy response in the predictive cohort is displayed on the left side of the table. The hormone/growth 
factor receptor expression values used in this table were determined by qPCR. *Cut-offs for positive and 
negative hormone receptor/growth factor status were established as previously described (van Agthoven 
et al., 2009; Sieuwerts et al., 2007). The same parameters are assessed with a multivariate model on the 
right side. n = number of patients, OR = odds ratio, CI = confidence interval, and P = p-value. Significant 
p-values are highlighted in bold.
We realised that the hazard ratios of the patients among the pre-menopausal patient 
age groups (≤55 years) were similar to one another, and the same was true for the 
hazard ratios for the post-menopausal patient age groups (>55 years). Due to this, the 
menopausal status was largely covered by the age groups, and due to the low patient 
numbers (n = 188) included in this cohort, we did not include menopausal status but 
rather the age categories in our analyses for the predictive cohort.
In the univariate analysis for response, only hsa-miR-7 was a predictive biomarker, 
namely for a poor response to treatment, a finding which remained significant in the 
multivariate analysis (odds ratio 0.73, 95% CI 0.57-0.95, P = 0.017).
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Hsa-miR-7, CDR1-AS and PFS in the predictive cohort
We subsequently investigated whether hsa-miR-7 or CDR1-AS expression could predict 
the length of PFS (Table 6). In the Cox regression analysis, we evaluated the contribution 
of our two markers in a univariate model as well as in a multivariate model containing 
the same additional parameters as used for the response analysis.
Table 6. Uni- and multivariate association of CDR1-AS, hsa-miR-7 and other clinical variables with PFS 
in the predictive cohort
Parameters base model
univariate model multivariate model
n HR (95% CI) P HR (95% CI) P
188
Age at start 1st-line tamoxifen
≤55 years 75 1 1
56-70 years 67 0.76 (0.54-1.07) 0.11 0.78 (0.54-1.13) 0.19
>70 years 46 0.57 (0.38-0.84) 0.005 0.65 (0.43-0.98) 0.039
Disease-free interval
≤1 year 76 1 1
1- 3 years 48 0.79 (0.54-1.14) 0.21 0.83 (0.56-1.22) 0.34
>3 years 64 0.68 (0.48-0.97) 0.032 0.74 (0.51-1.05) 0.09
Dominant site of relapse
Local regional 21 1 1
Bone 101 1.60 (0.96-2.65) 0.071 1.99 (1.16-3.43) 0.013
Other distant metastasis 66 1.34 (0.78-2.27) 0.28 2.00 (1.10-3.63) 0.023
Hormone/growth factor receptors*
ER (log continuous ESR1) 188 0.77 (0.67-0.89) <0.001 0.82 (0.69-0.96) 0.016
PR (log continuous PGR) 188 0.89 (0.83-0.96) 0.002 0.92 (0.84-0.96) 0.038
HER2 (ERBB2) status
Not amplified 165 1 1
Amplified 23 1.86 (1.19-2.90) 0.007 1.49 (0.89-2.50) 0.13
hsa-miR-7 separately 
added to the base model
CDR1-AS (log continuous) 188 0.97 (0.86-1.10) 0.62
hsa-miR-7 (log continuous) 188 1.18 (1.04-1.33) 0.008 1.22 (1.08-1.38) 0.002
≤median 94 1 1
>median 94 1.54 (1.14-2.09) 0.005 1.63 (1.18-2.25) 0.003
This table shows the associations of PFS with the cohort characteristics and CDR1-AS and hsa-miR-7 expression. 
The different metrics were examined with a univariate analysis on the left side of the table, while they were 
analysed with a multivariate model on the right side. n = number of patients, HR = hazard ratio, CI = confidence 
interval, and P = p-value. Significant p-values are printed in bold. The hormone/growth factor receptor 
expression values used in this table were determined by qPCR. *Cut-offs for positive and negative hormone/
growth factor status were established as previously described (van Agthoven et al., 2009; Sieuwerts et al., 2007).
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In the Cox univariate regression analysis, hsa-miR-7, but not CDR1-AS, was associated 
with the length of PFS and remained an independent predictive marker for poor PFS in 
the multivariate analysis (log continuous variable: HR = 1.22, 95% CI 1.08-1.38, P = 0.002; 
split on median: HR = 1.63, 95%CI 1.18-2.25, P = 0.003). The association of hsa-miR-7 
with PFS is visualised by a Kaplan-Meier plot after dividing our cohort into hsa-miR-7-
high and -low subgroups based on the median expression level (Fig. 2).
Figure 2. Hsa-miR-7 as a function of progression-free survival. The figure shows hsa-miR-7 expression split 
into two expression categories and its relationship with PFS in the predictive cohort in a Kaplan-Meier graph. 
The log rank test was applied to assess the significance and the obtained p-value is listed within the plot.
Hsa-miR-7 and CDR1-AS in regard to PR-OS in the predictive cohort
Finally, we related our markers to PR-OS after the beginning of tamoxifen therapy. 
While CDR1-AS did not show an association with PR-OS in the Cox univariate regression 
analysis, we did find an association between hsa-miR-7 expression and PR-OS, which 
remained significant in the multivariate analysis (HR = 1.22, 95% CI 1.06-1.40, P = 0.004; 
split on median: HR = 1.64, 95% CI 1.17-2.29, P = 0.004 (Table 7).
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Table 7. Uni- and multivariate association of post-relapse overall survival (PR-OS) with CDR1-AS, hsa-
miR-7 and other clinical variables in the predictive cohort
Parameters
univariate model multivariate model
n HR (95% CI) P HR (95% CI) P
188
Age at start 1st-line tamoxifen
≤55 years 75 1 1
56-70 years 67 1.04 (0.72-1.48) 0.85 0.98 (0.65-1.47) 0.93
>70 years 46 0.94 (0.62-1.45) 0.79 1.10 (0.70-1.73) 0.69
Dominant site of relapse
Local regional relapse 21 1 1
Bone metastasis 101 1.63 (0.94-2.83) 0.08 1.61 (0.92-2.84) 0.10
Other distant metastasis 66 1.55 (0.87-2.75) 0.14 1.81 (0.99-3.31) 0.06
Disease-free interval
≤1 year 76 1 1
1-3 years 48 0.83 (0.56-1.22) 0.34 0.93 (0.62-1.41) 0.75
>3 years 64 0.56 (0.38-0.82) 0.003 0.56 (0.38-0.85) 0.006
Hormone/growth factor receptors*
ER (log continuous ESR1) 188 0.80 (0.68-0.93) 0.005 0.79 (0.66-0.95) 0.012
PR (log continuous PGR) 188 0.88 (0.81-0.95) 0.001 0.90 (0.82-0.98) 0.020
HER2 (ERBB2) status
Not amplified 165 1 1
Amplified 23 1.45 (0.91-2.30) 0.12 1.15 (0.69-1.93) 0.59
hsa-miR-7 separately added 
to the base model
CDR1-AS (log continuous) 188 0.97 (0.83-1.13) 0.72
hsa-miR-7 (log continuous) 188 1.22 (1.07-1.39) 0.004 1.22 (1.06-1.40) 0.004
≤median 94 1 1
>median 94 1.70 (1.23-2.35) 0.001 1.64 (1.17-2.29) 0.004
The association of CDR1-AS and hsa-miR-7 expression and other clinical variables with PR-OS using 
the univariate model is shown on the left side and with the multivariate model on the right side. The 
hormone receptor/growth factor expression values used in this table were determined by qPCR. *Cut-
offs for positive and negative hormone receptor/growth factor status were established as previously 
described (van Agthoven et al., 2009; Sieuwerts et al., 2007). n = number of patients, HR = hazard ratio, 
CI = confidence interval, and P = p-value. Significant p-values are highlighted in bold.
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Discussion
Our study showed among the first results an inverse relationship between CDR1-AS and 
hsa-miR-7 expression. This finding is supported by previous studies in different cancer 
patient cohorts (Weng et al., 2017; Xu et al., 2017). Besides, we observed an inverse 
relationship between hsa-miR-7 and EGFR. This observation is in line with the known 
function of hsa-miR-7 to target the EGFR mRNA 3’ UTR and cause the downregulation 
of EGFR mRNA in this way (Webster et al., 2009). Due to the inverse relationship of 
hsa-miR-7 with CDR1-AS, CDR1-AS can be expected to be expressed at higher levels in 
EGFR-high tumours, and this was the case in our dataset.
One point of caution is, however, that EGFR is not very highly expressed in most breast 
tumour cells (Kersting et al., 2006; Möller et al., 1989; Pilichowska et al., 1997). As 
tumours consist not only of tumour cells, but also of stroma and immune cells (Allinen et 
al., 2004), CDR1-AS might be mainly expressed by non-tumour cell types. Supporting this 
hypothesis, we found that CDR1-AS was associated with tumours with a lower tumour 
cell content, and in our cell line expression study, CDR1-AS expression was amongst the 
highest in the stromal fibroblast strain (Fig. 1). However, higher expression in immune 
cells infiltrating the tumours (tumour-infiltrating leukocytes; TILs) could also be a 
possible explanation. Therefore, we assessed several immune cells (CD4+ T helper cells, 
CD8+ T helper cells, CD56+ granulocytic NK cells and HLA-DR+ antigen-presenting cells 
(APC)) for CDR1-AS expression in a healthy donor and found low CDR1-AS expression. 
To further examine the relationship of CDR1-AS expression with stroma, we performed 
correlations for hsa-miR-7 and CDR1-AS with several stromal markers (Allinen et al., 
2004; Ma et al., 2009; Riaz et al., 2012; van Roozendaal et al., 1996), a newly developed 
stromal gene expression signature and our developed TIL signature, which is a previously 
published gene expression signature for tumour-infiltrating leukocytes (Massink et al., 
2015; Smid et al., 2016) (see also Supplementary Methods). The TIL signature was 
established on breast tumours and was developed based on differential gene expression 
between breast tumours with pathologically high and low TIL scores and validated 
on an large independent cohort (data not shown) (Massink et al., 2015; Smid et al., 
2016). The correlation analyses showed that tumour cell content was strongly negatively 
correlated with the TIL signature (Spearman rs = -0.428; P = 2.47E-12), but showed 
slightly lower negative correlations with the set of individual stromal markers and the 
stromal signature (Supplementary Table S3). This indicates that the majority of non-
tumour cells in our tumour samples were mainly TILs and not stromal cells. That said, 
in our cohort, CDR1-AS correlated very strongly positively with the stromal signature 
(Spearman rs = 0.674, P = 8.30E-34) and the stromal markers (Spearman rs = 0.25 up 
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to 0.53; all P < 1E-05; see Supplementary Table S3 for details), but not with the TIL 
signature (P = 0.16). Based on these results we conclude that CDR1-AS appears to be 
mainly expressed by stromal cells and not by TILs or tumour cells.
Hsa-miR-7, was also not associated with the TIL signature. Furthermore, hsa-miR-7 was 
correlated negatively with the stromal signature as well as with the analysed stromal 
markers. In contrast hsa-miR-7 showed a positive association with the tumour cell 
content in the primary tumours from our recurrent breast cancer cohort (predictive 
cohort). These associations support the expression of hsa-miR-7 mainly by tumour cells.
Based on our correlative findings, it could be speculated that CDR1-AS’ role is to prevent 
hsa-miR-7 from being active in the stroma but future studies exploring this result in 
more detail are needed.
In our prognostic cohort, we observed that hsa-miR-7 expression was associated with 
tumour size, tumour grade, ER status and PR status. Looking at the expression levels of 
this microRNA, it displayed higher expression in the prognostic-wise worse parameter 
categories, such as pT3 and pT4 size status, poor tumour grade, ER-negative tumours 
and PR-negative tumours. Based on these findings, hsa-miR-7 appears to be associated 
with a generally more aggressive tumour type. Indeed, with respect to the prognosis 
of breast cancer patients with LNN disease who did not receive systemic adjuvant 
therapy, we confirmed a shorter MFS for patients with higher hsa-miR-7 levels in ER-
positive tumours, which is in line with our previous findings in a subset from this cohort 
(Foekens et al., 2008). Surprisingly, although overall hsa-miR-7 expression was higher in 
ER-negative tumours, this microRNA was not associated with prognosis in this subgroup. 
However, the microRNA was related to prognosis in ER-positive tumours, indicating 
that these tumours, despite being ER-positive, have more aggressive features similar 
to ER-negative tumours.
While CDR1-AS did not appear to correlate with either ER or PR expression, we did 
observe several associations for CDR1-AS with clinical parameters in our LNN cohort 
(e.g., tumour size and grade) which were inverse to those found for hsa-miR-7. 
Nevertheless, our data showed that the expression of this circRNA is not significantly 
(P > 0.05) related to relevant parameters such as hormone receptor expression or 
clinical outcomes; therefore, it is likely that factors other than sequestering hsa-miR-7 
play a more prominent role here.
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In our cohort of patients who received 1st-line tamoxifen treatment, we observed 
that high hsa-miR-7 levels were associated with a shorter time to progression, which 
remained significant after adjustment for known predictive factors in breast cancer. This 
finding indicates that high hsa-miR-7 levels are an independent predictor for shorter 
PFS. Furthermore, hsa-miR-7 was also associated with a worse clinical response to 1st-
line tamoxifen therapy. These observations not only confirm the general notion that 
hsa-miR-7 is a marker of more aggressive tumours but also that hsa-miR-7 is a predictor 
of poor tamoxifen therapy efficacy, irrespective of the intrinsically aggressive tumour 
type.
In addition to the associations of hsa-miR-7 with therapy response and progression, 
we also found an association with survival. The association with OS was weak in our 
prognostic cohort and only present in the ER-positive subset (P = 0.041), while in the 
predictive cohort, hsa-miR-7 was stronger associated with PR-OS (P = 0.004). These 
findings exemplify the potential of this microRNA as a biomarker in breast cancer.
Regarding the regulation of CDR1-AS and hsa-miR-7 expression, it has been found that 
the upregulation of c-Myc causes CDR1-AS downregulation in B cells, although it remains 
unclear whether c-Myc can bind the CDR1-AS promoter region directly (Gou et al., 2017). 
Interestingly, it has been shown that c-Myc upregulates hsa-miR-7 expression (Chang 
et al., 2008; Chou et al., 2010). This might indicate an additional level of regulation for 
both genes by c-Myc and the subsequent fine tuning of the RNA levels for these two 
genes through their interplay. One could hypothesise that hsa-miR-671, a negative 
regulator of CDR1-AS (Hansen et al., 2011), could be upregulated by c-Myc and in this 
way also downregulate CDR1-AS levels; however this does not seem to be the case as 
hsa-miR-671 levels have been investigated upon c-Myc induction and no change in 
expression was found (Liao and Lu, 2011).
Recently, several studies showed an association of CDR1-AS with clinical outcomes 
in different cancer types. Two studies reported that the circRNA was associated with 
poor survival in colorectal cancer patients (Tang et al., 2017; Weng et al., 2017), a 
cancer-type in which low hsa-miR-7 expression has previously been associated with 
poor survival (Suto et al., 2015). Interestingly there is a molecular subtype in colorectal 
cancer (CMS4) that is characterised by stromal invasion and has been linked to a worse 
overall survival, relapse-free survival and is frequently diagnosed at a higher stage 
(Guinney et al., 2015). This might explain the differential outcomes between our study 
and the previous colorectal cancer studies linking CDR1-AS to worse outcomes (Tang 
et al., 2017; Weng et al., 2017), if indeed subtype CMS4 is well-represented in those 
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cohorts, which would also support a link between CDR1-AS expression and stroma and, 
in colorectal cancer, poor outcome.
Another study on gastric cancer also found an association of increased CDR1-AS 
expression with poor survival (Pan et al., 2017). In hepatocellular carcinoma, the 
situation is less clear; while CDR1-AS was associated with several markers of poor 
prognosis, it was not significantly associated (P > 0.05) with recurrence (Xu et al., 2017).
Overall, there have been conflicting reports on hsa-miR-7, labelling it as an oncomir on 
the one hand and as a tumour suppressor microRNA on the other hand. Several cell 
line and animal studies support its tumour suppressor role with a specific focus on the 
target EGFR (Kefas et al., 2008; Wang et al., 2013a); associated proteins, such as PAK1 
(Puto et al., 2003; Reddy et al., 2008); as well as transcription factors, such as YY1 (Zhang 
et al., 2013). By contrast, others have found oncogenic roles for hsa-miR-7 by targeting 
a transcriptional repressor (Chou et al., 2010) or the tumour suppressor KLF4 (Meza-
Sosa et al., 2014). The associations with clinical outcomes in patients are conflicting 
for this microRNA as well. On the one hand, it has been found that lower hsa-miR-7 
expression is associated with poor survival in gastric cancer (n = 106) (Zhao et al., 2015) 
and with more metastases and a shorter OS in lung cancer patients (n = 108) (Cheng 
et al., 2017), indicating a tumour suppressor role of the microRNA. On the other hand, 
arguing for an oncogenic role, a study on colorectal cancer patients (n = 210) found an 
association of high hsa-miR-7 levels with several clinical markers for poor prognosis, 
different relapse types and lower overall survival (Nagano et al., 2016). Furthermore, 
a study on prostate cancer patients (n = 45) also showed that increased expression of 
this microRNA is associated with a worse OS. In the latter study, hsa-miR-7 expression 
was also linked to a shorter time span until the tumours became castration-resistant 
(Santos et al., 2014).
In the case of breast cancer, there has been one report associating lower hsa-miR-7 
expression levels with lymph node-positive breast cancer patients versus lymph node-
negative patients (Kong et al., 2012). However, in this small study, neither the tumour ER 
status nor information on potential treatments before surgery or adjuvant treatment 
were reported (Kong et al., 2012). Those factors could introduce a bias, especially when 
the patient numbers are small, and this could explain the different results from our 
study.
In general, the contradictions in different studies regarding the role of hsa-miR-7 might 
indicate that this microRNA is co-regulated with different causal factors making it a 
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biomarker of aggressive tumours in one cancer and a biomarker of less aggressive 
tumours in another. Further studies with large well-characterised patient cohorts as 
well as functional studies are needed to clarify the contradictions with regard to this 
microRNA and patient outcome.
Based on our findings in a 1st-line tamoxifen-treated patient cohort, we conclude that 
hsa-miR-7 is a predictive biomarker for poor response and PFS. Our previous study 
showed that hsa-miR-7 was a prognostic biomarker in a LNN breast cancer cohort 
(Foekens et al., 2008), and the present study confirmed this result in an, albeit not fully 
independent, extended LNN breast cancer cohort. Additionally, hsa-miR-7 was found 
to be associated with short OS in the ER-positive subset in the prognostic cohort and 
PR-OS in the predictive cohort. By contrast, CDR1-AS did not show associations with 
any clinical outcomes in our breast cancer cohorts.
In conclusion, we showed that in addition to the known association between high hsa-
miR-7 expression and a worse course of disease (earlier development of metastases) 
in primary breast cancer, high hsa-miR-7 levels are predictive of an adverse response 
to tamoxifen therapy and poor progression-free and post-relapse overall survival in 
patients with recurrent disease. These associations do not appear to be related to 
CDR1-AS. However, in light of recent reports describing the clinical utility of CDR1-AS 
expression in other cancer types (Pan et al., 2017; Tang et al., 2017; Weng et al., 2017; 
Xu et al., 2017), it will be interesting to study this gene further, including its stromal 
location, in large cohorts focused on those cancer types and to investigate its functional 
influence on cancer progression.
Materials and Methods
Patient samples
The protocol to study biological markers associated with disease outcome was approved 
in writing by the medical ethics committee of the Erasmus Medical Centre Rotterdam, 
The Netherlands (MEC 02.953) and was performed in accordance with the Code of 
Conduct of the Federation of Medical Scientific Societies in The Netherlands (https://
www.federa.org/codes-conduct). The use of anonymous or coded left over material 
for scientific purposes is part of the standard treatment agreement with patients and 
therefore informed consent was not required according to Dutch law. The results of 
this study are reported based on the REMARK criteria for clinical reporting (McShane 
et al., 2005).
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For our analyses we generated CDR1-AS and hsa-miR-7 expression data using qPCR 
(see below) for two different clinical cohorts. These assays were performed blinded to 
the study endpoint.
In this retrospective study, tumours of female patients were included, who underwent 
surgery for invasive primary breast cancer between 1980 and 1995 in the Netherlands. 
A further selection criterion was no previously diagnosed cancers with the exception 
of basal cell carcinoma or stage Ia/Ib cervical cancer.
Within this study only data from sections of primary tumours with at least 30% invasive 
tumour cells, evaluated as described before (Sieuwerts et al., 2005), were included. 
The primary tumour specimens used in this study for RNA isolation consisted of fresh 
frozen tissue that had been stored in liquid nitrogen. At least 100 mg of tumour material 
per patient had to be available. The details of tissue processing have been described 
previously (Sieuwerts et al., 2005).
No stratification or matching was used for our cohorts. The tumour grade was assessed 
according to standard procedures at the time of inclusion.
For the classification of patients’ RNA samples regarding ER expression, PR expression 
and HER2 amplification status, RT-qPCR was used with the following cut-offs: (1) ER 
(ESR1 mRNA) 0.2, (2) PR (PGR mRNA) 0.1 and (3) HER2 (ERBB2 mRNA) 18; the cut-offs 
were established as previously described (van Agthoven et al., 2009; Sieuwerts et al., 
2007).
The first cohort (prognostic cohort) included primary tumours from LNN breast cancer 
patients who had not received any systemic (neo)adjuvant therapy. The different 
inclusion criteria discussed within this section led to a cohort consisting of 120 ER-
negative and 225 ER-positive primary tumours. The median age of the patients in the 
study at time of surgery was 55 years (ranging from 27–88 years). The median follow-up 
time of living patients was 91 months (ranging from 8–319 months). MFS was defined as 
the time between surgery and the development of a distant metastasis. One-hundred-
seventy (49%) patients developed a distant metastasis that counted as an event in the 
MFS analysis. Patients who died without evidence of disease were censored at the last 
follow-up in the MFS and OS analyses. In total, 178 patients were censored in the OS 
analysis and 175 were censored in the MFS analysis. Additional patient and tumour 
characteristics are presented in Table 1.
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The second cohort (predictive cohort) consisted of 188 hormone-naïve breast cancer 
patients with ER-positive primary tumours who received tamoxifen as a 1st-line 
treatment for recurrent disease and fulfilled our inclusion criteria (discussed above). 
Thirty-five of the patients received adjuvant chemotherapy. The 188 patients [21 
patients with local-regional relapse (LRR) and 167 patients with a distant metastasis] 
were treated with tamoxifen (40 mg daily) therapy. The median age of the patients 
at the start of tamoxifen therapy was 61 years (ranging from 29–90 years). We used 
the primary tumours of these patients for our analyses. The median time between 
primary surgery and the start of therapy was 27 months (ranging from 2-115 months). 
To evaluate PFS, the start of the 1st-line tamoxifen therapy was set as zero and the 
end point was at the time of progression or the last date of follow-up. The median 
follow-up time for living patients at the end of follow-up was 64 months (ranging from 
8-272 months) after primary surgery and 10 months (ranging from 1-144 months) after 
the start of tamoxifen therapy. The disease-free interval was defined as the interval 
between the breast cancer diagnosis and the first recurrence of the disease. At the end 
of the follow-up period, 178 (95%) patients had developed tumour progression and 
154 (82%) patients had died. In the PFS analysis, 10 patients were censored, while 34 
patients were censored in the PR-OS analysis. Clinical response to tamoxifen therapy 
was defined by standard Unio Internationale Contra Cancrum criteria (Hayward et al., 
1977) and described previously (Sieuwerts et al., 2005). Those 126 patients with an 
evident tumour reduction of 50% or more (partial and complete remission) or no change 
in tumour volume after more than 6 months were defined as responders to 1st-line 
tamoxifen therapy.
Non-responders included the 62 patients who showed tumour progression (progressive 
disease) or no change in tumour volume after ≤ 6 months. The median PFS times were 
as follows: (1) complete remission (n = 7), 16 months; (2) partial remission (n = 34), 15 
months; (3) stable disease (n = 85), 14 months; (4) no change after ≤ 6 months (n = 9), 5 
months; and (5) progressive disease (n = 53), 3 months. Additional patient and tumour 
characteristics for this cohort are shown in Table 3.
An overview of the specifics for the clinical cohorts and cell lines [see below] are 
depicted in a flow diagram in Supplementary Fig. S1.
Cell lines, immune cells and tumour pool used in the expression experiment
For our cell line experiments, we used total RNA isolated from breast cancer cell lines 
with different intrinsic subtype characteristics described previously (Hollestelle et al., 
2010; Sieuwerts et al., 2009) (see Supplementary Table S4 for cell lines, subtypes and 
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normalised CDR1-AS expression values) supplemented with total RNA isolated from the 
endothelial cell line EA.hy926 and a fibroblast strain (M92-19T) derived from a primary 
breast cancer tumour (Foekens et al., 2008). Furthermore we included MACS sorted 
immune cell subsets from PBMCs which were isolated from buffy coats by Ficoll gradient 
centrifugation from a healthy donor. All cultured cell lines were established to be of 
correct identity by performing STR profiling analyses using the PowerPlex® 16 system 
(Promega, Madison, WI, USA). The breast tumour pool used in this experiment consisted 
of cDNA from 100 primary breast tumours from lymph node-negative and -positive 
patients who did not receive neo-adjuvant treatment. Overall, the samples were ESR1-
positive, PGR-positive, had no ERBB2 amplification and had a high proliferative index 
[GGI; 1.1] (Toussaint et al., 2009).
MACS
Magnetic-activated cell sorting (MACS) was performed using the MACS technology with 
an anti-PE positive selection kit (Miltenyi Biotec, Leiden, the Netherlands) according to 
the manufacturer’s protocol. Briefly, 5E06 PBMC in 100 μl MACS buffer were stained 
with 10μl PE-labelled primary antibody conjugate (CD4, CD8, CD56 or HLA-DR) and 
incubated for 10 minutes at 6-8°C, in the dark. Following washing with MACS buffer 
the cells were labelled with 20μl anti-PE magnetic beads for 15 minutes at 6-8°C in the 
dark. After additional washing, the cells were applied to MACS MS columns which were 
placed in a magnetic field. Finally, the positively selected cell fraction was eluted, cells 
were counted and the purity (percentage of PE labelled cells) was analysed by flow 
cytometry using a BD FACSCelesta (BD Biosciences, San Jose, CA, USA). Purities of the 
cell sorting per targeted immune cell population are given in Supplementary Table S5.
RNA isolation, cDNA synthesis and quantitative real time PCR (RT-qPCR)
Tissue processing, total RNA isolation and total RNA quality control checks have been 
described elsewhere (Sieuwerts et al., 2005, 2014). Briefly, total RNA was isolated with 
RNA Bee (Thermo Fisher Scientific, Waltham, MA, USA) from 30 µm tissue sections. 
MRNAs/circRNAs were reverse-transcribed with the RevertAid H Minus First Strand 
cDNA Synthesis Kit from Thermo Fisher Scientific, followed by an RNAse H step (Ambion, 
Thermo Fisher Scientific). QPCR reactions were performed in a 25 µL final volume 
using an Mx3000PTM Real-Time PCR System (Agilent Technologies, Amstelveen, the 
Netherlands). All qPCR assays were established to have an efficiency of at least 90% 
and did not generate a product within 35 cycles in the absence of reverse transcriptase. 
Three reference genes were selected based on the literature and tested for their signal 
intensity and stable expression level between both LNN and lymph-node positive 
(LNP) as well as ESR1-high and ESR1-low samples, using GeNorm (Vandesompele et 
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al., 2002) and NormFinder (Andersen et al., 2004) software packages available in 
GenEx 6.1.1.550 (MultiD Analyses AB, Gotenborg, Sweden). mRNA/circRNA levels were 
assessed relative to the average expression of HMBS, HPRT1 and TBP using the delta 
Cq method (dCq = 2^(average Cq reference genes - Cq target gene)). Hsa-miR-7 levels 
were measured and quantified relative to hsa-miR-132 and hsa-miR-374 as described 
previously (Foekens et al., 2008). For the cultured cell lines and clinical specimen we 
incorporated only samples in our study in which we could detect the reference gene 
HMBS within 25 qPCR cycles when using 10 ng of total RNA as input. This to ensure only 
RNA samples with sufficient quantity and of good quality are measured.
All of the primers and hydrolysis probe assays used for gene expression are shown in 
Supplementary Table S6.
Figure preparation and statistical analysis
Figures were generated using SPSS version 24 (IBM, Armonk, NY, USA), Excel (Microsoft 
Corporation, Redmond, WA, USA) and/or Inkscape (Free Software Foundation Inc., 
Boston, MA, USA). All statistical analyses were performed in SPSS (version 24). Cox 
univariate and/or multivariate regression analysis were used for the survival analyses 
(MFS, PFS, OS and PR-OS). MFS was defined as the time between the primary surgery 
and the first distant metastasis. PFS was defined as the time between the start of the 
first line therapy (tamoxifen) and the first sign of progression. OS was defined as the 
time between the primary surgery and death or the last follow up. PR-OS was defined 
as the time between relapse and death or the last follow-up. Mann-Whitney tests 
were used to analyse CDR1-AS and hsa-miR-7 with clinical parameters (except for cases 
when more than 2 groups were analysed; then a Kruskal-Wallis test was performed); 
the clinical parameters were used as grouping variables. Logistic regression was used 
to assess whether treatment responses were associated with CDR1-AS and hsa-miR-7 
expression. The non-parametric Kaplan-Meier estimator was used to estimate and plot 
the survival functions, with the log-rank test to assess for differences. All statistical tests 
were two-sided and P < 0.05 was considered statistically significant.
Data availability
The full data sets used in this paper are available upon request.
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Abstract
Circular RNAs (circRNAs) are a class of RNAs that is under increasing scrutiny, although 
their functional roles are debated. We analyzed RNA-seq data of 348 primary breast 
cancers and developed a method to identify circRNAs that does not rely on unmapped 
reads or known splice-junctions. We identified 95,843 circRNAs, of which 20,441 were 
found recurrently. Of the circRNAs that match exon-boundaries of the same gene, 
668 showed a poor or even negative (R < 0.2) correlation with the expression level 
of the linear gene. In silico analysis showed only a minority (8.5%) of circRNAs could 
be explained by known splicing events. Both these observations suggest that specific 
regulatory processes for circRNAs exist. We confirmed the presence of circRNAs of 
CNOT2, CREBBP and RERE in an independent pool of primary breast cancers. We 
identified circRNA profiles associated with subgroups of breast cancers and with 
biological and clinical features such as amount of tumor lymphocytic infiltrate and 
proliferation index. siRNA-mediated knockdown of circCNOT2 was shown to significantly 
reduce viability of the breast cancer cell lines MCF-7 and BT-474, further underlining the 
biological relevance of circRNAs. Furthermore, we found that circular, and not linear, 
CNOT2 levels are predictive for progression-free survival time to aromatase inhibitor 
(AI) therapy in advanced breast cancer patients, and found that circCNOT2 is detectable 
in cell-free RNA from plasma. We showed that circRNAs are abundantly present, show 
characteristics of being specifically regulated, are associated with clinical and biological 
properties, and thus are relevant in breast cancer.
Keywords: circular RNA, RNA-sequencing, breast cancer, CNOT2, Aromatase Inhibitor
Introduction
It is a sign of the times that the ubiquitous use of massive parallel sequencing data 
has delivered a parade of new insights in the cancer field and has enriched our 
genomic vocabulary with events like chromothripsis, kataegis, and mutational and 
rearrangement signatures (Alexandrov et al., 2013; Maher and Wilson, 2012; Nik-Zainal 
et al., 2012, 2016; Stephens et al., 2011). Sequencing RNA has had less of an impact on 
this vocabulary, with many reports concerning traditional gene expression analysis. 
However, depending on the methodology of generating the sequencing library, RNA-
seq has the potential to study the large variety of RNA species, including noncoding 
RNAs, fusion transcripts, known and novel isoforms, and, recently gaining attention, 
circular RNAs (circRNAs). This class of RNA was discovered many decades ago (Hsu and 
151
The circular RNome of primary breast cancer
Coca-Prados, 1979), and circRNAs were long considered idiosyncrasies of the splicing 
machinery processing precursor mRNA into mature mRNA. More recent studies showed 
an unanticipated abundance of circRNAs (Memczak et al., 2013; Salzman et al., 2012) in 
(normal and malignant) human cells and became particularly interesting for the cancer 
research field with the description (Hansen et al., 2013; Memczak et al., 2013) of a 
circRNA that functions as a highly potent miR-7 sponge. miR-7 has a well-described role 
in several malignancies, including breast cancer, and functions as a tumor suppressor in 
most cancers (for review, see (Zhao et al., 2015)) but has also been reported (Foekens et 
al., 2008) as a potential tumor promoter in breast cancer. Other circRNAs and additional 
regulatory transcriptional roles have subsequently been described in cancer (Guo et al., 
2014; Kristensen et al., 2018; Li et al., 2015b; Salzman et al., 2013). Because circRNAs lack 
a free 5’ or 3’ end, such molecules escape exonucleic acid degrading enzymes, making 
them more stable (Memczak et al., 2013) than their linear counterparts. Therefore, 
circRNAs represent potentially useful biomarker candidates for diagnosis and therapy-
monitoring; indeed, cell-free circRNAs are present in exosomes (Li et al., 2015a) and 
saliva (Bahn et al., 2015). In breast cancer, little has been described except for one study 
(Nair et al., 2016) using the The Cancer Genome Atlas (TCGA) data bank. However, this 
cohort has a huge limitation because the RNA-seq data were prepared using a poly(A) 
selection step, thereby omitting the majority of circRNAs (as these lack a poly(A) tail).
Here we describe the identification of an extensive catalog of circRNAs in a large cohort 
of 348 primary breast tumors, using RNA-seq data obtained via random-primed cDNA 
synthesis (Smid et al., 2016), likely preserving all the circRNAs. We developed a circRNA 
mapping algorithm that, in contrast to previous identification methods (Guo et al., 2014; 
Memczak et al., 2013; Nair et al., 2016; Salzman et al., 2012; Szabo and Salzman, 2016), 
does not rely on unmapped reads or on known splice junctions and that was applied 
directly on transcriptome sequence BAM files, thereby allowing the identification of 
circRNAs in a genome-wide and annotation-independent (Szabo and Salzman, 2016) 
fashion.
Results
Identification of a plethora of circRNAs in primary breast cancer
In total, 95,843 circRNAs were identified (Fig. 1), of which 27% (n = 25,783) had a start 
and end position exactly matching to an exon belonging to the same gene (Fig. 2A). The 
vast majority (79%) of all circRNAs were not recurrent (i.e., only found in one sample). 
The number of circRNAs per sample (Fig. 2B) ranged from 37 to 7105 (median, 966). 
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For recurrent circRNAs, found in at least two samples, the range per sample was 33 to 
5269 (median, 834.5). Figure 2B also shows that the number of (recurrent) circRNAs is 
significantly higher in estrogen receptor (ER)-negative compared with ER-positive breast 
cancers (Mann-Whitney U test, P < 1 x 10-5 for both all and recurrent circRNAs). Because 
of the extraordinary abundance of candidate circRNAs, we focused on the – still sizeable 
– number of recurrently found circRNAs (n = 20,441) (total number in second bar of 
Fig. 2A). The most frequent recurring region in our cohort was the well-characterized 
(Hansen et al., 2013; Kristensen et al., 2018; Memczak et al., 2013) circRNA of CDR1, 
which was found in 339 out of 348 cases. Other previously reported and validated 
(Salzman et al., 2012) circRNAs such as CAMSAP1, FBXW4, MAN1A2, RNF220, ZBTB44, 
and XIST were also identified in our cohort. A full list of identified circRNAs is provided 
in Supplemental Table S1.
Figure 1. Schematic overview of identifying circular RNA (circRNA) regions. Assuming a circRNA molecule 
is present, a sequence read crossing the junction (green arrow) and its read-mate (gold arrow) would map 
to a linear reference in the manner depicted. The junction read would get multiple alignments, and the 
read-mate would be located in between the position of the junction read. Multiple read-pairs at the same 
junction strengthen the support for the circRNA. Subsequent additional filtering (details are in the Methods 
section) and annotation produced the list of circRNA regions.
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Figure 2. General characteristics of circRNAs in primary breast cancer. (A) Numbers of unique and recurrent 
circRNAs. Purple and gold indicate the number of circRNAs that, respectively, did or did not have a start and 
end position of a circRNA region exactly matching the start and end position of an exon of the same gene. 
(B) The number of circRNAs per sample, grouped by ER status. In black, the total number of circRNAs; in 
peach, the number of recurrent (identified in at least two samples) circRNAs. (C) Violin plots of the intron 
size (in log base pair) of noncircular regions and those located directly upstream of or downstream from 
a circRNA region.
General characteristics
Recurrent circRNAs were distributed across the genome, with one region on 
Chromosome 11 showing many closely spaced circRNAs (Supplemental Fig. S1). This 
region contains MALAT1, a highly abundant long noncoding RNA that is also frequently 
mutated in breast cancer (Nik-Zainal et al., 2016). Next, we evaluated the intron 
sizes upstream of and downstream from the circRNAs that match exon boundaries. 
Confirming previously reported results (Ivanov et al., 2015; Jeck et al., 2013; Zhang et al., 
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2014), Figure 2C shows that introns next to circRNA regions are significantly larger than 
introns not adjacent to circRNAs: on average 2.33 and 2.27 times larger, respectively, 
for introns upstream of and downstream from the circRNA (Mann-Whitney U test, both 
P < 1 x 10-5).
Next, we correlated the number of circRNA reads per circRNA with the expression of 
the respective full, linear gene, because a previous report in a limited cell line panel 
reported no genome-wide correlation between the circular and linear counterpart 
(Salzman et al., 2013). To avoid spurious correlations, only those circRNAs found in 
at least 50 samples were considered (n = 1625), and data were first normalized using 
the trimmed mean of M-values (TMM) (Robinson and Oshlack, 2010). Correlations are 
listed in Supplemental Table S1 and ranged between -0.34 and 0.97, with 210 circRNAs 
showing a negative correlation to the linear gene in which the circRNA is located. When 
considering the average and standard deviation of the distribution of all correlation 
coefficients, 30 circRNAs are at the low end of the distribution (P < 0.05), showing a 
correlation below R = -0.182 . Finally, by using GENCODE information, the position of 
annotated start codons was matched to the circRNA positions. circRNAs recurring in at 
least 50 samples showed an almost threefold higher than expected presence of a start 
codon compared with circRNAs that were not recurring (χ2, P < 0.0001; 557 circRNAs; 
expected 207.3 circRNAs).
Are circRNAs distinct molecules, specifically regulated, or splicing residues?
Many of the circRNAs that are positively correlated with the expression level of the 
full-length linear transcript are thought to be a residue of splicing. Figure 3A shows 
an example; the circRNA of exons 3, 4 and 5 of the WDR1 gene (Chr 4: 10,097,711-
10,103,986, with a correlation coefficient of R = 0.66 to overall gene expression) exactly 
matches the difference between the known linear isoforms of this gene (Ensembl 
transcript ENST00000499869 includes exons 3, 4 and 5; ENST00000502702 lacks these 
exons). As current quantification methods do not take circRNAs into account, reads 
originating from the circular molecule are erroneously included in the read count of a 
linear isoform, resulting in an overestimation of the overall expression level. Another 
comprehensive example of a circRNA as splicing residue is shown in Figure 3B for ESR1. 
Full-length ESR1 (ENST00000206249) has eight exons, whereas ENST00000406599 is 
a splice variant of ESR1 that skips exons 2 to 5. circRNAs are found for several of these 
exons, indicating that they are likely splicing residues. We speculate that a single splice 
event from exon 1 to 6 generates an RNA molecule containing exons 2–5, from which a 
multitude of distinct circRNAs can be derived. In total, 23 patients show both a circESR1 
exon 2-3 and a circESR1 of exon 4-5. If these circRNAs are derived from the same RNA 
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molecule, the linear transcript would be ENST00000406599. A sequential model, in 
which first exons 2 and 3 are spliced out would prohibit the formation of a circRNA 
molecule of exons 3 to 4. However, we observed circESR1 exon 2-3 in 110 patients and 
circESR1 exon 3-4 in 64 patients, with 29 patients showing both these circRNAs. These 
must be derived from separate RNA molecules.
Figure 3. circRNAs are not just residues of splicing. (A) Sashimi plot of the number of reads that are aligned 
to WDR1, showing only the reads that span exons. In red are the normal exon-exon reads; in purple, the 
reads that span the circular junction. The line and boxes indicate the exons of the gene (the whole gene is 
not shown). (B) Isoform of ESR1. The arcs indicate the number of samples that have a particular circRNA. 
(C) Two isoforms of CREBBP that are known in the first five exons (other isoforms are described, but these 
start downstream from exon 5). Exon 2 (purple box) is an identified circRNA that is not a remainder of a 
splicing event.
To investigate whether or not in general circRNAs should be considered splicing residues, 
we systematically evaluated how many of the identified circRNAs exactly match 
those exons that make up the difference between known linear isoforms of a gene. 
By using the GENCODE annotation for each gene, every possible known combination 
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of spliced exons was matched to our circRNA catalog. Of the 25,783 circRNAs that 
matched to exons of the same gene, only 2193 (8.5%) exactly matched exons known 
to differ between described isoforms of a gene. This was 16.9% for the circRNAs with a 
correlation coefficient of R > 0.5 to linear gene expression. This suggests that the vast 
majority of circRNAs that matched to exons of the same gene are generated by yet-
unknown splicing events of the gene.
Because the majority of circRNAs did not match to known spliced exons, we manually 
inspected several highly recurrent circRNAs in the UCSC Genome Browser. For example, 
two isoforms of CREBBP are described (ENST00000262367 and ENST00000382070) that 
differ in the presence of exon 5 (of note, there are 10 additional known transcripts, 
but all of these transcripts start downstream from exon 5). However, we observed 
exon 2 as circRNA (Chr 16: 3,850,297-3,851,009) that was present in 160 patients (Fig. 
3C), indicating that this circRNA is either specifically generated or is a splicing residue 
of a yet-undescribed isoform of CREBBP that skips this exon. Visual inspection of 10 
samples that had high levels of circCREBBP exon 2 (at least 30 circular junction reads) 
showed two samples that each had one read that crossed the junction from exon 1 
to exon 3, whereas the other samples showed no evidence of an isoform that skipped 
exon 2. This favors the notion that the circRNA of exon 2 is not a byproduct of splicing 
at this location.
Finally, we matched publicly available circRNA lists to gather (indirect) evidence of 
functional roles for circRNAs. Rybak-Wolf and colleagues reported (Rybak-Wolf et 
al., 2015) 4522 circRNAs in the mammalian brain that were evolutionary conserved 
between human and mouse, which is considered an indication of function (Barbosa-
Morais et al., 2012; Merkin et al., 2012). Of these, 2259 circRNAs (49.9%) were also 
present in our catalog. In addition, 3271 circRNAs were reported in an MCF-7 breast 
cancer cell line panel (Coscujuela Tarrero et al., 2018). In total, 922 circRNAs showed 
(increased) expression in estrogen-stimulated MCF-7 cells compared to cells cultured 
in hormone-deprived medium, of which 733 circRNAs (79.5%) were present in our list. 
A poor correlation (R < 0.2) with the linear transcript was observed in our data for 78 
of these circRNAs, suggesting independent regulation from their linear gene instead of 
ER-induced overall higher expression of all transcripts from that gene.
Validation of circRNAs
Besides the fact that we detected several already published circRNAs, thereby in part 
validating our method, we performed RT-PCR on a previously established independent 
cDNA pool of 100 primary breast tumors to confirm expression of three circRNAs, 
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namely, RERE (circRNA Chr 1: 8,541,214-8,614,686), CNOT2 (circRNA Chr 12: 70,278,132-
70,311,017) and CREBBP (circRNA Chr 16: 3,850,297-3,851,009), all of which were 
poorly correlated with their linear counterpart. Figure 4 shows the PCR fragment 
sizes; expected and observed sizes were 89 and 155 bp for the small and bigger CNOT2 
fragment, 100 bp for RERE and 91 bp for CREBBP. The primer pair for CNOT2 was able 
to amplify the circRNA of exon 2 to exon 3 of CNOT2 but also the circRNA of exons 2, 3, 
and 4 of this gene (a circRNA that was also identified in the RNA-seq cohort).
A different primer pair to PCR circCNOT2 showed additional fragments in addition to 
the expected fragments of 140 and 206 bp (Supplemental Fig. S2A). Sanger sequence 
analysis confirmed the circular junction sequence from exon 3 to exon 2 of CNOT2 
(Supplemental Fig. S2B) and from exon 4 to exon 2 (Supplemental Fig. S2C). After 
using BLAST to identify the sequence, the largest excised PCR fragment was found to 
contain an additional exon of CNOT2 (Chr 12: 70,294,237-70,294,293) located between 
exon 2 and exon 3 that is not present in most isoforms of CNOT2 (Supplemental Fig. 
S2D). The sequence showed exon 3, across the circular junction to exon 2, but reading 
through the location where the reverse primer was located, continuing the whole of 
exon 2, the additional exon, and ending in exon 3 again (Supplemental Fig. S2D). A likely 
explanation for this observation is that during cDNA generation, the RT polymerase 
generated a linear cDNA molecule containing multiple copies of the circular transcript 
(Supplemental Fig. S2E). In summary, the investigated circRNAs were all confirmed to 
be truly present in primary breast cancer.
Figure 4. PCR products of circRNAs. PCR product sizes of circRNAs visualized using the MultiNA Microchip 
Electrophoresis System. (M) DNA size marker (25-bp fragment ladder); (–) the negative control (genomic 
DNA).
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Functional relevance of circRNAs in breast cancer cells
The potential functional relevance of the validated circCNOT2 and circCREBBP 
transcripts, which were both poorly correlated with their corresponding linear 
transcript, was evaluated in breast cancer cell lines. First, expression levels of circCNOT2 
and circCREBBP were established in a panel of 55 cell lines, showing variable levels 
(Supplemental Fig. S3). Next, an siRNA was designed to specifically target the circular 
junction of circCNOT2 in both MCF-7 (moderate expression level) and BT-474 (high 
expression level). This siRNA reduced expression of circCNOT2 by 76% in MCF-7 and 71% 
in BT-474 breast cancer cells, relative to cells transfected with a non-targeting control 
(NTC), which resulted in significantly reduced viability of both MCF-7 and BT-474 cells 
(Student’s t-test P < 1 x 10-5 and P = 4.94 x 10-4, respectively) (Fig. 5).
Figure 5. siRNA-mediated knockdown of circCNOT2 affects viability in breast cancer cells. The effect 
of reduced circCNOT2 expression on viability is shown in MCF-7 and BT-474 cells. Both cell lines show a 
significant decrease in viability (P < 0.01) following circCNOT2 knockdown relative to cells transfected with 
nontargeting control (NTC). Error bars, SD of five wells.
circRNAs in driver genes
We matched our previously reported breast cancer driver gene list (Nik-Zainal et al., 
2016) to our circRNA list. In total, 235 recurrent circRNAs were identified in 54 breast 
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cancer driver genes. To integrate the data and obtain sufficient observations for analysis, 
we selected samples for which we had both RNA and genomic DNA sequencing results 
available and selected the genes with somatically acquired genetic events (mutations, 
copy number variants and rearrangements) in at least 10 patients, yielding a list of 10 
genes; TP53, PIK3CA, PTEN, MAP3K1, CDH1, RB1, MAP2K4, ARID1B, ARID1A, and MLLT4. 
For genes with multiple circRNAs, the circular region with the highest recurrence was 
chosen for analysis, with the exception of TP53, for which we only found two circRNAs 
in just one sample each (see Table 1). Only for MAP2K4 was mutual exclusivity observed 
between the presence of a somatic mutation or a circRNA in this cohort, in which 
20 samples had a somatic mutation, 77 samples had a circRNA (Chr 17: 12,054,889-
12,113,360) and only two samples had both a mutation and a circRNA (P = 0.025, CoMEt 
exact test (Leiserson et al., 2015)). For PIK3CA, 25 patients showed a DNA event and a 
circRNA, three patients with a copy number aberration (amplification), and 22 patients 
with a base substitution in PIK3CA. These substitutions were located in four hotspots, 
p.H1047 (13 cases), p.E545 (n = 4), p.E542 (n = 3) and p.E726 (n = 2). None of these 
hotspots was located in the circRNA region that was found in these samples.
Table 1: Number of samples with a DNA event and/or circRNA
circRNA region
Gene No. of samples
Symbol DNA events circRNA Both
Chr 17: 7,673,535-7,674,290 TP53 105 1 0
Chr 17: 7,674,859-7,676,622 TP53 105 1 1
Chr 3: 179,203,544-179,204,588 PIK3CA 84 77 25
Chr 10: 87,925,513-87,952,259 PTEN 47 13 4
Chr 5: 56,864,734-56,865,977 MAP3K1 30 210 22
Chr 16: 68,801,670-68,815,759 CDH1 22 7 0
Chr 13: 48,342,599-48,349,023 RB1 22 4 0
Chr 17: 12,054,889-12,113,360 MAP2K4 20 77 2
Chr 6: 156,829,227-156,935,576 ARID1B 14 28 1
Chr 1: 26,729,651-26,732,792 ARID1A 12 213 11
Chr 6: 167,870,383-167,889,326 MLLT4 10 28 0
Breast cancer relevance
To investigate common biology in the samples, we used multiple correspondence 
analysis (MCA) to find naturally occurring subgroups. MCA is a generalized principle 
component analysis, suitable for categorical data. We used recurrent circRNAs (at least 
50 cases) with the junction annotated to exons of the same gene (n = 1625) and labeled 
these per sample as circular or not circular, based on the presence or absence of junction 
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reads in a sample. The main patient groups were, not unexpectedly, divided by ER status 
(Fig. 6A, left), whereas within circRNAs, the main division was whether or not the gene 
had a circRNA (Fig. 6A, right). Additional variation within the circRNAs was explained by 
the level of recurrence of the circRNAs (see Supplemental Fig. S4). Next, the presence/
absence of circRNAs in a sample was used to cluster all samples into groups with distinct 
circRNA profiles. We used the gap statistic (Tibshirani et al., 2001) to determine the 
optimal number of sample groups, yielding six clusters (Fig. 6B; Supplemental Fig. 
S5). We evaluated these six sample groups on ER and tumor infiltrating lymphocyte 
(TIL) status (Fig. 6C, D), number of circRNAs (Fig. 6E), and outcome for the patients 
in the clusters (Fig. 6F). Samples in cluster 1 and 3 were predominantly ER-negative, 
whereas ER positivity was predominantly present in groups 2, 4, 5, and 6. TIL status 
was established using a previously reported gene expression signature (Massink et al., 
2015; Smid et al., 2016), labeling samples as high-TIL if the average expression of the 
TIL signature genes fell into the top quartile (n = 87, 45 ER-negative and 42 ER-positive) 
(Fig. 6D, respectively, labeled as red and orange). High-TIL cases were significantly (χ2 
P < 1 x 10-5) more often present in clusters 1 (71% of cases) and 3 (45% of cases). 
Furthermore, the number of circRNAs per sample clearly distinguished the six clusters 
(Fig. 6E), showing a decreasing number of circRNAs from clusters 1 to 6. Finally, for a 
subset of 186 patients, relapse-free survival data were available; a survival plot for 
the six clusters (Fig. 6F) showed that the major difference was between clusters 1 and 
3, that are both predominantly ER-negative. Although the number of events was low, 
direct comparison of cluster 1 with cluster 3 showed a significant difference in survival 
curves (log rank P = 0.04).
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Figure 6. Analysis of sample groups according to circRNA presence. Multiple correspondence analysis 
(MCA) was used to find naturally occurring groups in the circRNA data. In an MCA plot, samples and circRNAs 
are projected onto the same plane, in which the relative distance to either the samples or the circRNAs is 
meaningful. The 0,0 point corresponds to a sample or circRNA with an average profile. (A, left) Samples are 
colored according to ER status: red, ER-positive; black, ER-negative. (Right) Purple and green indicate genes 
with or without circRNA expression, respectively. (B) Clustering identified samples with similar circRNA 
profiles; samples in the MCA plot are colored according to the cluster to which the sample belongs. (C) ER 
status (purple, ER-positive; peach, ER-negative) and (D) TIL status of the six sample groups: Red and orange 
are high-TIL cases and blue and green are low-TIL cases for ER-negative and ER-positive, respectively. (E) 
Number of circRNAs per sample group. (F) Relapse-free survival plot by sample group. (N) number of 
patients; (F) number of patients who relapse; (x-axis) months; (y-axis) the cumulative probability of relapse-
free survival.
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Differentially expressed circRNAs
We investigated if circRNA expression levels were associated with clinically relevant 
features of primary breast cancer, such as presence of TILs, the tumor’s stromal content, 
proliferation, and hypoxia status. These features were inferred from generated (stroma; 
see Methods) or reported (Massink et al., 2015; Smid et al., 2016; Winter et al., 2007) 
gene expression signatures. By using these, we grouped our samples in a similar manner 
as explained earlier for the TIL status (Fig. 6D), labeling samples as high if the average 
expression of the signature genes fell into the top quartile. To identify significantly 
differentially expressed circRNAs, we compared the top quartile of samples to the 
remaining samples separately for the ER-positive and ER-negative cases. circRNAs with 
FDR-corrected P-values < 0.05 and a fold-change greater than two were selected. Of 
these, the circRNAs that had a negative correlation with the linear gene expression were 
considered of particular interest and are listed in Table 2. Several of these circRNAs 
may thus potentially play a role in, or are at least connected to, the tumors that show 
hypoxic characteristics (e.g., circKMT2C) or accumulate in highly proliferative cells (e.g., 
circRERE, circATXN2), whereas, for example, circASH1L and circPCH3 may be generated 
by surrounding stromal cells or infiltrating cells.
Table 2: Fold-change of circRNAs in top quartile of samples versus remaining samples in ER-subgroups of tumors
Regions
Gene 
Symbol
Hypoxia Proliferation Stroma TIL
ER-
negative
ER-
positive
ER-
negative
ER-
positive
ER-
negative
ER-
positive
ER-
negative
Chr 1: 155,438,327-155,459,898 ASH1L 2.0 2.1 2.0
Chr 1: 8,541,214-8,557,523 RERE 2.4 2.1
Chr 1: 8,655,973-8,656,441 RERE 2.0
Chr 2: 112,399,632-112,400,194 RGPD8 2.5 2.3 2.6
Chr 3: 170,136,419-170,149,244 PHC3 3.4 2.1 2.6 2.8 2.5
Chr 5: 140,440,119-140,449,305 ANKHD1 2.2 2.2
Chr 7: 152,309,966-152,315,338 KMT2C 2.1
Chr 7: 155,672,867-155,680,908 RBM33 2.4 2.4 2.6 2.5 2.3
Chr 7: 17,868,407-17,875,790 SNX13 2.4 2.3
Chr 10: 32,543,300-32,584,304 CCDC7 2.2 2.4
Chr 12: 111,554,158-111,555,919 ATXN2 2
Chr 13: 75,560,753-75,569,507 UCHL3 2.0
Chr 15: 25,405,461-25,411,971 UBE3A 2.7 2.2 2.4 2.1
Chr 15: 92,996,957-92,998,621 CHD2 2.4 2.3
Chr 18: 76,849,526-76,851,939 ZNF236 2.1 2.0
Chr 20: 35,716,740-35,725,155 RBM39 2.5 2.2
No significant circRNAs were identified in the TIL ER-positive group.
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Clinical relevance
One of the reasons CNOT2 was selected for validation was because of the poor 
correlation with expression of the linear gene (R = -0.09, P = 0.34). This was more 
prominent in ER-positive (R = -0.14) compared with ER-negative cases (R = 0.097). We 
validated this finding by making use of in-house array data (Smid et al., 2008) for linear 
CNOT2 expression and a quantitative RT-PCR assay to measure circCNOT2 (exon 2-3 
Chr 12: 70,278,132-70,311,017). The Spearman’s correlation in ER-positive cases of 
circCNOT2 with linear CNOT2 was 0.079 (n = 187, P = 0.28) and in ER-negative cases 
Rs = 0.42 (n = 111, P = 2.9 x 10-6), again showing absence of correlation in ER-positive 
cases. Thus, the role of circCNOT2 apparently differs between ER-positive and ER-
negative cases, and in the ER-negative cases, the significance of circCNOT2 cannot be 
easily segregated from the linear counterpart. Therefore, we evaluated two different 
ER-positive breast cancer cohorts (Supplemental Table S3 shows clinical characteristics) 
for the potential clinical value of circCNOT2. We studied progression-free survival of 
aromatase inhibitor (AI) therapy in a multicenter cohort of 84 ER-positive patients 
who received this treatment for advanced disease. Quantitative reverse transcriptase-
PCR (RT-qPCR) levels of circCNOT2 showed a significant hazard ratio (HR) of 1.75 (95% 
confidence interval 1.32-2.33, P = 1.06 x 10-4), whereas RT-qPCR levels of linear CNOT2 
were not significant: HR 1.28, P = 0.187. Figure 7A shows a survival curve after grouping 
patients’ circCNOT2-levels into three equally sized groups. A similar analysis in another 
cohort (Sieuwerts et al., 2005), which included patients receiving first-line tamoxifen 
treatment (n = 295 patients), did not show a significant HR (0.97, P = 0.57) for circCNOT2 
or for linear CNOT2 (HR 1.16, P = 0.21).
As circular molecules are expected to be more stable than their linear counterparts, we 
explored whether circCNOT2 is a potential candidate as minimally invasive biomarker. 
To this end, we used cell-free RNA (cfRNA) from plasma samples of four breast cancer 
patients and amplified circCNOT2 by RT-qPCR. All samples showed detectable and 
variable levels of circCNOT2 (Fig. 7B), indicating that detection of circRNAs in plasma 
seems attainable in this exploratory setting.
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Figure 7. Clinical evaluation and presence in plasma samples. (A) Kaplan-Meier survival curve of 
progression-free survival for AI therapy in which patients were grouped in three equally sized groups based 
on their circCNOT2 expression: red, blue and green indicate the samples with high, intermediate, and low 
expression. The x-axis is in months; y-axis depicts the cumulative probability of progression-free survival on 
AI therapy. The P-value is the logrank test for trend. (B) Expression levels of circCNOT2 in plasma samples. 
Four metastatic breast cancer patients were evaluated. The y-axis depicts delta-Ct values of circCNOT2 
relative to GUSB. Error bars, SD of two measurements.
Discussion
To our knowledge, we are the first to analyze RNA sequencing data using random-primed 
cDNA libraries from a large primary breast cancer cohort for the presence of circRNAs, 
using a method that does not rely on unmapped reads. Previously, Nair and colleagues 
(Nair et al., 2016) analyzed TCGA RNA-seq data that were obtained using a poly(A)-
based method. Although we identified 25,783 circRNAs that matched with an exon 
boundary of the same gene, Nair et al. (Nair et al., 2016) reported 2146 circRNAs when 
we applied the same selection criteria as for our data set, and after transferring the hg37 
coordinates (Nair et al., 2016) to hg38 (our dataset), only 45 circRNAs were found that 
had the exact same start and end coordinates in both datasets. Thus, a random-primed 
method identifies many more circRNAs than when using poly(A)-selected material. On 
the other hand, there seem to be many uniquely identified circRNAs in these datasets. 
This could stem from differences in the methodology to detect or report the circRNAs 
but also could reflect the fact that many circRNAs are nonrecurrent.
We showed that circRNAs are found throughout the genome and have significantly 
larger-sized introns located directly adjacent to the region on the genome that borders 
the circRNA, as also reported previously (Ivanov et al., 2015; Jeck et al., 2013; Zhang 
et al., 2014). Based on the presence/absence of circRNAs, six groups of samples 
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were observed that differed in their ER status, TIL content, number of circRNAs, and 
prognosis. This indicates that there appears to be a functional biology associated with 
the biogenesis of circRNA molecules or at least a biology that cancerous cells can use 
to their advantage. Whether or not the circRNAs themselves serve that function or 
whether the process that generates differences in circRNA levels is the cause for the 
results presented here remains unknown at this time. The fact that several circRNAs 
were found differentially expressed in breast cancer subgroups, although these circRNAs 
are negatively correlated with the expression of the linear gene from which the circRNA 
is derived, corroborates the notion of functional circRNAs. Further experimentation 
is required to investigate the functional relationship of the differentially expressed 
circRNAs in the hypoxia, proliferation, stroma, and TIL phenotypes.
Although a synthetic circRNA construct including an internal ribosome entry site (IRES) 
can be translated (Wang and Wang, 2015), current literature (Guo et al., 2014; Jeck et 
al., 2013; Liang et al., 2017; Liu et al., 2018; Szabo and Salzman, 2016; Wang et al., 2018; 
Zeng et al., 2018) describes mostly noncoding functions for circRNAs, for example, as 
miRNA sponge circCDR1 (Hansen et al., 2013; Kristensen et al., 2018; Memczak et al., 
2013; Zhao et al., 2015) and circZNF91 (Guo et al., 2014), whereas associative evidence 
was reported (Rybak-Wolf et al., 2015) of evolutionary conserved circRNAs between 
human and mouse. Further support that circRNAs may be specifically generated and 
regulated was derived from a study using (estrogen-stimulated) MCF-7 cells (Coscujuela 
Tarrero et al., 2018), showing higher levels of H3K36me3 (posttranscriptional histone 
modification) and a higher number of Ago binding sites in circularizing exons.
Here, we contribute to the search for relevant circRNAs in three ways; first, expression 
levels of circRNAs that are not, or even negatively correlated with the linear transcript 
of the gene may point to an intentional process. Although differences in degradation 
rates between the circular and linear isoforms may influence the correlation, we did 
not find systemic evidence for this (Supplemental Fig. S6). Furthermore, for genes that 
generate several distinct circRNAs, correlations can vary, indicating that degradation 
of the linear transcript cannot be the only explanation for the observed correlations. 
Second, circRNAs that include the start codon could potentially influence the expression 
of the linear gene, because the linear transcript from which the circRNA was spliced 
is now forced to use another start codon for its translation; if none is available, the 
transcript may be degraded. For example, circCNOT2 (exon 2-3 Chr 12: 70,278,132-
70,311,017) contains the start codon of the consensus (Pruitt et al., 2009) transcript 
(CCDS31857.1). Annotation shows that exon 1 is untranslated and both exon 2 and exon 
4 start with the methionine codon (ATG). Thus, the linear transcript wherein exon 1 
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is ligated to exon 4 lacks the start codon from exon 2 and may use the ATG in exon 4 
for its translation. Third, we observed that circRNAs matching exon boundaries of the 
same gene rarely (8.5%) overlap with known spliced exons. It could be that our analysis 
overlooked possible splice variants from the GENCODE annotation (both HAVANA and 
Ensembl exon annotations were included), but if the concordance is indeed this low, 
two scenarios may be applicable: Either circRNAs are still mostly a remnant of splicing, 
implying that many more transcript isoforms of genes exist, or otherwise circRNAs are 
specifically generated, implying that they do have a biological role. The observations 
of variable expression levels of circCNOT2 and circCREBBP in cell lines and especially 
the effect of circCNOT2 knockdown on cell viability corroborate a biological role for 
circRNAs. Future studies are needed to systematically evaluate if the correlation 
between a circRNA and its linear transcript, the presence of a start codon and/or known 
splice junctions are reliable criteria to prioritize circRNAs of interest.
Regardless, we were able to show clinical potential for circCNOT2 by showing its 
association with the response to AI therapy. Knowing that circular molecules are not 
targeted by exonucleases, these molecules may be suitable candidates to be detected 
in cell-free environments (Li et al., 2015a), and in a pilot experiment, we showed that 
circCNOT2 can indeed be detected in cfRNA from plasma samples of breast cancer 
patients. As such, circCNOT2 could prove to be a useful biomarker to choose the right 
type of therapy or to monitor disease in a minimally invasive manner. Furthermore, we 
observed that very likely because of the strand displacement activity of the reverse 
transcriptase during cDNA generation, multiple concatemeric copies of a single circular 
molecule are made, contributing to the sensitive detection of circRNAs. In conclusion, 
we have demonstrated the abundance and potential roles of circRNAs in primary breast 
cancer. The methodology and selection criteria we used may help in making more 
sense of the seeming chaos and disorder existing in the flow from DNA to RNA to 
protein. circRNAs show the potential to function as relevant actors in the transcriptional 
regulation of RNA in addition to their promise as stable biomarkers that can be used 
for disease progression.
Methods
Sequencing
Internal review boards of each participating institution approved collection and use of 
samples of all patients in this study. RNA-seq data were generated by our consortium 
(Nik-Zainal et al., 2016; Smid et al., 2016) for 348 primary breast cancer tumors that are 
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available through the European Genome-phenome Archive under accession number 
EGAS00001001178. Sequence protocols of the samples were previously described 
in detail (Nik-Zainal et al., 2016); in short, total RNA after gDNA removal, clean-up, 
and depletion of ribosomal RNA using duplex-specific nuclease (DSN) treatment, was 
used as input for random-primed cDNA synthesis. Paired-end (75 bases) sequencing 
was performed on an Illumina HiSeq 2000. The resulting FASTQ files were mapped to 
GRCh38 using STAR (version 2.4.2a) (Dobin et al., 2013), and the resulting BAM files were 
sorted and indexed using Sambamba (version 0.6.6; https://github.com/lomereiter/
sambamba/) (Tarasov et al., 2015). Gene annotation was derived from GENCODE 
Release 23 (https://www.gencodegenes.org/).
Identification of circular RNAs
A detailed explanation of the methodology to identify circRNA reads, including the Perl 
script, is stated in the Supplemental Methods. The script is also available at https://
bitbucket.org/snippets/MSmid/Le949d/identify-circularrna-reads. In short, the method 
developed here uses sequence reads that have a “secondary alignment” (SA) tag. When 
using paired-end sequence data and assuming a circular RNA molecule is present (Fig. 
1, top), the sequence read that aligns over the crossing of the junction (green arrows) 
would “point toward” its read-mate (orange arrow) somewhere in the circle. Aligning 
these reads to the linear reference (Fig. 1, middle), the junction read will get an SA tag 
and will be assigned to two locations if and only if this is the one and unique alignment 
configuration the STAR software can find. The read-mate aligns somewhere in between 
these two locations. Finding additional read-pairs showing this configuration, with a 
breakpoint at the exact same location, strengthens the evidence for circular transcripts. 
Only regions with at least five reads crossing the circular junction were included. After 
filtering (for details, see Supplemental Methods), GENCODE annotation was used to 
obtain the exon locations of genes that exactly matched to the circular region. For each 
sample, STAR also gives the raw read counts for all genes. These were normalized (TMM 
implemented in edgeR) (Robinson and Oshlack, 2010) and used to correlate with the 
number of junction reads of the circular transcripts.
Multiple correspondence analysis
Because many genes only show a linear transcript in many samples, standard cluster 
analysis to identify groups of samples with similar circRNA-related biology is problematic 
because of the many missing values. Thus, the circRNA data were considered categorical 
using “circular” or “not circular” if a circRNA was present or absent in a sample. These 
categorical data are suitable for an MCA, a generalization of a principle component 
analysis. The MCA generates a combined plot that shows both patients and circRNAs 
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such that patients/circRNAs that have similar patterns are closer together. R-packages 
“ade4”, “canceracm”, and “cluster” were used to perform the MCA and determine 
the optimum number of clusters. The latter was determined using the clusGap option 
(k-means to partition the samples) in the cluster package. R version 3.4.1 was used (R 
Core Team, 2017).
Reverse transcription, PCR, and Sanger sequencing
Candidate circRNAs were selected and primers were designed such that a PCR would 
only yield a product when the RNA was circular, whereas in the linear situation, the 
primers would be divergent. Primer sequences are listed in Supplemental Table S2.
First, total RNA, isolated with RNA-Bee according to the manufacturer’s instructions 
(CS105B, TEL TEST) was reverse transcribed into cDNA with the RevertAid H Minus 
first-strand cDNA synthesis kit (K1632; Thermo Fisher Scientific), followed by a RNase H 
step (AM2293; Ambion). Next, circRNAs were real-time PCR amplified at 10 ng input in 
a final volume of 25 μL using 40 PCR cycles and an annealing temperature of 67°C with 
330 nM of each primer and SensiFAST SYBR Lo-ROX mastermix (BIO-94050, Bioline), 
followed by a final 5-min extension at 72°C, in a MX3000P (Agilent Technologies). PCR 
products were visualized using a MultiNA microchip electrophoresis system (Shimadzu).
For sequencing, PCR fragments were separated on a standard agarose gel and were 
excised from gel using the QIAquick gel extraction kit from Qiagen according to 
manufacturer’s protocol. The sequencing reaction contained 2 μL of gel-extracted PCR 
product, 1 μL BigDye terminator v3.1 reaction mix (Thermo Fisher Scientific), 1x BigDye 
terminator sequencing buffer (Thermo Fisher Scientific), and 0.16 μM of sequencing 
primer in a final volume of 10 μL and was performed using an ABI2720 thermal cycler 
according to the following protocol: one step for 2 min at 96 °C and 25 cycles of 30 sec 
at 96 °C , 30 sec at 58 °C, and 2 min at 72 °C. Subsequently, the sequencing product 
was precipitated with absolute ethanol and 3 M of NaAc, resuspended in 20 μL of 
Hi-Di formamide (Thermo Fisher Scientific), and ran on an ABI3130XL genetic analyzer 
(Thermo Fisher Scientific).
RT-qPCR
After RNA isolation and cDNA synthesis performed as described above, circCNOT2 (Chr 
12: 70,278,132-70,311,018) and circCREBBP (Chr 16: 3,850,297-3,851,009) transcripts 
were real-time PCR amplified at 10 ng input in a final volume of 25 μL in 40 PCR cycles 
and an annealing temperature of 60°C with 200 nM of each primer and 100 nM FAM-
labeled TaqMan MGB probe that covers the circular junction (Thermo Fisher Scientific) 
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(Supplemental Table S2) in SensiFAST Probe Lo-ROX mastermix (BIO-84020, Bioline) 
using a MX3000P (Agilent Technologies). Levels were quantified relative to the average 
expression of three reference genes (HPRT1, HMBS, and TBP) (Supplemental Table S2) 
using the delta Cq method (dCq = 2(average Cq reference genes - Cq target gene)) (Schmittgen and Livak, 
2008). A serially diluted cDNA pool (Sieuwerts et al., 2014) of 100 independent breast 
tumor samples (containing both ER-positive/-negative and ERBB2-positive cases) was 
included in each experiment to evaluate the linear amplification and efficiencies for all 
genes and absence of amplification in the absence of reverse transcriptase. Samples in 
the cDNA pool were independent from the cases that were used for the RNAseq cohort.
Detection of circRNAs in plasma
cfRNA was isolated with the Maxwell RSC miRNA tissue kit (Promega) adapted for 
plasma according to the manufacturer’s instructions. One milliliter of EDTA plasma of 
different metastatic breast cancer patients was used. These patients provided written 
informed consent. Six microliters of the resulting 50 μL cfRNA (3.8-7 ng RNA/μL) was 
used to generate 20 μL cDNA with the SuperScript IV VILO cDNA synthesis kit (Thermo 
Fisher Scientific). Next, 2 μL of the cDNA was preamplified in the presence of 0.50 nM 
of the reverse primers of the hydrolysis probe assays for circCNOT2 and GUSB as a 
reference marker during 15 cycles with TaqMan preamp mastermix (Thermo Fisher 
Scientific). Finally, 0.5 μL of the preamplified product was measured real-time with the 
hydrolysis probe assays (200 nM forward primer, 200 nM reverse primer, and 100 nM 
FAM-labeled hydrolysis MGB probe) during 40 cycles with SensiFAST Probe Lo-ROX 
mastermix (BioLine) in a final qPCR volume of 25 μL in a MX3000P qPCR machine 
(Agilent Technologies).
siRNA-mediated knockdown of circRNAs and cell viability assay
All cell lines in this study were established to be genetically unique and monoclonal 
and of correct identity by performing STR profiling using the PowerPlex 16 system 
(Promega). MCF-7 and BT-474 were plated at 60-70% confluency in six-well plates 
and transfected with 50 nM ON-TARGETplus siRNA targeting circCNOT2 (Horizon 
Discovery) using 4 µl (MCF-7) or 8 µl (BT-474) DharmaFECT 1 (Horizon Discovery) 
following the manufacturer’s instructions. Used sequences (5’-3’) were as follows: 
sense, AAAGAUAGGGAGACGUGGUUU; antisense, 5’-PACCACGUCUCCCUAUCUUUUU. 
The ON-TARGETplus nontargeting pool and On-TARGETplus human UBB smart pool were 
included in each experiment as negative and positive controls, respectively (Horizon 
Discovery). After 24 h of transfection, cells were trypsinized, counted, and seeded in 
quintuplicate at 20,000 cells per well in 96-well plates. Cell viability was determined 
using the CellTiter-Blue cell viability assay (Promega) at day 0 and day 3. Viability 
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measurements at day 3 were corrected for baseline viability values by subtracting the 
average measurement of day 0.
Gene expression signatures
We used several signatures: a TIL and proliferation signature (Smid et al., 2016), a 
hypoxia signature (Winter et al., 2007), and a stroma-specific signature using public 
data GSE5847 (Gene Expression Omnibus) (Boersma et al., 2008). We performed a 
paired t-test to obtain genes significantly higher expressed in microdissected stroma 
(FDR < 0.05 and fold-change > 1.7). For all signatures, genes that were up-regulated in 
the category of interest were matched to our data set, and the average expression of 
the signature genes was calculated per sample. Samples were labeled as high-TIL (or 
stroma, proliferation, hypoxia) if the average expression of the signature genes fell into 
the top quartile. To identify significantly differentially expressed circRNAs, we compared 
the top quartile of samples versus the rest, per ER-group. circRNAs were only included 
when detected in >50% of the samples and matched known exon locations of the same 
gene. Analyses were performed using BRB-ArrayTools developed by Dr. Richard Simon 
and the BRB-ArrayTools development team. circRNAs were considered significant when 
the FDR corrected P-value was below 0.05 and the fold-change greater than 2.
Breast cancer cohort treated with endocrine therapy
RT-qPCR was performed on a linear and circular isoform of CNOT2 (Chr 12: 70,278,132-
70,311,017) in a first-line TAM (Sieuwerts et al., 2005) and a first-line AI cohort to study 
the predictive value of circCNOT2 on therapy response. The AI cohort was a multicenter 
cohort consisting of 30 patients from Erasmus MC, Rotterdam; 35 patients from The 
Netherlands Cancer Institute, Amsterdam; and 19 patients from the Translational Cancer 
Research Unit, Antwerp (Belgium). All 295 patients in the TAM cohort are patients of the 
Erasmus MC, Rotterdam. Patient characteristics are listed in Supplemental Table S3.
Statistical analyses
STATA version 14 was used to perform the statistical tests that are indicated in the text. 
P-values are two-sided, corrected for multiple testing when necessary, and considered 
significant below 0.05.
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Supplemental files
Supplemental files can be accessed via: https://doi.org/10.1101/gr.238121.118
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The aim of this thesis was to investigate ncRNAs in breast cancer, focusing on their 
relationship with drug response and clinical outcome. With regard to the former, a 
large drug screening was performed in cell lines (chapter 3), which was subsequently 
used to study drug sensitivity in relation to miRNA expression (chapter 4), as well as 
genomic characteristics (chapter 5). With regard to the latter, the landscape of circRNAs, 
a relatively novel ncRNA species, is described in breast tumors (chapter 7) as well as 
the association of a subset with clinical parameters including response to treatment 
(chapter 6, 7) and survival (chapter 6).
Overview on the outcome of the drug association studies
An important part of this thesis involved a drug screening on breast cancer cell lines and 
the association of different genomic features with the respective drugs to identify markers 
for predicting drug response. While not all of the drugs studied in this thesis are currently 
used in clinical practice to treat breast cancer, those drugs might become of interest 
in the future for the treatment of breast cancer or other cancer types. By associating 
miRNA expression, mutational status and copy number aberration with drug response 
we provided an extensive characterization of drug sensitivity for 34 drugs with multiple 
genomic features. Furthermore, we investigated the relation with breast cancer subtype 
as well as undertook analyses to reveal the biology associated behind our observations. 
This rich data source aids in elucidating resistance mechanisms for these 34 drugs as well 
as confirms previously identified resistance mechanisms. For the drugs studied in this 
thesis we have summarized our findings per drug in Table 1. Twenty-eight of the drugs 
studied were correlated positively or negatively with another drug suggesting shared or 
opposing biology behind the observed drug sensitivity. Subtype, however, played a minor 
role in drug response since only one drug exhibited subtype-dependent sensitivity. Looking 
further at Table 1, several drugs were not only associated with miRNAs but also with 
mutations and CNAs. This raises the question whether the respective genomic features 
might be associated with each other. While an earlier study investigated whether mutations 
associated with miRNA expression (Riaz et al. 2013), not all mutations studied within this 
thesis were covered. Furthermore, Riaz et al. (Riaz et al. 2013) restricted their analysis 
to mutations in certain breast cancer subtypes. Therefore, it is useful to look within the 
restricted cell line dataset used for our miRNA study (Uhr et al. 2019) whether associations 
between miRNAs and the mutations studied in chapter 5, are present. Another point to 
add, is, that while miRNAs associating with a breast cancer subtype were excluded from 
the analyses in chapter 4, an association with subtype was not widely tested for mutations, 
and affected mutations were not excluded from the analyses in chapter 5.
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Table 1. Genomic features found associated with drug response within this thesis
Drug Correlated drugs
Genes overlapping 
with other drugs
Genomic features 
associated with 
sensitivity
Genomic features 
associated with 
resistance
5-Fluorouracil Decitabine (R = 0.58) 13 genes 
(Mitoxantrone, 
Veliparib)
30 genes 
(Mitoxantrone)
2 gains and 2 
losses
1 gain
Azacitidine Doxorubicin (R = 0.7), 
Cisplatin (R = - 0.55)
2 gains
Belinostat Vorinostat (R = 0.92), 
Panobinostat 
(R = 0.91), 
Quisinostat (R = 0.85)
6 genes (Vorinostat)
6 genes 
(Panobinostat, 
Quisinostat, 
Sirolimus, 
Vorinostat)
6 genes 
(Panobinostat, 
Vorinostat)
21 genes 
(Panobinostat)
2 losses and 1 
gain,
PIK3CA,
CDH1
Bortezomib Vandetanib 
(R = 0.47),
JNJ-208 (R = -0.66)
3 genes 
(Vandetanib)
2 gains,
hsa-let-7a
1 gain
Brivanib JNJ-707 (R = 0.46) 65 genes (Paclitaxel) 4 gains MAP3K1
Cisplatin Doxorubicin 
(R = -0.73), 
Azacitidine 
(R = -0.55), Sunitinib 
(R = 0.47)
1 gain
Dasatinib 2 gains
Decitabine 5-Fluorouracil 
(R = 0.58),
Serdemetan 
(R = 0.56), Lapatinib 
(R = 0.52), Veliparib 
(R = 0.48)
11 genes 
(Doxorubicin)
1 gain
Docetaxel Paclitaxel (R = 0.73), 
Tivantinib (R = 0.47)
1 gene 
(Methotrexate, 
Paclitaxel)
1 gene (Paclitaxel)
1 gain 1 gain,
hsa-miR-106a-3p, 
hsa-miR-187-5p
Doxorubicin Cisplatin (R = -0.73), 
Azacitidine (R = 0.7)
11 genes 
(Decitabine)
2 gains and 1 loss MLL3
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Table 1. Continued
Drug Correlated drugs
Genes overlapping 
with other drugs
Genomic features 
associated with 
sensitivity
Genomic features 
associated with 
resistance
Erlotinib Gefitinib (R = 0.88), 
Vandetanib (R = 0.47)
17 genes (Gefitinib) 2 gains,
ERBB2 
amplification
PTEN
Gefitinib Erlotinib (R = 0.88), 
Vandetanib (R = 0.56)
17 genes (Erlotinib) 2 gains
JNJ-208 Bortezomib 
(R = -0.66)
2 gains and 1 
loss, MDM2 
amplification
JNJ-493 
(Erdafitinib)
JNJ-707 (R = 0.62), 
Sunitinib (R = 0.48)
2 losses and 1 
gain
1 gain
JNJ-707 Erdafitinib (R = 0.62), 
Brivanib (R = 0.46), 
Mitoxantrone 
(R = 0.45), Nutlin-3 
(R = -0.45)
hsa-mir-135a-3p
Lapatinib Decitabine (R = 0.52)
Methotrexate 1 gene (Docetaxel, 
Paclitaxel)
CDH1 2 gains,
PIK3CA, ATM, 
CSMD3, NAV3
MI-219 Nutlin-3 (R = 0.98) 23 genes (Nutlin-3 
and, in the opposing 
direction, with 
Sunitinib)
103 genes (Nutlin-3)
3 losses 1 gain,
TP53
Mitoxantrone JNJ-707 (R = 0.45) 13 genes (Veliparib, 
5-Fluorouracil),
30 genes 
(5-Fluorouracil)
1 gene 
(Serdemetan)
1 gain,
CDH1,
CDH1 methylation
1 gain
Nutlin-3 MI-219 (R = 0.98),
JNJ-707 (R = -0.45)
23 genes (MI-219 
and, albeit in the 
opposing direction, 
with Sunitinib)
103 genes (MI-219)
3 losses 1 gain,
TP53
Paclitaxel Docetaxel (R = 0.73) 1 gene (Docetaxel, 
Methotrexate)
1 gene (Docetaxel)
65 genes (Brivanib)
3 gains,
hsa-miR-556-5p,
p14ARF (CDKN2A)
1 gain,
hsa-miR-106a-3p,
hsa-miR-187-5p
183
Discussion
Table 1. Continued
Drug Correlated drugs
Genes overlapping 
with other drugs
Genomic features 
associated with 
sensitivity
Genomic features 
associated with 
resistance
Panobinostat Vorinostat (R = 0.96), 
Quisinostat 
(R = 0.93), Belinostat 
(R = 0.91)
6 genes (Sirolimus, 
Quisinostat),
3 genes 
(Quisinostat)
14 (Vorinostat)
6 genes (Belinostat, 
Vorinostat, 
Quisinostat, 
Sirolimus)
6 genes (Belinostat, 
Vorinostat)
21 genes 
(Belinostat)
1 gain and 1 loss,
hsa-miR-185-3p, 
PIK3CA
CDH1 methylation
Quisinostat Panobinostat 
(R = 0.93),
Vorinostat (R = 0.87), 
Belinostat (R = 0.85)
6 genes (Sirolimus, 
Panobinostat),
3 genes 
(Panobinostat),
6 genes (Belinostat, 
Panobinostat, 
Sirolimus, 
Vorinostat)
1 gain and 1 loss, 
CDH1,
UNC13C
CDH1 methylation
Serdemetan Decitabine (R = 0.56), 
Tipifarnib (R = 0.52), 
Veliparib (R = 0.51)
1 gene (Serdemetan, 
Mitoxantrone)
1 gain 1 gain and 2 
losses,
ERBB2 
amplification,
CCND1 
amplification
Sirolimus 1 gene (17-AAG),
1 gene (Sorafenib),
6 genes 
(Panobinostat, 
Quisinostat),
6 genes (Belinostat, 
Panobinostat, 
Quisinostat, 
Vorinostat)
3 gains,
PIK3CA,
breast cancer 
subtype: luminal 
and ERBB2-
overexpressing 
cell lines are 
more sensitive
BRCA1
Sorafenib 1 gene (Sirolimus) 1 gain 1 gain
Sunitinib Erdafitinib (R = 0.48), 
Cisplatin (R = 0.47)
23 genes (Nutlin-
3 and MI-219, 
however, in the 
opposing direction)
1 gain 1 gain and 1 loss
Tamoxifen 1 gain
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Table 1. Continued
Drug Correlated drugs
Genes overlapping 
with other drugs
Genomic features 
associated with 
sensitivity
Genomic features 
associated with 
resistance
Tanespimycin 
(17-AAG)
1 gene (Sirolimus) 2 gains 1 gain,
p16INK4A (CDKN2A),
RB1 signaling 
pathway (p16INK4A 
functions within 
this pathway)
Tipifarnib Serdemetan 
(R = 0.52)
7 genes (Tivantinib) 2 gains 1 gain and 1 loss, 
hsa-miR-629-5p, 
DST
Tivantinib 
(ARQ197)
Docetaxel (R = 0.47) 7 genes (Tipifarnib) 1 gain,
hsa-let-7d-5p, 
hsa-miR-18a-5p
hsa-miR-637
Vandetanib Gefitinib (R = 0.56), 
Erlotinib (R = 0.47), 
Bortezomib (R = 0.47)
3 genes 
(Bortezomib)
3 gains 2 gains
Veliparib Serdemetan 
(R = 0.51), Decitabine 
(R = 0.48)
13 genes 
(Mitoxantrone, 
5-Fluorouracil)
1 gain
Vorinostat Panobinostat 
(R = 0.96), 
Belinostat (R = 0.92), 
Quisinostat (R = 0.87)
14 genes 
(Panobinostat),
6 genes (Belinostat),
6 genes (Belinostat, 
Panobinostat, 
Quisinostat, 
Sirolimus) 6 
genes (Belinostat, 
Panobinostat)
2 gains and 2 
losses,
PIK3CA
1 gain
For each drug the correlated drugs, including the correlation coefficient R, are displayed. The number 
of genes within the CNAs that also associated with another drug is listed. At the right side of the table 
all associated genomic features are listed in separate columns depending on their association with drug 
sensitivity or resistance. The gene CDKN2A encodes two structurally unrelated proteins within different 
reading frames (p16INK4A and p14ARF). Associations with both proteins were found and are listed for the 
respective protein.
Overall our studies showed that most drugs exhibited an association with CNAs (32 
of 34) while associations with mutations (17 of 34) were less common and the least 
associations were seen with miRNAs (8 of 34). Among the drugs associating with a 
mutation, three showed an additional association with a miRNA (Paclitaxel, Tipifarnib 
and Panobinostat). While for Paclitaxel and Tipifarnib none of the associated miRNAs 
were associated with the respective aberration, this was not the case for Panobinostat. 
The Panobinostat-associated miRNA hsa-miR-185-3p did associate with CDH1 
methylation, with lower expression of this miRNA in CDH1-methylated cell lines. This 
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association is likely indirect as it cannot be explained by location of the two genes, given 
that CDH1 lies on chromosome 16 and hsa-miR-185-3p on chromosome 22.
In the case of CNAs, several drug-associated miRNAs were associated with drug-
associated CNAs. Two of the Bortezomib-associated CNAs showed higher hsa-let-7a-
5p expression in samples with gains of these regions, however, all three genomic loci 
encoding hsa-let-7a-5p lie on different chromosomes than the respective gains. In the 
case of Docetaxel, a decrease in hsa-miR-106a-3p was seen in samples with a gain of a 
Docetaxel-associated CNA, while samples with a loss of this region showed the highest 
miRNA expression in line with the association of this gain with drug sensitivity while 
this miRNA was associated with resistance. Hsa-miR-106a-3p also associated with a 
Paclitaxel-associated CNA, again showing highest expression in samples with a loss 
and lowest in those with a gain – in line with the association of this gain with Paclitaxel 
sensitivity and hsa-miR-106a-3p with Paclitaxel resistance. Interestingly this Paclitaxel-
associated CNA shares one gene, olfactory receptor family 4 subfamily C member 11 
(OR4C11), with the aforementioned Docetaxel-associated CNA. However, besides a 
role as olfactory receptor, little is known about this gene and how it could potentially 
influence expression of this miRNA. The Tipifarnib-resistance associated miRNA hsa-
miR-629-5p did show an association with a Tipifarnib-associated CNA, showing higher 
expression in those cell lines with a gain in the respective region albeit miRNA and CNA 
lie on different chromosomes. The respective gain, however, consists of eight zinc finger 
proteins and one zinc finger pseudogene. The positive association between this miRNA 
and the gain could potentially represent a regulatory role of one or of the several zinc 
finger proteins on expression of hsa-miR-629-5p.
A Veliparib-associated gain was furthermore associated with an increased expression 
of hsa-miR-182-5p, in line with the association of both with resistance to this drug. 
However, this miRNA and the respective CNA are located on different chromosomes 
and the association with upregulation of this miRNA is therefore not directly due to the 
gain but due to a different mechanism or coincidental.
Looking next whether drug-associated mutations were in addition associated with 
drug-associated CNAs, the following associations were significant: amplified ERBB2 
associated with an Erlotinib-associated gain. This gain encompasses only the gene 
CDK12, which lies a bit upstream of ERBB2. Not surprising the majority of the cell lines 
(37 of 42) showed the same copy number for CDK12 as well as ERBB2, explaining the 
association found here. Amplification of MDM2 was associated not only with JNJ-208 
but also with a JNJ-208 associated gain. However, the respective CNA lies on a different 
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chromosome than MDM2. Mutated CSMD3 was not only associated with Methotrexate 
resistance but as well with a Methotrexate-resistance associated gain. Four CNAs, that 
were associated with Nutlin-3 as well as MI-219, were associated with TP53 mutation 
status, in line with their association with MI-219/Nutlin-3 resistance/sensitivity. PIK3CA 
mutation was associated with a Belinostat-associated gain, a Panobinostat-associated 
gain, two Sirolimus-associated gains and two Vorinostat-associated gains. The gains, 
as well as PIK3CA mutation associated with drug sensitivity and encompassed as 
minimum overlap the three genes MIPOL1, FOXA1 and SSTR1 (except for one Sirolimus-
gain and one of the Vorinostat-gains). CDH1 methylation showed an association with a 
Panobinostat-associated gain and a Quisinostat-associated gain. In both cases the gains 
were associated with sensitivity to the respective drug, while CDH1 methylation was 
associated with drug resistance. These gains had 12 genes in common.
The loss of a CNA was associated with Serdemetan resistance and this CNA was 
additionally associated with the resistance-associated CCND1 amplification. 
Interestingly two miRNA genes (MIR34B and MIR34C) lie within this CNA region. One 
could hypothesize that these miRNAs might target CCND1 and loss of this region as well 
as amplification of CCND1 could represent two ways that increase the CCND1 protein 
amount in cells. While there are two studies describing miRNAs from these genetic 
loci as targeting CCND1 (Lee et al. 2011; Wang et al. 2016), the study of Lee et al. (Lee 
et al. 2011) shows this is only in certain scenarios the case (ER+ and TP53 wt cells), 
while Wang et al. (Wang et al. 2016) do not show direct target-miRNA interaction. In 
our miRNA study we did not find an association between expression of miRNAs from 
the MIR34B and MIR34C genetic loci and Serdemetan response. This could have been 
influenced by the restricted number of cell lines in the miRNA study, by the fact that 
other genomic features play simply a greater role or there is a more complex regulation 
scenario which requires a more specialized data analysis to unravel. Of note is also that 
among the 36 cell lines used within the miRNA study (chapter 4) only one single cell 
line was ER+, TP53 wt and without CCND1 amplification.
A Brivanib-sensitivity associated gain was also associated with mutated MAP3K1, albeit 
in the opposing direction. Cell lines with mutated MAP3K1 had predominantly no gain 
in this region, in line with the association of mutated MAP3K1 with resistance while 
the gain was associated with drug sensitivity. A Doxorubicin-sensitivity associated gain 
associated also with mutated MLL3. None of the MLL3 wildtype cell lines exhibited this 
gain, fitting the association of the gain, as well as mutated MLL3 with drug sensitivity. 
Overall, several of the drug-associated genomic features also associate with each 
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other, albeit in most cases insufficient information is available to deduce whether this 
association presents different mechanisms to affect response to the same drug.
While our drug screening (chapter 3) and the association with mutations/CNAs (chapter 
5) encompassed a large number of cell lines, drugs and genetic aberrations, there have 
been a number of similar studies (Heiser et al. 2012; Garnett et al. 2012; Barretina et 
al. 2012). Although there is some overlap between studies in regard to drugs and cell 
lines, and some findings were confirmed, there is less concordance between studies 
than one might expect. Extensive analyses have been performed comparing the two 
largest studies, the CCLE study (Barretina et al. 2012) and the GDSC (Garnett et al. 2012) 
in detail for agreements, discordance and potential reasons thereof (Haibe-Kains et 
al. 2013; The Cancer Cell Line Encyclopedia Consortium and The Genomics of Drug 
Sensitivity in Cancer Consortium 2015). These two analyses greatly illustrate common 
caveats in associating genomic features with drug response. Haibe-Kains and colleagues 
(Haibe-Kains et al. 2013) elaborate on differences between the studies and conclude 
that the main culprit for the differing outcomes lies within the drug screening, while 
measurements of genomic features show greater agreement between the studies by the 
GDSC (Garnett et al. 2012) and the CCLE (Barretina et al. 2012). A subsequent analysis by 
the CCLE and GDSC also comparing the two datasets (The Cancer Cell Line Encyclopedia 
Consortium and The Genomics of Drug Sensitivity in Cancer Consortium 2015), argues 
that the agreement between studies is better than presented by Haibe-Kains (Haibe-
Kains et al. 2013), as e.g. analysis methods should take into account that typically only 
few cell lines respond versus an overwhelming majority of non-responders. Summarizing 
the lessons from these large drug screenings and their critical comparisons, one can 
state that when including different cancer types within one screening, it is useful to 
also account for this, as some cancer types are intrinsically resistant and common 
mutations in such a type represent an important confounding factor, leading to drug-
mutation associations that cannot be reproduced in cell lines of a different cancer type 
(Garnett et al. 2012). Further challenges lie in the choice of analysis methods for drug 
screening data, due to very different drug response profiles. This includes the definition 
of resistance/sensitivity, as well as sufficient methodological sensitivity (data analysis 
statistics) in drug screening scenarios with only few responders; the last scenario and 
the impact of different analysis methods is well-illustrated by the CCLE/GDSC study 
(The Cancer Cell Line Encyclopedia Consortium and The Genomics of Drug Sensitivity 
in Cancer Consortium 2015). Finally, most pharmacogenomic studies differ in several 
points in regard to the actual drug screening, concentrations used and analysis methods 
used (Heiser et al. 2012; Garnett et al. 2012; Barretina et al. 2012). All these are further 
sources for differences in outcomes, well-illustrated also by Haibe-Kains et al. (Haibe-
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Kains et al. 2013) and the shared CCLE/GDSC analysis (The Cancer Cell Line Encyclopedia 
Consortium and The Genomics of Drug Sensitivity in Cancer Consortium 2015). Of note 
is also, that known pharmacogenomic associations identified in one study but not in 
the other, often lie just below cut-off (The Cancer Cell Line Encyclopedia Consortium 
and The Genomics of Drug Sensitivity in Cancer Consortium 2015). Another issue is that 
different genomic features can lead to the same phenotypic drug sensitivity such as a 
mutation in one cell line, transcriptional regulation in another and gene expression in a 
third. This genomic redundancy greatly increases challenges in regard to data analysis to 
uncover such relationships, even more so, when only few cell lines are sensitive (Garnett 
et al. 2012; Barretina et al. 2012; The Cancer Cell Line Encyclopedia Consortium and 
The Genomics of Drug Sensitivity in Cancer Consortium 2015).
Based on the challenges observed with comparability of large pharmacogenomic 
studies, improvements in comparability could be made by greater standardization. 
A promising endeavor could be investments into the development as well as the 
implementation of gold-standard techniques/protocols to ensure lower variability 
within cell line screenings as well as in the subsequent analyses. Such an effort would 
improve comparability between studies and hopefully increase the success of such pre-
clinical studies, decrease costs, speed up progress in the development of new cancer 
therapeutics as well as identification of sensitive patients.
circRNAs as cancer biomarkers
Besides the aforementioned drug screening, expression levels of circRNAs were in-
depth characterized in 348 primary breast tumors (chapter 7). This study provided 
a detailed overview on circRNAs in regard to abundance, variance of expression as 
well as their expression specifics (e.g. size of adjacent introns, correlation with linear 
host transcript). Furthermore, associations of circRNAs with clinical and pathological 
features such as infiltration with lymphocytes, and prognosis were investigated. Finally, 
the potential of circRNAs as biomarkers was studied in chapter 6 and chapter 7. While 
circCNOT2 showed an association with clinical outcome, namely a worse progression-
free survival in advanced breast cancer treated with aromatase inhibitors (AI) (chapter 
7), CDR1-AS (circCDR1) was not associated with clinical outcome in ER-positive primary 
or advanced breast cancer (chapter 6). The fact that circCNOT2 could be measured 
in plasma from breast cancer patients is promising (chapter 7) and could represent 
a clinical value of circCNOT2 as a useful biomarker once validated in an independent 
cohort of AI-treated advanced breast cancer patients for sensitivity and specificity.
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Next to these two circRNAs studied in more detail, a number of other circRNAs have 
been reported as biomarkers of patient outcome or other clinical parameters. Low 
expression of circPVT1 is associated with decreased overall survival (OS) and disease-
free survival (DFS) as well as T4 tumor stage and neural invasion in gastric cancer (Chen 
et al. 2017). In osteosarcoma, high circUBAP2 expression was found to be prognostic for 
reduced OS and its expression was positively correlated to tumor stage; furthermore 
this circRNA exhibited oncogenic properties in functional studies (Zhang et al. 2017). 
In hepatocellular carcinoma low expression of circMTO1 was associated with reduced 
survival, and functional experiments confirmed a tumor suppressor role of this circRNA 
(Han et al. 2017). Another circRNA, circITCH, showed an improved survival rate among 
hepatocellular carcinoma patients with high circITCH expression, as well indicative of a 
tumor suppressor role in this disease (Guo et al. 2017). While quite some studies have 
found circRNAs to be prognostic in different cancer types, only few have described a 
predictive role in patients. In osteosarcoma patients the circRNA hsa_circ_0081001 
was associated with chemoresistance, with higher expression levels in patients which 
exhibited chemoresistance, as well as showing higher expression in patients with a 
decreased OS and lung metastasis (Kun-Peng et al. 2018). In acute myeloid leukemia 
(AML), decreased hsa_circ_0004277 expression was observed in newly diagnosed 
cases as well as refractory cases, while patients exhibiting complete remission showed 
the same levels of this circRNA as healthy controls (Li et al. 2017), indicating a role of 
this circRNA in monitoring chemotherapy success, albeit its predictive capability was 
not assessed in this study. Further research looking into the potential of circRNAs as 
predictive biomarkers in cancer are therefore warranted, especially in light of their 
stability (Jeck et al. 2013) as well as presence in plasma (Li et al. 2018), important 
characteristics for stable & easy-to-measure biomarkers.
Outlook – systems biology to improve therapy choices
This thesis showcases that resistance/sensitivity to a certain drug can be associated 
with – and potentially influenced by – multiple genomic features and that the type 
of feature associated with a drug varies substantially between drugs. It is therefore 
recommendable to perform broad investigations including miRNA expression, circRNA 
expression, mutations and CNAs to not overlook potential biomarkers for specific 
drugs. In the era of personalized medicine characterizing patients for biomarkers on 
the molecular biological level and combining these to a grand picture, next to traditional 
clinical information such as results from the pathological examination, will likely provide 
better guidance in regard to therapy choice and as a result optimize patient care.
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In the future therefore, such a combination of several different genomic features might 
provide a more detailed insight into the tumor’s biology as well as taking the individual 
genomic background of a patient into account when predicting aggressiveness of a 
tumor. Furthermore, it will help to determine which drugs would be the most promising 
and which ones will likely not bring benefit in defeating the cancer.
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Summary
Significant progress has been made in breast cancer research over the last decades 
to reduce the number of cancer related deaths and to increase the quality of life by 
improving early detection as well as through the introduction of novel therapies to treat 
primary disease. On top of that, companion diagnostics research has been performed to 
identify patient populations which require additional treatment as well as those that are 
most receptive to a specific treatment. Current patient stratification is based on classical 
clinical and pathological markers as well as innovative genomic biomarkers such as multi-
gene predictors (detailed in the introduction in chapter 1). Despite these improvements 
a significant portion of breast cancer patients develop resistance to currently available 
treatments. Also, current biomarkers for predicting a patient’s response to known and 
novel drug treatments are sparse and there is an urgent need for development of such 
markers. This thesis focused on the clinical value of various types of non-coding RNAs 
as biomarkers with regard to drug response and clinical outcome (in the scope of the 
thesis, chapter 2). In chapter 3, within a significant drug screening effort currently 
clinically used drugs, newly developed drugs as well as drugs used in other disease 
scenarios were investigated for their sensitivity profiles in breast cancer cell lines. This 
study showed that various drugs exhibited positively or negatively correlated response 
patterns, indicating that sensitivity to one drug might be indicative of (in)sensitivity to 
another. Breast cancer subtype played only a minor role when looking at drug sensitivity 
with only one drug showing a subtype-dependent response. Interestingly, the majority 
of correlated drugs did not share biological pathways based on gene expression, except 
for one highly correlated drug pair having one pathway in common. In chapter 4, we 
studied miRNAs for their potential as biomarkers to predict response to the drugs 
screened in chapter 3. MiRNA expression was influenced by breast cancer subtype and 
upon exclusion of subtype-associated miRNAs, eleven different miRNAs were found to 
be associated with response to eight of the 34 investigated drugs. Highly-correlated 
drugs shared miRNAs, albeit none of the drugs shared all associated miRNAs. Pathway 
analyses led to the discovery of several miRNA-associated pathways known to be also 
affected by the respective drugs (e.g. the G2-M checkpoint is targeted by taxanes and 
associated with hsa-miR-187-5p). In chapter 5, somatically acquired mutations, as well as 
copy number aberrations, which can influence drug response as well, were investigated 
for their potential as biomarkers using the drug screening dataset generated in chapter 
3. Mutation, methylation or amplification of 17 genes was associated with response to 
17 drugs, including several earlier reported findings (e.g. mutated TP53 with Nutlin-3 
and MI-219 resistance or ERBB2 amplification with Erlotinib sensitivity to name two 
examples). In one instance we discovered that the inactivation of different genes within 
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the RB1 tumor-suppressor pathway (p16INK4A mutation, p16INK4A methylation and RB1 
mutation) showed an even stronger association with 17-AAG resistance than p16INK4A 
mutation alone, which corroborated earlier published observations on single genes 
within this pathway and response to 17-AAG. Besides mutations, 89 associations 
between copy number aberrations and drug response were found. Several of the drug-
associated regions spanned known breast cancer driver genes such as ARID1A, FOXA1 
or ZNF217.
With regard to the biomarker value of non-coding RNA species studied in this thesis, 
in chapter 6 specific non-coding RNAs were investigated for their predictive and 
prognostic value. In this respect, the miRNA hsa-miR-7 had been previously identified 
as a prognostic marker in ER-positive breast cancer for poor metastasis-free survival, 
and since the non-coding RNA CDR1-AS counteracts hsa-miR-7, the role of CDR1-AS as 
a prognostic marker in breast cancer was studied. Additionally, hsa-miR-7 and CDR1-
AS were examined for their potential as predictive biomarkers in tamoxifen-treated 
advanced breast cancer patients. Hsa-miR-7 exhibited, next to the known prognostic 
capability, predictive value for poor tamoxifen response as well as shorter progression-
free survival and overall survival in the advanced setting. CDR1-AS, however, apart from 
some weak associations with clinical parameters and mainly stromal cell expression, 
neither showed prognostic nor predictive biomarker capability. In chapter 7, the 
global circRNA expression landscape was described in primary breast tumors and 
the discovered circRNAs were characterized in regard to their genetic environment, 
their relation to the linear transcript of their host gene, and their relevance in breast 
cancer. Clustering of breast tumors based on circRNA expression identified subgroups 
with differences in biological and clinical characteristics. One of the discovered 
circRNAs, circCNOT2, showed an impact on breast cancer cell line viability in functional 
experiments. Furthermore, this circRNA could predict progression-free survival in 
aromatase inhibitor treated advanced breast cancer patients and was also found in 
cell-free RNA of patients’ plasma.
Finally, in the discussion in chapter 8, the results of the studies linked to the cell line drug 
screening (chapter 3, 4, 5) were summarized and analyzed for potential connections 
between drug-associated miRNAs and drug-associated genetic changes. Furthermore, 
since drug screening studies show so far limited inter-study comparability, an overview 
of the important culprits (drug screening protocols, analyses methods) is described, 
and better standardization is suggested as a solution. Additional problems in biomarker 
identification for drug response are also discussed. As circRNAs have been gaining a 
lot of attention recently, and many studies investigated their role in cancer, several 
9
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circRNAs capable to predict prognosis were identified and an overview of these is given 
in chapter 8. So far, however, hardly any circRNAs predictive of drug response have 
been reported in cancer and the predictive circRNA identified in chapter 7 is therefore 
thus far only one of few at this moment.
To conclude this thesis: The studies on cell lines provided a broad overview of drug 
sensitivity and associated genomic characteristics (miRNAs, mutations, CNAs) in breast 
cancer which are, when validated, potentially useful as biomarkers; the studies in breast 
tumors extensively describe the relatively new RNA species, circRNAs, and determine 
their predictive and prognostic potential in breast cancer.
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Samenvatting
De afgelopen decennia is door vroeg-detectie en de introductie van nieuwe therapieën 
het aantal sterfgevallen aan borstkanker sterk verminderd en als mede de kwaliteit 
van leven met de ziekte sterk verbeterd. Aanvullend diagnostisch onderzoek heeft 
er bovendien voor gezorgd dat patiënten geïdentificeerd kunnen worden voor wie 
aanvullende systemische behandeling noodzakelijk is en wie het meest ontvankelijk 
is voor een specifieke behandeling. Zoals gedetailleerd beschreven in de inleiding 
(hoofdstuk 1) is de huidige patiëntenstratificatie gebaseerd op klassieke klinische en 
pathologische factoren aangevuld met innovatieve genomische biomerkers zoals multi-
gen-gebaseerde voorspellers. Ondanks deze vooruitgang ontwikkelt een aanzienlijk 
deel van de borstkankerpatiënten resistentie tegen de momenteel beschikbare 
medicijnen. Ook zijn biomerkers die de respons van een patiënt op bekende en 
nieuwe medicamenteuze behandelingen kunnen voorspellen schaars. Kortom er is een 
dringende behoefte aan de ontwikkeling van dergelijke merkers en het doel van dit 
proefschrift zoals geschreven in hoofdstuk 2 was om te onderzoeken of niet-coderende 
RNA’s bruikbare biomerkers zouden kunnen leveren om de gevoeligheid van nieuwe en 
bestaande medicijnen of het ziektebeloop in algemene zin te voorspellen. In hoofdstuk 
3 hebben we in een uitgebreid aantal cellijnmodellen voor borstkanker de gevoeligheid 
voor 34 gangbare en nieuw-ontwikkelde geneesmiddelen in kaart gebracht. Deze studie 
toonde aan dat de gevoeligheid van cellijnen voor verschillende geneesmiddelen positief 
of negatief gecorreleerd gedrag vertoonde, hetgeen aangeeft dat gevoeligheid voor één 
geneesmiddel een indicatie kan zijn voor (on)gevoeligheid voor een ander. Bestaande 
sub-groepering van borstkanker (bijvoorbeeld hormoon gevoelig of niet) speelde 
hierbij een ondergeschikte rol. Opmerkelijk genoeg konden we in het onderzochte 
borstkankercellijnpanel met uitzondering van één sterk gecorreleerd geneesmiddelpaar, 
op basis van genexpressie geen biologische processen identificeren die gedeeld werden 
door de 29 geneesmiddelen die een gecorreleerd gedrag vertoonden. In hoofdstuk 
4 hebben we vervolgens bestudeerd of kleine RNAs, de zogenaamde microRNA’s, als 
biomerkers kunnen dienen om de gevoeligheid voor de in hoofdstuk 3 onderzochte 
geneesmiddelen te voorspellen. Om potentiële bias te voorkomen hebben we microRNAs 
die sterk met bestaande borstkankersubgroeperingen geassocieerd waren buiten het 
onderzoek gelaten. Hierna bleven er elf verschillende miRNA’s over die geassocieerd 
waren met respons van de cellijnen op acht van de 34 onderzochte medicijnen. Sterk 
gecorreleerde geneesmiddelen deelden miRNA’s, hoewel geen van de geneesmiddelen 
alle geassocieerde miRNA’s met elkaar deelde. Biologische proces-analyses leidden tot 
de ontdekking van verschillende miRNA-geassocieerde processen waarvan reeds bekend 
is dat ze ook worden beïnvloed door de respectieve geneesmiddelen (bijv. het proces 
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dat de transitie van G2 naar M in celdeling controleert is een doelwit van taxanen en is 
eveneens geassocieerd met de expressie van hsa-miR-187-5p). In hoofdstuk 5 werden 
met behulp van de in hoofdstuk 3 gegenereerde geneesmiddelengevoeligheidsdata 
somatisch verworven mutaties en genkopieën onderzocht op hun potentieel als 
biomerkers. Mutatie of methylatie of amplificatie van 17 genen waren geassocieerd met 
gevoeligheid voor 17 van de geteste geneesmiddelen. Onder de gevonden associaties 
bevonden zich verschillende eerder gerapporteerde bevindingen. Om twee voorbeelden 
te noemen: TP53 gemuteerde cellijnen vertoonden resistentie tegen Nutlin-3 en 
MI-219 en ERBB2-amplificatie voorspelde Erlotinib-gevoeligheid. Het onderzoek gaf 
ook nieuwe inzichten. Zo ontdekten we dat de inactivatie van verschillende genen uit 
het RB1 gedreven signaalpad dat tumorgroei onderdrukt (p16INK4A-mutatie, p16INK4A-
methylatie en RB1-mutatie) tezamen een sterkere associatie met 17-AAG-resistentie 
vertoonde dan p16INK4A-mutatie alleen, hetgeen in overeenstemming is met eerder 
gepubliceerde waarnemingen dat deze genen elk individueel de 17-AAG gevoeligheid 
beïnvloeden. Naast mutaties vonden we 89 gebieden op het humane genoom, inclusief 
regio’s waar bekende borstkanker-stimulerende genen zoals ARID1A, FOXA1 of ZNF217 
liggen, waarvan het aantal kopieën de medicijngevoeligheid bepaalde.
In aanvulling op bovenstaand onderzoek in cellijnmodellen is in het tweede deel 
van het proefschrift in weefsels van borstkankerpatienten de klinische waarde van 
niet-coderende RNA’s onderzocht met de focus op hun voorspellende waarde m.b.t. 
agressiviteit en/of gevoeligheid voor hormonale therapie. In eerder onderzoek was 
aangetoond dat hsa-miR-7 in ER-positief borstkanker een voorspeller was voor een korte 
metastasevrije overleving, en aangezien het niet-coderende RNA CDR1-AS hsa-miR-7 
tegenwerkt, werd in hoofdstuk 6 de rol van CDR1-AS als voorspeller van aggressiviteit bij 
borstkanker bestudeerd. Bovendien werden zowel hsa-miR-7 als CDR1-AS onderzocht op 
hun potentieel als voorspellende biomerkers bij gevorderde borstkankerpatiënten die 
behandeld waren met het anti-hormoon tamoxifen. Naast de eerder aangetoonde maat 
voor agressiviteit, vertoonde hsa-miR-7 in deze patientengroep eveneens voorspellende 
waarde voor een slechte respons op tamoxifen evenals een kortere progressievrije en 
totale overleving. CDR1-AS bleek daarentegen, afgezien van enkele zwakke associaties 
met klinische parameters en voornamelijk expressie in stroma van de tumor, noch 
een maat te zijn voor aggressiviteit noch voorspellende waarde m.b.t. gevoeligheid 
voor hormonale therapie te bezitten. In hoofdstuk 7 is voor het eerst in een groot 
primair borstkankercohort het expressiepatroon van alle circulaire RNAs beschreven. 
Tevens werden de ontdekte circRNA’s gerelateerd aan de lineaire transcripten waaruit 
ze zijn ontstaan, aan de genetische karakteristieken van de tumoren, en aan klinisch 
relevante factoren bij borstkanker. Groepering van borsttumoren op basis van de 
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expressie van deze circulaire RNAs identificeerde subgroepen met verschillen in 
biologische en klinische karakteristieken. Eén van de ontdekte circRNA’s, circCNOT2, 
bleek in functionele experimenten de vitaliteit van borstkankercellijnen negatief te 
beïnvloeden. Bovendien kon dit circRNA de progressievrije overleving voorspellen bij 
gevorderde borstkankerpatiënten die behandeld waren met een aromataseremmer en 
was het detecteerbaar in het plasma van borstkankerpatiënten.
Tot slot zijn in hoofdstuk 8 de resultaten van het proefschrift bediscussieerd. Het 
onderzoek naar geneesmiddelgevoeligheid van borstkankercellijnen (hoofdstuk 3, 
4, 5) en geassocieerde miRNA’s en genetische veranderingen is geïntegreerd waaruit 
bleek dat de relatie tussen medicijngevoeligheid gerelateerde miRNAs en gevonden 
genetische factoren met name indirect was. Daarnaast, aangezien onderzoeken 
naar medicijngevoeligheid in cellijnen een beperkte vergelijkbaarheid tonen, wordt 
een overzicht van de belangrijkste oorzaken beschreven (gebruikte protocollen en 
analysemethoden) en wordt een standaardisatie daarvan als oplossing voorgesteld. 
Bijkomende problemen met betrekking tot de identificatie van biomerkers met 
voorspellende waarde m.b.t. geneesmiddelgevoeligheid worden ook besproken. Omdat 
circRNA’s de laatste tijd veel aandacht hebben gekregen, en diverse studies hun rol 
in kanker onderzochten en hun waarde als prognostische merkers beschreven, werd 
in hoofdstuk 8 hiervan een overzicht gegeven. CircRNA’s met voorspellende waarde 
m.b.t. geneesmiddelgevoeligheid zijn er nog nauwelijks en het voorspellende circRNA 
dat geïdentificeerd werd in hoofdstuk 7 is daarom tot nu toe één van eerste.
Dit proefschrift samenvattend kunnen we stellen dat de studies op cellijnen inzicht 
hebben gegeven in de relatie tussen genomische kenmerken (miRNA’s, mutaties, 
kopieënaantal van gebieden op het humane genoom) en de gevoeligheid van 
borstkanker voor een breed scala aan geneesmiddelen, die, indien onafhankelijk 
gevalideerd, mogelijk gebruikt kunnen worden als predictieve biomerkers; de studies 
in borsttumoren van patiënten beschrijven uitgebreid het relatief nieuwe RNA-soort, 
circRNA’s, en stellen hun voorspellende potentieel bij borstkanker vast.
9
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